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CHAPTER 1 
General Introduction 
Introduction 
INTRODUCTION 
The function of the liver is to keep the human body in physiological equilibrium. 
This equilibrium is regulated by several metabolic pathways such as the 
production of plasma proteins and detoxification. Inflammation of the liver is 
known as hepatitis and as entity it has been recognized since the days of 
Hippocrates. The most important etiology of hepatitis is viral infection of the 
liver. 
Five distinct hepatitis viruses are known. The hepatitis A virus (HAV) is 
orally transmitted and liver disease has a sudden onset after a short incubation 
period with an average of 4 weeks. HAV is a small cubic RNA virus of 27nm 
and belongs to the family of picorna viruses. Hepatitis B virus (HBV) is 
parenterally transmitted and onset of liver disease is usually slow after a long 
incubation period with an average of 12 weeks. The HBV virion is a spherical 
particle of 42nm, contains a partially double stranded DNA genome and is 
classified as a Hepadnavirus [Tiollais et al., 1985]. Hepatitis Delta virus (HDV) 
has been recognized as a defective RNA virus in the presence of HBV antigens 
[Rizetto et aI., 1983J. 
Besides HAV, HBV and HDV another form of viral infections of the liver, 
with an intermediate incubation period between HAV and HBV, was postulated 
in the early 1970's [Prince et al., 1974; Feinstone et aI., 1975]. These 
infections were mainly associated with blood transfusion and therefore, 
provisionally designated as post-transfusion non-A, non-B hepatitis (PT-NANBH). 
The name, PT-NANBH, reflects that the diagnosis was based on exclusion of 
HAV and HBV, as well as other hepatotropic agents such as HDV, 
Cytomegalovirus, Epstein-Barr virus, Varicella Zoster virus and Yellow Fever 
virus. 
NANBH could be transmitted enterically as well as parenterally. Recently, 
hepatitis E virus (HEV), the enteric ally form of NANBH, was characterized. HEV 
is an RNA virus and belongs to the Caliciviridae [Reyes et aI., 1990J. 
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From non-A, non-B to hepatitis C 
After the recognition of parenterally transmitted NANBH as a distinct entity 
[Feinstone et aI., 1975), many attempts were made to characterize the viral 
agent. Over 50 serological or virological assays have been developed in the 
period from 1975 to the late eighties. None of them proved to be specific for 
NANBH in well characterized coded test panels [Purcell et aI., 1994). 
Experimental infections of chimpanzees with contaminated sera [Alter et 
aI., 1978J or clotting factor VIII preparations [Bradley, 1979 and 1981 J were 
successful. After approximately a decade of studies in chimpanzees, obtained 
physico-chemical data resulted in the hypothesis that the causative agent might 
belong to the Togaviridae [Bradley et al., 1985J. Togaviruses are small 
enveloped viruses and contain a single stranded, positive sense RNA genome. 
Plasma samples from a persistently infected chimpanzee [Bradley et aI., 
1985J were pooled and subsequently used for construction of a CDNA 
expression library. Expressed viral antigens were detected by serum from 
chronically infected PT-NANBH patients. The first clone, designated as clone 5-
1-1, was found in 1987 [Houghton et aI., 1990; Choo et aI., 1989J and used as 
a probe for detection of overlapping clones covering the entire viral genome 
[Choo et aI., 1991 J. 
The hepatitis C virus genome 
Sequence analysis of the HCV genome revealed that the genomic organization 
and hydrophobicity profile were similar to viruses belonging to the family of 
Flaviviridae. Therefore, HCV was classified as a separate genus within this 
family [Miller et aI., 1990). 
The HCV genome is a single-stranded, positive-sense RNA molecule of 
approximately 9,400 nucleotides (nt). It contains one large open reading frame 
(ORF) which encodes for a polyprotein of 3,010-3,033 amino acids [Kato et aI., 
1990; Takamizawa et aI., 1991 J. This polyprotein is cleaved into functional 
proteins by host and viral proteases. The N-terminal region encodes for the 
structural core and envelope proteins (El and E2/NS1). The C-terminal region 
encodes for the non-structural (NS) proteins which are involved in the replication 
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cycle (Figure 1). 
The RNA genome contains an untranslated region (UTR) at both ends. 
The 5'UTR is involved in initiation of translation [Han et aI., 1991J. The putative 
secondary structure of this region has been determined and one of the stem-
loop structures was characterized as an internal ribosomal entry site (IRES) 
[Brown et al., 1992; Tsukiyama-Kohara et aI., 1992). The 3'UTR appeared to be 
variable in length as well as sequence and this region is probably involved in 
termination of translation and initiation of replication [Kato et aI., 1990; Choo et 
aI., 1991, Han et aI., 1991; Takamizawa et aI., 1991; Okamoto et aI., 1991 and 
1992a]. 
Clinical characteristics of HCV infection 
In the acute phase of HCV infection the clinical symptoms are indistinguishable 
from HAV and HBV. Jaundice has been observed in approximately 10% of the 
infections [Miyamura et aI., 1990; van der Poel et aI., 1991 a]. HCV RNA is 
detectable within the first week of infection and elevation of liver-specific 
enzymes such as alanine aminotransferase (AL T) is observed with an average 8 
weeks peak after infection. The first HCV antibodies are directed to the core 
antigen and become detectable at the onset of ALT elevation. HCV C100-3 
antibodies are usually found after the AL T peak (Figure 2). Approximately 80% 
of the HCV infected patients develop a chronic infection [Alter et aI., 1989; van 
der Poel et aI., Lancet 1991 b; Gerber et aI., 1993) with characteristic 
fluctuations of the AL T level. HCV has been recognized as a significant risk 
factor in the development of cirrhosis and liver cancer [Bruix et aI., 1989; 
Colombo et aI., 1989; Kew et aI., 1990; Saito et aI., 1990], although there is no 
evidence for direct oncogenic activity of HCV. 
Diagnosis of HCV infection 
After discovery of HCV, immunoassays became available for specific screening 
of HCV instead of diagnosis by exclusion. In the first generation anti-HCV 
assays the recombinant proteins 5-1-1 and C100-3, both derived from the NS4 
region, were used in radio immunoassays (RIA) for the detection of HCV anti-
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bodies. By this assay, HCV antibodies were detected in approximately 80% of 
chronically infected PT-NANBH patients and in 58% of those with no identifiable 
exposure to the virus (Kuo et aI., 19891. Additionally, in prospective PT-NANBH 
studies, 60-80% of the implicated blood donors were anti-HCV positive (van der 
Poel et al., 1990; Esteban et aI., 1990; Alter et aI., 19891. These initial results 
suggested that the first generation assay could be improved. 
The second and third generation screening assays were extended with 
recombinant antigens core (C22) and NS3 (C33c) and synthetic peptides derived 
from the NS5 region. These antigens were also used in a HCV specific 
recombinant immunoblot assay (RIBA; Ortho Diagnostics, Raritan, N.J., USA) 
for confirmation of anti-HCV screening results (Follett et aI., 1991; van der Poel 
et al., 1991b; Nakatsuji et aI., 1992; Garda-Samaniego et aI., 1993), Similarly, 
screening results can be confirmed by a Line Immuno Assay (LlA; Innogenetics 
NV, Ghent, Belgium) which contains several peptides derived from the structural 
regions core and E2 as well as the nonstructural regions NS3, NS4 and NS5. 
In HCV diagnosis antibody assays can only provide evidence of previous 
exposure to the virus but are unable to detect actual viremia. Acute infections 
can only be detected by HCV antibody assays after a seronegative window 
(Farci et aI., 1991) and antibodies are even absent in immuno-suppressed 
patients. Due to the high rate of chronicity of hepatitis C infection, elevated AL T 
levels together with detectable HCV antibodies suggest HCV viremia. However, 
both are indirect markers. 
HCV RNA detection 
In the absence of a tissue culture system and antigen assays, detection of the 
viral RNA genome seems to be the only marker for HCV viremia. Highly sensitive 
nucleotide amplification methods such as the polymerase chain reaction (PCR), 
Nucleic Acid System Based Amplification (NASBA) and Ligase Chain Reaction 
(LCR) allows detection of HCV RNA. Application of these nucleic acid based 
techniques require conserved viral sequences for development of universal 
assays. Since the 5'UTR is highly conserved, primers directed to this region 
were superior when compared to other regions (Bukh et aI., 1992al. HCV RNA 
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detection is performed to confirm an anti-HCV positive test result for actual 
viremia, in diagnosis of early HCV infections i.e. during the seronegative 
window and to monitor the effects of antiviral therapy. Prior to commercial 
available HCV viremia assays, many hepatitis C research centers have 
developed an "in-house" HCV RNA PCR assay. In order to evaluate the "in-
house" developed assay two HCV proficiency panels have been provided 
[Zaaijer et aI., 1993]. 
HCV sequence diversity 
Mixed populations of closely related HCV RNA sequences, so called "quasi-
species", have been observed in the same individual {Oshima et aI., 1991; 
Okada et aI., 1992; Tanaka et aI., 1992]. Differences among HCV genomes in 
the same individual can be caused by replication errors in the growing RNA 
chain. The mutations in the HCV RNA sequence as in any other virus are 
tolerated if they do not disturb the virus life cycle. In the genetic drift of HCV, 
rates of nucleotide changes per site per year have been estimated over a 
relatively short time interval and varied from 1.44xl0-3 (complete genome) 
{Okamoto et aI., 1992bJ to 1.92xl0·3 (5' half of the genome) {Ogata et aI., 
1991J. About one third of the nt changes resulted in a different amino acid (aa). 
The mutation rate in the HCV genome is similar to that of other RNA viruses 
[Domingo et aI., 1988]. 
The full-length HCV sequence of the chimpanzee isolate as characterized 
by Houghton and co-workers {Houghton et aI., 1990J is known by several 
names: HCV prototype, HCV-US, HCV-l and "American" strain. Comparison to 
full-length HCV sequences from Japanese patients {HCV-J, Kato et aI., 1990; 
HCV-BK, Takamizawa et aI., 1991 J revealed 78-79% nt sequence homology 
with HCV-l {Choo et al., 1991], while the homology among Japanese isolates 
was 92%. The isolates were therefore classified as the "American" and 
"Japanese" strain. Later obtained full-length HCV sequences from Japanese 
patients, HC-J6 and HC-J8 {Okamoto et aI., 1991 and 1992aJ appeared to be 
substantially distinct from HCV-l, HCV-J and HCV-BK {Okamoto et aI., 1992aJ. 
Similarly, sequence analysis of a part of the NS5 region revealed considerable 
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sequence variation between HCV isolates, suggesting the existence of at least 2 
HCV types in Japan [Enomoto et al., 1990). 
The awareness that HCV exists as a number of distinct types has led to 
sequence analysis of numerous HCV isolates from different geographical origins 
[Bukh et aI., 1992b and 1993; Chan et aI., 1992] and the development of fast 
HCV genotyping assays [Okamoto et aI., 1992c; Stuyver et aI., 1993]. 
Epidemiology 
The prevalence of HCV infection as estimated by first generation antibody 
assays ranged from 0.2-1.7% in blood donors from the United States [Weiner et 
aI., 1990], Europe [van der Poel et aI., 1991 a; Contreras et aI., 1991; Kuhnl et 
aI., 1989; Janot et aI., 1989; Esteban et aI., 1990] and Japan [Miyamura et aI., 
1990). After the introduction of more specific screening and confirmation 
assays, the estimated prevalence of HCV among blood donors in Scotland was 
lowered from 0.5% to 0.09% [Follett et aI., 1991; Crawford et aI., 1994]. 
Interestingly, an extraordinarily high rate of 20% anti-HCV positivity was 
observed in Egyptian volunteer blood donors. This antibody test result was 
confirmed by HCV RNA analysis [Saeed et aI., 1991], 
The parenteral route of HCV by transfusion of blood and by use of blood 
products is well-known. High seroprevalence rates have also been observed in 
intravenous drug abusers (lVDA], hemophiliacs and hemodialysis patients 
[Makris et aI., 1990; Jeffers et aI., 1990]. Transmission by needlestick injury, 
tattooing and even by a human bite have been reported [Abildgaard et aI., 1991; 
Dusheiko et aI., 1990]. HCV transmission among sexual partners was below 3% 
[Brettier et aI., 1992] or even absent [Bresters et aI., 1993). Also, transmission 
from mother to child is exceptional [Inoue et aI., 1991; Reinus et aI., 1992; 
Wejstal et aI., 1992; Lam et aI., 1993). However, vertical transmission of HCV 
occurs frequently in mothers who are HIV coinfected [Thaler et aI., 1991; 
Novati et aI., 1992]. 
Treatment 
For treatment of chronic NANBH, corticosteroids did not appear to be beneficial 
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[Alter et ai., 19841. The availability of recombinant interferon (lFN) has allowed 
clinical trials of this antiviral and immuno-modulatory agent for treatment of viral 
infections such as chronic HBV [Sherlock et ai., 1985]. A first attempt in 
treatment of chronic NANBH patients with recombinant IFN alpha-2b was made 
in 1986 IHoofnagle et ai., 19861. Normalization in activity of liver disease, as 
estimated by AL T levels, was obtained in 8 of the 10 patients during treatment. 
Similar results were obtained by Thompson et al in a pilot study with 
Iymphoblastoid alpha-interferon [Thompson et ai., 19871. 
These results were promising and have led to larger studies. Three 
randomized controlled studies confirmed that IFN alpha could reduce the activity 
(AL T) of liver disease to normal in about 50% of the patients with chronic 
NANBH [Jacyna et ai., 1989; Di Bisceglie et ai., 1989; Davis et ai., 19891. 
However, after cessation of treatment liver disease activity relapses in 
approximately 50% of the patients with an initial response. In fact only 25% of 
the patients remained in a biochemical remission after a 6 months IFN course. 
The effect of IFN alpha on HCV viremia has been addressed in more recent 
studies [Shindo et aI., 1991; Bresters et aI., 1992]. 
Benelux Study Group on treatment of chronic hepatitis C virus 
In 1990, a multi center study on treatment of chronically infected HCV patients 
was initiated in Rotterdam (Prof. Dr. S.W. Schalm). Eighteen clinical centers 
from Belgium, the Netherlands and Luxembourg (Benelux) participated in a 
randomized controlled study. At the close of the study 354 patients had 
enrolled. The patients were either treated with interferon alpha 2B (lntron-A, 
Schering-Plough) according to a "Standard" schedule, 3MU 3 times a week for 
24 weeks, or an "Experimental" schedule comprising a high-dose (6MU 3 times 
a week) induction phase of 8 weeks followed by a maintenance phase of 
titrated doses of IFN (3 and 1 MU) till biochemical and virological remission has 
been obtained during the 1 MU dose of IFN therapy. The experimental therapy 
was either also discontinued if AL T levels remained elevated after 12 weeks or 
HCV RNA was still detected after 1 year of treatment. In this thesis, blood 
samples from these patients were used for characterization of the hepatitis C 
virus. 
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Outline of the thesis 
The major objective of this thesis was to characterize hepatitis C virus isolates 
from chronically infected patients and is discussed in three parts. 
The first part focuses on the detection of HCV viremia. Chapter 2 
describes the development of a universal HCV RNA PCR assay. The "in-house" 
HCV RNA assay has been evaluated in 2 Eurohep HCV proficiency panels. This 
HCV RNA test was developed for diagnostic purposes and in particular for 
endpoint determination of antiviral therapy with interferon alpha 2B. Chapter 3 
describes the application of the HCV RNA assay to investigate the predictive 
value of HCV RNA detection at an early stage (week 4) during interferon 
treatment. 
The second part of this thesis focuses on the characterization of HCV 
patient isolates. Classification of HCV isolates by sequence analysis of 5'UTR 
amplification products is described in Chapter 4. In Chapter 5 a fast 5'UTR 
genotyping method is evaluated by comparison to sequence data. The 
correlation between HCV types and antibody profiles to HCV type 1 epitopes is 
also discussed. Whether sequence variation in the 5'UTR is sufficient to 
discriminate between the different viral types is described in Chapter 6 by 
sequence analysis of the core and E1 regions. Chapter 7 compares the 
classifications of HCV isolates by 2 fast genotyping methods. 
The third part of this thesis, in Chapter 8. describes the relationship 
between the HCV (sub)types and demographical, epidemiological and 
pathobiological parameters in order to assess the relevance of HCV genotyping. 
Finally, the overall results and conclusions of this thesis are discussed and 
summarized in Chapter 9. 
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Evaluation of several 5'UTR primer sets for detection 
of hepatitis C virus RNA by single and nested PCR 
G.E.M. Kleter 
Evaluation of several 5'UTR primer sets for HCV RNA detection 
ABSTRACT 
An "in-house" developed HCV RNA assay was evaluated in two quality control 
studies with 38 and 97 participants which supplied respectively 31 and 136 
data sets for evaluation. The two HCV RNA panels each consisted of 10 
undiluted samples and two dilution series. These samples were analyzed by 
single round and nested PCR with four different primer sets, respectively NC, 
NCC, NC3 and HC3/4, and two probes, HCV17 and NC-71, based on 
sequences of the 5'untranslated region. Obtained PCR data were confirmed by 
repeating the experiment. The NC primer set was not able to detect HCV RNA 
at all in one of the dilution series. This lack in HCV RNA detection was probably 
caused by sequence variation in the target region of the NC primerset. The 
primer sets NCC and NC3 were almost similar in sensitivity and HCV specific in 
the analysis of both panels. First round PCR product analysis by nested PCR 
with inner primer set HC3/4 did not improve the sensitivity when compared to 
Southern blot hybridization with probe NC-71. In comparison to the reference 
laboratory with the highest sensitivity and participants with a higher sensitivity 
as we, HCV RNA could not be detected by us in one of the 20 undiluted 
samples, suggesting that it was a borderline sample. In conclusion, the "in-
house" developed HCV RNA PCR assay meets the standards of specificity and 
sensitivity of the reference laboratories. 
INTRODUCTION 
Hepatitis C Virus (HCV) is the causative agent of parenterally transmitted non-A, 
non-B hepatitis (NANBH) [Chao et al., 1989L and belongs to the family of 
Flaviviridae [Miller et aI., 19901. The viral RNA genome encodes 3 structural 
antigens (core, El and E2/NS1) and 4 non-structural antigens (NS2 to NS5). 
One of the first assays for detection of hepatitis C viral sequences in 
NANBH patients was reported in 1990 by using primers in the NS3/NS4 region 
(Weiner et aI., 1990]. In the last two years several papers have discussed 
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technical aspects of HCV RNA detection by PCR. Various parts of the 
procedures like method of isolation, handling and storage of materials, choice of 
primers and PCR product analysis have been investigated extensively. A 
summary of these technical reports is given below. 
HCV RNA can be efficiently isolated from blood or liver tissue by lysis 
with the chaotropic detergent guanidinium thiocyanate (Chomczynski et aI., 
1987] and by proteinase K digestion (Houghton et aI., 19901. Almost similar 
results were obtained by these two methods (Wolff et aI., 1992; Tilston et aI., 
1993; Castillo et aI., 19921, although chemical lysis is preferable above 
enzymaticallysis, due to a more rapid denaturation of RNases. 
False-negative results can be obtained by suboptimal specimen handling 
i.e. repeatedly freezing and thawing of samples. Also storage at ambient 
temperature and 4°C resulted in a reduction of the yield of PCR product (Busch 
et aI., 1992; Cuypers et aI., 1992]. Blood samples are the most convenient 
specimens for HCV RNA detection, although it has been reported that 
heparinized plasma samples are not suitable, due to the inhibitory effect of 
heparin on Taq DNA polymerase (Willems et aI., 1993]. For proper analysis of 
these samples the isolation procedure can be extended by a heparinase 
treatment or alternatively HCV RNA can be isolated by capture onto 
paramagnetic beads (van Doorn et aI., 19941. 
Primers are crucial for efficient detection of HCV RNA since they 
determine specificity as well as sensitivity. Analysis of the NS4 region with five 
primer sets revealed a lack of sensitivity for HCV RNA detection (Cristiano et aI., 
19911. Highest specificity and sensitivity was obtained by primer sets directed 
to 5'UTR when compared to the core, NS2, NS3, NS4 and NS5 regions (Garson 
et aI., 1990 and 1991; Inchauspe et aI., 1991; Bukh et aI., 1992a; Cuypers et 
aI., 1992; Castillo et aI., 19921. Currently, at least 9 major HCV types exist 
(Bukh et aI., 1993; Simmonds et aI., 1993a; Tokita et aI., 1994]. Within the 
5' UTR approximately 90% sequence homology is observed among HCV types 
(Chan et aI., 1993]. The conservation of this region is probably caused by 
functional restrictions (Brown et aI., 1992; Tsukiyama-Kohara et aI., 1992; Yoo 
et aI., 1992; Wang et aI., 19931 and sequence variation was mainly observed 
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in two sequence motifs [Bukh et aI., 1992b; Simmonds et aI., 1993b; Kleter et 
aI., 1994]. Therefore, 5'UTR appears to be the best region for detection of HCV 
viremia. 
Analysis of PCR products can be performed by hybridization with a probe 
or by subsequent nested PCR with an inner primer set. Nested PCR has higher 
specificity and probably a higher sensitivity but is more prone to contamination 
than hybridization. Comparison of single round and nested PCR by analysis of a 
cDNA dilution series resulted in similar sensitivity and specificity [Gretch et aI., 
1993]. 
The "in-house" developed HCV RNA PCR assay as described in this 
chapter was the basis of all studies in this thesis. Over time the "in-house" 
assay has been adapted by changing primers and probes due to obtained 
knowledge on HCV RNA sequences and HCV RNA detection results on several 
HCV samples for first diagnosis. Here, the assay was evaluated in two quality 
control studies organized in 1992 and 1993 by the Central Laboratory for Blood 
transfusion (CLB, Amsterdam the Netherlands) under auspices of the "Eurohep" 
group (I.e. an European expert group on viral hepatitis). Blood samples were 
analyzed by single round and nested PCR with several 5'UTR primer sets to 
determine their specificity and sensitivity for detection of HCV RNA. 
MATERIALS AND METHODS 
Plasma samples 
Coded plasma samples for the HCV RNA quality control panels from study 1992 
and 1993 were provided by the Central Laboratory of The Netherlands Red 
Cross Blood Transfusion Service (Amsterdam, the Netherlands). 
The 1992 HCV RNA quality control panel ("1992 panel") consisted of 22 
EDTA-plasma samples, including 10 undiluted blood donor samples (6 without 
HCV RNA and 4 with different quantities of HCV RNA). The remaining 12 
samples were divided into two tenfold dilution series of 6 samples each (10.2 to 
10"); one from an infected donor with HCV type 1 and the other from a 
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chimpanzee infected with a known infectious dose of the HCV-H strain. This 
coded test panel was sent to 38 hepatitis C research laboratories in Europe (30), 
the USA (7) and Japan (1); 7 laboratories did not supply results and 31 
laboratories returned evaluable data sets [Zaaijer et ai., 19931. 
The 1993 HCV RNA quality control panel ("1993 panel") consisted of 26 
EDTA-plasma samples, including 10 undiluted samples (6 without HCV RNA, 3 
were of HCV type and in 1 sample a discordant test result was obtained by the 
2 reference laboratories). The remaining 16 samples were divided in two dilution 
series, containing HCV type 1 and type 3, respectively. This coded test panel 
was sent to 97 hepatitis C research laboratories around the world; 86 
laboratories participated actually and returned 136 evaluable data sets [Cuypers 
et ai., 1994]. 
Primers and Oligonucleotide probes 
Known HCV CDNA sequences [Kato et ai., 1990; Takamizawa et ai., 1991; 
Okamoto et ai., 1990, 1991 and 1992; Choo et ai., 19911 were used for 
selection of the primers and probes. The sequences of primers and probes are 
shown in Table 1. Relative positions of applied primer sets and probes are 
shown in Figure 1. Primers and probes were synthesized on an Applied 
Biosystems 381 A DNA synthesizer using the B-cyano-ethylphosphoramidite 
method. 
HCV RNA isolation 
HCV RNA was extracted from plasma samples by a modification of the 
guanidinium method as described by Chomczynski [Chomczynski et ai., 1987]. 
In detail, 100 III plasma was dissolved in 500 III of a solution containing 4 M 
guanidinium thiocyanate, 25 mM sodium citrate pH 7.0, 0.5% (wt/vol) sarcosyl, 
0.1 M B-mercaptoethanol and 20 IIg poly A. This mixture was extracted twice 
with an equal volume of phenol/chloroform (1: 1!v:v) and once with 
chloroform/isoamyl-alcohol (49: 1) by shaking 10 min and subsequently 
centrifuged for 20 min in the first extraction, and 5 min for the remaining. The 
aqueous phase was precipitated with one volume of isopropanol for 1 hour at 
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Table 1. HCV oligonucleotide sequences 
name position polarity sequence (5'-3') 
HCV18 -324 to -305 + GGCGACACTCCACCATAGAT 
HCV35 -318 to -296 + TTGGCGGCCGCACTCCACCA 
TGAATCACTCCCC 
NCR3 -314 to -288 + GGGGCGGCCGCCACCATRRA 
TCACTCCCCTGTGAGG 
HC3 -264 to -239 + TCTAGCCATGGCGTTAGTRYGAGTGT 
HCV17 -86 to -67 + GAGTAGTGTTGGGTCGCGAA 
NC-71 -71 to -52 + GCGAAAGGCCTTGTGGTACT 
HC4 -29 to -54 CACTCGCAAGCACCCTATCAGGCAGT 
HCV19 -1 to -20 GTGCACGGTCTACGAGACCT 
+ indicates sense, - indicates antisense orientation. Underlined sequences are not 
complementary to the Hev sequence. R := A or G; Y = Tor C, 
-70 0 C. After 20 min centrifugation at 4°C the RNA pellet was resuspended in 
80% ethanol and centrifuged for 15 min. The pellet was vacuum dried and 
dissolved in 30 pi diethylpyrocarbonate-treated H,O. 
RNA peR 
For eDNA synthesis 20 pmol of an antisense HCV primer (Table 1) was added to 
10 pi HCV RNA solution. The mixture was heated at 80 0 C for 2 min and 
immediately cooled on ice to allow annealing of the eDNA primer. eDNA 
synthesis was performed in a final volume of 25 pi after adjustment of the 
mixture to contain 50 mM Tris-HCI pH 8.3, 75 mM KCI, 3 mM MgCI" 1 0 mM 
dithiothreitol, 0.5 mM of dNTP, 30 U RNasin (promega, Madison, Wis.) and 200 
U Moloney murine leukemia virus reverse transcriptase (GIBCQ-Bethesda 
Research Laboratories, Gaithersburg, Md.) and incubated at 42°C for 30 min. 
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5' UT~LC---LI E_1...LI_E_2---L1 _NS_2--LI_N_S_3 _LI _N_S4-L1 ___ NS_5_---lf!' UTR 
NC -71 
Hev 17 --
--+ Hev 18 
--+ Hev 35 
--+ NCR 3 
---+ He 3 
Figure 1. Relative position of HeV primers and probes 
Hev 19 +-- NC primer sat 
Hev 19 +-- Nee primer set 
HeV 19 +-- NC 3 primer sel 
He 4 +-- HC3!4 primer set 
Amplification of HCV CDNA sequences was in accordance with the PCR method 
originally described by Saiki [Saiki et aI., 1988]. PCR was performed in a final 
volume of 100 pI. Taq buffer, dNTP's, 20 pmol of the sense primer (Table 1) 
and 1 U of Taq DNA polymerase (Promega, Leiden, the Netherlands) were added 
to the cDNA reaction after an initial 5 min denaturation at 95°C. The PCR 
solution was covered with two drops of mineral oil (Sigma, St. Louis, Missouri), 
to prevent evaporation, and sUbjected to 40 cycles of amplification using a PCR 
thermocycler (Biomed, Bitfurth, FRG). Each reaction cycle consisted of a DNA 
denaturation step at 94°C for 1 min, a primer annealing step at 52°C for 2 min 
and a primer extension step at 72°C for 2 min. 
PCR product analysis 
After amplification 20 pi of the first round product was electrophoresed on a 2% 
agarose gel. For Southern blot analysis the gel was denatured for 15 min in 0.5 
M NaGH, 1.5 M NaCI and neutralized for 15 min in 3 M Na-Acetate pH 4.8. The 
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amplification products were transferred to a nylon membrane (Hybond N, 
Amersham, Buckinghamshire, United Kingdom) by blotting in 10xSSC (1 xSSC is 
15 mM sodium citrate, 150 mM NaCI). The blots were baked for 2 hours at 
80°C. The filters were hybridized with an internal probe 5'-end labelled with 32p 
(Sambrook et aI., 1989). Hybridization was performed in 5xSSC, 5xDenhardt's 
(0.1 % bovine serum albumin, 0.1 % Ficoll, 0.1 % polyvinyl pyrrolidone), 0.5% 
SDS, 75 mM EDTA and 100 pg/ml herring sperm DNA with 106 cpm of probe 
per ml for 16 hours at 37°C in a shaking water bath. After hybridization filters 
were rinsed briefly in 6xSSC and subsequently washed twice in 2xSSC, 0.1% 
SDS for 15 min at 37°C and once in 1 xSSC, 0.1 % SDS for 15 min at 45°C. 
The filters were autoradiographed between intensifying screens at -70°C on Fuji 
RX 100 X-ray films. 
For analysis by nested PCR (40 cycles of 1 min at 94°C, 2 min at 55 °C, 
2 min at 72°C) 1 pi of the first round product was transferred to a solution 
containing: 10 mM Tris-HCI pH 8.3, 50 mM KCI, 1.5 mM MgCI" 0.01 % gelatin, 
200 pM of dNTP, 1 U Taq DNA polymerase and 10 pmol of each inner primer 
(Table 1). Finally, 20 pi of the nested PCR product was visualized by ethidium 
bromide staining after 2% agarose gel electrophoresis. 
peR control 
In each experiment, along with a maximum number of 15 test samples, 2 water 
samples and 1 HCV RNA positive sample were included for reproducibility of 
HCV RNA extraction, reverse transcription and amplification. The sensitivity of 
each assay is controlled by three members of a tenfold dilution series of the 
positive control. All samples were tested in at least two independent 
experiments, starting from HCV RNA isolation. To prevent the possibility of 
cross contamination the process steps, plasma preparation, HCV RNA isolation 
and cDNA synthesis, peR and product analysis, were performed in different 
rooms. Additionally, sterile filter tips and disposable paste lies were used as 
recommended by Kwok and Higuchi [Kwok et aI., 19891. 
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Strategy and interpretation of PCR results 
The plasma samples were analyzed in two independent experiments. Confirmed 
results of the tested sample were accepted as valid and formed the final test 
result. If a positive result was obtained in two experiments, the interpretation 
was HCV RNA positive. Samples in which no HCV RNA could be detected after 
two experiments were considered as "HCV RNA undetectable" rather than 
negative, because of a limited detection of nucleic acids obtained from clinical 
specimens. In case of a discordant result, the sample was analyzed again in two 
independent experiments. If the result was still discordant then the sample was 
classified as indeterminate. 
RESULTS 
HCV quality control panel 1992 
In this coded panel HCV RNA was detected by single PCR with 5'UTR 
primersets NC, NCC and NC3 and the amplification products were analyzed by 
Southern blot hybridization with probe HCV17 (Figure 1). Identical test results 
were obtained in the 10 undiluted plasma samples in 2 experiments. Besides the 
6 negative and 3 "strongly" positive samples, the "weakly" positive sample was 
detected by all three primer sets. In the coded samples of the "donor" and 
"chimpanzee" dilution series, a distinct end point in detection of HCV RNA was 
obtained by the three primer sets (Table 2). The NC3 primer set was slightly 
more sensitive than the NCC primer set and the NC primer set was not able to 
detect any HCV RNA in the "donor" dilution series (Table 2). 
HCV quality control panel 1993 
The coded plasma samples of this test panel were analyzed by single round PCR 
as well as nested PCR. First round PCR was performed with the primer sets 
NCC and NC3 and obtained PCR products were subsequently analyzed by either 
Southern blot hybridization with probe NC-71 or nested PCR with primer set 
HC3/4 (Figure 1). After two independent experiments, discordant test results 
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were obtained in 7 of the 26 samples. After repeating the procedure (see 
strategy) the interpretation in these 7 cases was negative in 5 and positive in 2. 
By applying the four described combinations of primers for the detection of HCV 
RNA (Figure 1), identical test results were obtained in all 10 undiluted plasma 
samples. In comparison to test results obtained by both reference laboratories, 
discrepancy was observed in one sample. HCV RNA was undetectable by us as 
well as by reference laboratory number 2. Reference laboratory number 1 
classified this sample as "weakly" positive (Cuypers et aI., 19941. The HCV type 
of this isolate is yet not known while the other positive samples were identified 
as HCV type 1. 
TABLE 2. 
Serie 
Donor 
Chimp. 
Detection of HCV RNA in two dilution series from the 1992 HCV quality 
control panel. 
primer set 
Dilution Refa NC3 NCC NC 
10" + + + 
10'3 + + + 
10" + + + 
10" + 
10'6 
10" 
10" + + + + 
10'3 + + + + 
10" + + + ± 
10" 
10'6 
10" 
+ HCV RNA positive; ± indeterminate test result; - HCV RNA undetectable 
a peR results by the reference laboratory 
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After breaking the code, it appeared that in the two dilution series a clear 
end point in detection of HCV RNA was obtained ITable 3). The sensitivity for 
detection of HCV RNA was almost similar by the four combinations of primers. 
In detection of the HCV RNA in the type 3 dilution series, the combination of 
TABLE 3. HCV RNA detection in two dilution series from the 1993 HCV quality 
control study by single and nest~d peR with different 5'UTR primer sets 
primer sets 
Reference single PCR nested PCR 
Dilution 2 NC3 NCC NC3 NCC 
series and and 
HC3/4 HC3/4 
HCV type 1 
100 + + + + + + 
1,000 + + + + + + 
4,000 + + + + + + 
16,000 + 
64,000 ± 
256,000 
1,024,000 
4,096,000 
HCV type 3 
10 + + + + + + 
100 + + + + + + 
1,000 + + + + + + 
4,000 + + 
16,000 ± 
64,000 
256,000 
1,024,000 
+ HCV RNA positive; ± indeterminate test result; ~ HCV RNA undetectable 
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nested PCR by outer primer set NC3 and inner primer set HC3/4 was 4 times 
more sensitive than the other three approaches. In both dilution series 2 
samples had to be analyzed in four experiments instead of two. These samples 
contained HCV RNA levels close to the detection limit of the applied primer sets 
(Table 3; type 1, dilution 1/4,000 and 1/16,000; type 3, dilution 1/1,000 and 
1/4,0001. 
DISCUSSION 
The specificity and sensitivity of the "in-house" developed HCV RNA assay was 
determined by analysis of two coded hepatitis C quality control panels. A total 
of four 5'UTR primer sets and two probes were used in the evaluation of HCV 
RNA detection by single round and nested PCR. 
HCV quality control panel 1992 
Analysis of the" 1992 panel" revealed that the NC primer set was not universal 
for detection of HCV viremia. HCV RNA isolated in the "donor" dilution series, 
characterized as type 1 by the reference laboratory, could not be detected. This 
lack in detection by the NC primer set was caused by mismatching of primer 
HCV18. Comparison of several reported 5'UTR HCV sequences, revealed 
sequence heterogeneity in the target region near the 3' end of HCV18 [Kato et 
aI., 1990; Takamizawa et aI., 1991; Okamoto et aI., 1990, 1991 and 1992; 
Chao et aI., 1991]. Similarly, Probe HCV17 contained two mismatches when 
compared to HCV type 2 sequences (positions -80 and -72). But stili, ali known 
HCV types could be detected by probe HCV17 after washing at low stringency 
(data not shown). In contrast, the primer sets NC3 and NCC were HCV specific 
and highly sensitive in HCV RNA detection when compared to the reference 
laboratory. The data obtained in both dilution series showed a clear end point in 
the detection of HCV RNA. This distinct point of detectable HCV RNA is an 
indication for a good performance of the PCR assay. 
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HCV quality control panel 1993 
Analysis of the" 1992 panel" revealed a slight difference in sensitivity between 
the NCC and NC3 primer set. Therefore, both primer sets were used in the 
analysis of the" 1993 panel". Obtained first round PCR products were analyzed 
by Southern blot hybridization with probe NC-71 and nested PCR which is 
potentially more sensitive as single PCR. 
In comparison of HCV RNA results in the 10 undiluted plasma samples 
discrepancy was observed in one sample. By the used four primer sets a 
discordant test result was initially obtained by the NCC primer set in this 
particular sample. After repeating the procedure this sample was also classified 
as HCV RNA undetectable by the NCC primer set. The discrepant result could 
be caused by either specificity or sensitivity of the HCV RNA assays. The 
possible lack of specificity could be caused by crucial mutationls) in this 
particular HCV isolate at the primer target region to prevent proper amplification 
by the NC3 and NCC primer sets. However, this explanation is not likely 
because the primer sets NC3 and NCC are able to detect HCV types 1 to 5 
IKleter et al., 1994). The most likely explanation for the discrepancy is the slight 
difference in sensitivity between our HCV RNA assay and that of reference 
laboratory number 1 ITable 3). The detection level of the primer sets NCC and 
NC3 was 500-1000 HCV equivalents per ml as estimated by the branched DNA 
assay IQuantiplex, Chiron Emeryville, CAl in dilution series. Moreover, in 30 
122%) of the 136 received data sets HCV RNA was detected, suggesting that it 
was a borderline sample [Cuypers et aI., 1994]. 
When analyzing the two dilution series, a minimal difference in sensitivity 
between single round PCR and nested PCR was obtained ITable 3). These 
results revealed that the performance of nested PCR, which is highly prone to 
contamination, is not really necessary to improve the sensitivity of HCV RNA 
detection. It should be noted that the 4 to 16 times higher degree in sensitivity 
obtained by reference number 1 was achieved by single PCR at the 5'UTR 
followed by liquid hybridization. 
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Interpretation of test results 
The overall results of the 1992 HCV RNA quality control study revealed that 
only 5 (16%) of the 31 participating centers were able to produce PCR data 
without false-positivity and a high sensitivity. The results of the "1992" study 
and also that of other quality control studies revealed that false-positive results 
were the main problem in the application of PCR technology [Zaaijer et ai., 
1993; Quint et ai., 1995; Bootman et ai., 1992; Kuypers et ai., 1993]. 
As indicated in this study and by others, results of enzymatic 
amplification methods should be confirmed by two independent experiments or 
performing duplicates to exclude false-positivity andlor false-negativity [Gerken 
et ai., 1992; Mahony et ai., 1994; Kitchen et ai., 1993]. Samples with a 
discordant result are a matter of concern. The discrepancies can be caused by 
either contamination and the sensitivity of the assay. In the 1993 panel 7 
samples had to be assayed again. After breaking the code it appeared that the 
amount of HCV RNA in 4 of these samples was close to the detection limit of 
the applied primer sets. The performed strategy for interpretation of test results 
was useful in the analysis of both quality control panels. No false-positive final 
test results were produced. Therefore, one could consider application of our 
strategy for every HCV RNA test. 
When starting this thesis HCV RNA detection was performed with the NC 
primer set and a primer set directed to the NS5 region (Chapter 3). In the 
analysis of the "1992 panel" and isolates obtained from chronically infected 
non-A, non-B hepatitis patients it appeared that these two primer sets lacked 
sensitivity. This sensitivity problem was mainly caused by sequence variation 
and especially observed after introduction of second generation antibody 
screening assays. In chapter 4 to 7 HCV RNA isolates were therefore analyzed 
by the NCC primer set. 
In conclusion, evaluation of HCV RNA detection in the two analyzed 
coded quality control panels revealed that the HCV RNA data obtained by our 
technology and strategy were of high sensitivity and specificity. 
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HCV RNA detection during and after interferon therapy 
ABSTRACT 
In 24 patients with hepatitis C virus (HCVI infection who participated in a 
randomized trial with alpha 2B interferon, HCV RNA analysis by the polymerase 
chain reaction with two separate primer sets was performed at weeks 0, 4, 24, 
and during a follow-up period of 6 to 9 months. Prior to therapy all patients 
were HCV RNA positive. During therapy HCV RNA decreased to an undetectable 
level « 1 chimpanzee infectious dose per mil in nine patients at week 4. After 
week 4, no additional cases of HCV RNA disappearance « 1 chimpanzee 
infectious dose per mil were observed. During follow-up, HCV RNA could not be 
detected in four of the six patients with a sustained alanine aminotransferase 
response. These results suggest the probable predictive value of HCV RNA 
levels for detecting the failure of therapy in an early stage of treatment. 
INTRODUCTION 
In recent years, several randomized controlled studies were performed with 
alpha interferon (IFNI for treatment of non-A, non-B hepatitis (NANBHI [Davis et 
al., 1989; Di Bisceglie et aI., 1989; Jacyna et aI., 1989; Marcellin et aI., 1991; 
Saez-Royuela et aI., 1991; Shindo et aI., 19911. The effect of interferon was 
evaluated by measuring the alanine aminotransferase (AL TI level in serum, 
which reflects the activity of liver disease. 
Recently, the etiological agent for NANBH has been identified [Choo et 
aI., 1989; Hosoda et aI., 19921. The causative agent is now known as Hepatitis 
C Virus (HCVI. The HCV genome is a positive stranded RNA molecule of about 
9,400 nucleotides. Sequence homology between the known HCV strains is 
about 80% [Chan et aI., 1992; Choo et aI., 1991; Kato et aI., 1990; Okamoto 
et aI., 1991; Takamizawa et aI., 19911. 
In the study described here, 24 patients were investigated for the 
presence of HCV RNA during and after IFN therapy, to determine directly the 
effect of IFN treatment on viremia. HCV RNA analysis by the polymerase chain 
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reaction was performed using primer sets from the highly conserved non-coding 
(NC) region and a conserved sequence from non-structural region 5 (NS5). 
MATERIALS AND METHODS 
Patients between 18 and 70 years of age with elevated AL T levels 1.2':.2 times 
the upper limit of normal). a biopsy-proven chronic NANBH, antibodies to HCV 
determined by a second-generation enzyme immunosorbent assay (Abbott, 
North Chicago, 111.) and a confirmatory assay RIBA IV (Ortho, Raritan, N.J.), and 
no recent history of hepatitis A virus, hepatitis B virus, cytomegalovirus, or 
Epstein-Barr virus were included in the study. All patients gave informed consent 
prior to participation in the study. Patients were treated in a randomized 
controlled trial with either a standard scheme (12 patients) consisting of 3 MU 
of recombinant IFN a2B (Intron A, Schering Plough, Kenilworth, N.J.) three 
times a week for 24 weeks or an experimental scheme (12 patients). In the 
experimental scheme, therapy started with 6 MU of recombinant IFN a2B three 
times a week for at least 8 weeks. Therapy was stopped at week 12 if AL T 
levels remained elevated. If the AL T level normalized, therapy was continued 
with 3 MU of recombinant IFN a2B three times a week for 8 weeks; this was 
followed by treatment with 1 MU of recombinant IFN a2B three times a week 
until a normal AL T was accompanied by an undetectable HCV RNA level for a 
period of one month. 
Blood samples were taken prior to treatment and at least every fourth 
week during treatment and follow-up. For HCV RNA detection, EDTA-blood was 
collected and plasma was prepared within 2 hours after sampling; aliquots were 
quickly frozen in liquid nitrogen and stored at -70°C. 
HCV RNA was extracted from 100 III plasma by a modification of the 
guanidinium thiocyanate method as described by Chomczynski and Sacchi 
(19871. eDNA synthesis was performed with 200 U of Moloney murine leukemia 
virus reverse transcriptase (GIBCO-Bethesda Research Laboratories, 
Gaithersburg, Md.) and 20 pmol of antisense primer in a 25 III reaction volume. 
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Antisense primers were chosen as follows (positions according to Okamoto et 
al. [1991 J): for the NC region, residues 323 to 304 
(GTGCACGGTCTACGAGACCT, HCV19); for the NS5 region residues 7020 to 
7001 (AGGAGGTTGGCCTCTATGAG). For amplification of HCV cDNA (40 
cycles of 1 min at 94°C, 2 min at 48°C, 3 min at 74°C) 1 U of Taq DNA 
polymerase (promega, Madison, Wis.), reaction buffer and 20 pmol of sense 
primer Were added to a final volume of 100 pi. Sense primers were chosen as 
follows: for NC region residues 1 to 20 (GGCGACACTCCACCATAGAT, 
HCV18); for NS5, CCCTCCCATATAACAGCAGA, residues 6857 to 6877). 
Twenty microliter of the amplification product were analyzed by Southern blot 
hybridization. The probe for the NC region (GAGTAGTGTTGGGTCGCGAA, 
residues 239 to 258, HCV17) detects a product of 324 bp. For detection of the 
NS5 product (164 bp) two probes were used: probe A 
(GGGTCTCCCCCCTCCTTGGCCAGCTCTTCAGCTA, 6902 to 6931) is identical 
to HCV-J [Kato et ai., 1990) and HCV-BK [Takamizawa et ai., 1991), and probe 
B (CATGACTCCCCTGATGCTGA, 6980 to 6999) is identical to HCV-1 [Choo et 
ai., 1991). In all cases HCV RNA was sought with both primer sets. Known 
HCV cDNA sequences (Choo et aI., 1991; Kato et ai., 1990; Maeno et ai., 
1990; Okamoto et ai., 1990; Takamizawa et ai., 1991) were used for selection 
of the primers and probes. The detection limit of our assay is 1 chimpanzee 
infectious dose per ml, as estimated with challenge plasma in the Eurohep HCV 
RNA proficiency panel (provided by dr P.N. Lelie, CLB, Amsterdam, the 
Netherlands). Both primer sets showed the same sensitivity. Distilled water, 
anti-HCV negative and positive plasma as negative and positive controls, 
respectively, were used in each experiment. All results were confirmed by 
repeat testing. 
RESULTS AND DISCUSSION 
Prior to IFN treatment, all patients were HCV RNA positive as determined with 
the NC primer set. In one patient, HCV RNA was not detected by the NS5 primer 
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TABLE 1. Biochemical response and HCV RNA results in 24 patients during and 
after IFN therapy 
No. (%) of patients negative 
ALT No. of for HCV RNA 
response patients 
Owk 4 wk 24 wk Follow-upa 
Sustainedb 6 0 5 (83) 5 (83) 4(67) 
TransientC 2 0 2 (100) 1 (50) 0 
None 16 0 2 (13) 1 (6) 0 
Total 24 0 9 (37) 7 (29) 4 (16) 
a Follow-up was at 6 to 9 months after the end of therapy. 
b Decrease in ALT levels during treatment and normal ALT levels during Follow-up. 
C Normalization in Al T levels during treatment and elevation in Al T levels during follow-up. 
set. Four patients, which were treated by the experimental scheme, stopped 
therapy before week 24. Two of them stopped therapy after 12 weeks and one 
stopped therapy after 20 weeks because ALT remained elevated. One patient 
stopped therapy at week 20 because of non-compliance. 
After 4 weeks of treatment, 9 of the 24 patients (5 in the standard 
scheme and in the experimental 4 scheme) showed a decrease in HCV RNA and 
HCV RNA became undetectable by both primer sets. At the end of therapy 
(week 24), HCV RNA reappeared in two patients (standard scheme) and after 6 
to 9 months of follow-up in another three patients (one of the standard scheme, 
two on the experimental schemei. A normal AL T « 30 UII) was observed at 
week 4, 24 and the follow-up period in respectively 8 (33%), 8 (33%) and 6 
(25%) patients, respectively. A simultaneous absence of HCV RNA and a normal 
AL T level in the follow-up study was limited to four patients (two on the 
standard scheme, two on the experimental scheme) (Table 1). The rapid decline 
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in the amount of HCV RNA in responders between weeks 0 and 4 and the lack 
of an increase in the number of patients with HCV RNA present at a level of less 
than 1 chimpanzee infectious dose per ml after 4 weeks of treatment are of 
considerable interest; if confirmed, these findings may have implications for the 
duration of IFN therapy. 
Similar results on the transient nature of HCV RNA disappearance, 
discrepancies between normalization of AL T levels and the presence of HCV 
RNA [Bresters et aI., 1992; Brillanti et aI., 1991 L and relapse within 6 months 
after termination of therapy were also observed by other investigators who used 
primers directed to the NC or NS4 regions [Chayama et aI., 1991; Shindo et aI., 
19911. 
The use of 2 primer sets, NC and NS5, resulted in differences between 
the outcomes in plasma samples from five patients in our study. The HCV RNA 
was consistently undetectable with the NS5 primer set in one patient (non-
responder; standard scheme). In three other patients (non-responders; two on 
the standard scheme, one on the experimental scheme), HCV RNA was not 
detected with the NS5 primer set at week 4 but was detected at week 24 or 
48. During therapy, a change in HCV RNA positivity depending on the primer set 
was observed in one patient (non-responder; experimental scheme), 
The NC primer set was very suitable for monitoring HCV RNA levels 
during IFN therapy [Chao et aI., 1991; Han et aI., 1991; Kato et aI., 1990; 
Okamoto et aI., 1991; Takamizawa et aI., 1991; Takeuchi et aI., 19901. The 
discongruent results for the two sets of primers at the beginning and during 
therapy could not be the result of a reduced sensitivity of the assay [Cristiano et 
aI., 1991 J. In fact, these results are suggestive for the presence of HCV variants 
in these patients, and the individual sensitivities of these variants for interferon 
therapy are under investigation. 
In conclusion, results of the present study suggest that monitoring of 
HCV RNA levels in the first months of IFN therapy may be of prognostic value 
for failure of therapy aimed at eradicating HCV RNA (in the present study four 
patients [16%]). However, the normalization of AL T levels alone, as observed in 
an additional two patients, could be beneficial if sustained for long periods of 
time. 
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Sequence analysis of the 5'UTR 
ABSTRACT 
The RNAs of hepatitis C virus (HCV) from 62 patients with chronic HCV 
infection were analyzed by direct sequencing of the 5' untranslated region. Two 
important sequence motifs were recognized: one between position -170 and -
155 and the other between -132 and -117. These motifs are partly complemen-
tary. All three previously published genotypes were observed; 34 (55%) isolates 
were classified as type 1 (including prototype from the [United States] and HCV-
BK [from Japan] sequences), 11 (18%) were classified as type 2 (including HC-
J6 and HC-J8), and 12 (19%) were classified as type 3 (including EB1); one 
patient was infected with genotypes 1 and 2. Four (6%) isolates showed 
aberrant sequences and were therefore provisionally classified as type 4. These 
results indicate the significance of sequence variation among the 5'untranslated 
regions of different HCV genotypes and indicate that this region could possibly 
be used for consistent genotyping of HCV isolates. 
INTRODUCTION 
Since the discovery of hepatitis C virus (HCV), a flavi-like virus with a positive-
sense, single stranded RNA genome of approximately 9.400 nucleotides [Choo 
et aI., 1989], several full length sequences have been obtained from various 
isolates [Choo et aI., 1991; Kato et aI., 1990; Okamoto et aI., 1991; Okamoto 
et aI., 1992a; Takamizawa et aI., 1991] and investigators have proposed [Cha 
et aI., 1992; Chan et aI., 1992; Enomoto et aI., 1990; Houghton et aI., 1991; 
Mori et aI., 1992; Okamoto et aI., 1992a] that HCV isolates can be classified 
into different types and subtypes. On the basis of all available sequence 
information, Chan et al. [1992] distinguished three HCV types. Type 1 isolates 
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include the prototype strain HCV-1 [Chao et aI., 1991), and strains HCV-H 
[Ogata et aI., 1991 J, HCV-K1 [Enomoto et aI., 1990), HCV-J (Kato et aI., 1990J 
and HCV-BK [Takamizawa et aI., 1991 J; type 2 includes strains HCV-K2 
[Enomoto et aI., 1990), HC-J6 [Okamoto et aI., 1991 J and HC-J8 [Okamoto et 
aI., 1992aJ; type 3 includes strains HCV E-b1 [Chan et aI., 1992), HCV-T [Mori 
et aI., 1992J and HCV1196 [Lee et aI., 1992J. 
HCV genotyping is of interest in viral transmission studies and HCV epide-
miology. Furthermore, the success of interferon treatment may be type or 
subtype related [Pozatto et aI., 1991; Yoshioka et aI., 1992J. 
There are several reasons to choose the 5' untranslated region (5' UTR) 
for HCV genotyping. (i) Analysis of a large number of HCV isolates resulted in 
similar phylogenetic trees for the 5' UTR, the core, NS3, and NS5 regions [Chan 
et al., 1992J; (ii) the observed mutation rate of the 5' UTR is extremely low 
[Ogata et aI., 1991; Okamoto et aI., 1992bJ; (iii) sequence variation within the 
conserved 5' UTR is mainly limited to specific regions; and (iv) the putative 
secondary structure of the 5' UTR, as established from biochemical and phylo-
genetic data [Brown et al., 1992), suggests functional conservation of this 
region. 
In the study described here, the RNAs of 62 HCV isolates from patients in 
the Netherlands with chronic HCV infections were investigated to determine 
whether HCV genotyping by sequence analysis of PCR products' derived from 
the 5'UTR could be performed. 
MATERIALS AND METHODS 
Patients 
Sixty-two patients from the Netherlands between the ages of 26 and 74 years 
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with elevated alanine aminotransferase (AL T) levels, a biopsy-proven chronic 
non-A, non-B hepatitis, antibodies to HCV, and no recent history of infection 
with hepatitis B virus, hepatitis A virus, cytomegalovirus or Epstein-Barr virus 
were analyzed. 
Anti·HCV 
Antibodies to HCV were tested by a second generation enzyme immunoassay 
(Abbott, North Chicago, 111.) and were confirmed by the recombinant immunoblot 
assay (RIBA-4, Ortho Diagnostics, Raritan, N.J.) according to the instructions of 
the manufacturer. 
Blood plasma 
For HCV RNA detection, EDTA-blood was collected by venipuncture, and 
plasma was prepared within 2 hours after sampling. One-milliliter aliquots were 
quickly frozen in liquid nitrogen and stored at ·700C until use. 
HCV RNA PCR 
HCV RNA was isolated from 100pl of plasma by a modified version of the 
guanidinium method described previously (Chomczynski & Saccki, 1987). cDNA 
synthesis was performed on one-third of the isolated RNA in a 25 pi reaction 
volume (Kleter et aI., 1993J using 20 pmol antisense primer HCV19 (GTGCACG-
GTCTACGAGACCT; positions -1 to -20). 200 U of Moloney murine leukemia 
virus reverse transcriptase (Gibeo-Bethesda Research Laboratories, Gaithersburg, 
Md.), 30 U RNasin (Promega, Madison, Wis.), and 0.5 mM (each) deoxyribonu-
cleotide (Boehringer, Mannheim, Germany) at 42°C for 30 min after brief 
denaturation at 80°C. PCR was performed (40 cycles of 1 min at 94°C, 2 min 
at 48°C, and 3 min at 74°C) with antisense primer HCV19 and the sense 
primer HCV18 (GGCGACACTCCACCATAGAT; positions -304 to -324) or the 
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sense primer HCV35 (TTGGCGGCCGCACTCCACCA TGAA TCACTCCCC; positi-
ons -296 to -318; underlined sequences are not complementary to the HCV 
sequence). For diagnosis, the first round PCR products were analyzed by Sout-
hern blot hybridization with probe HCV17 (GAGTAGTGTTGGGTCGCGAA; 
position -86 to -67); this was followed by washing at low stringency. 
Direct sequencing of peR products 
For direct sequencing [Hultman et aI., 1991], a second round of PCR (40 cycles 
of 1 min at 94°C, 2 min at 48°C, and 3 min at 74°C) was performed with the 
sense primer NCR3 (GGGGCGGCCGCCACCATRRATCACTCCCCTGTGAGG; 
positions -288 to -314) and the antisense primer LD58 (5' bio-GGCCGGGGCGG-
CCGCCAAGCACCCTATCAGGCAGTACCACAAGGC; positions -37 to -64). 
LD58 is biotinylated at the 5' end. Biotinylated PCR products (estimated by 
agarose gelelectrophoresis at approximately 100 ng) were captured onto 
streptavidin-coated paramagnetic particles (Dynabeads M-280, Dynal, Oslo, 
Norway). Single-stranded DNA was prepared by denaturation of the captured 
amplification product by alkaline treatment according to the instructions of 
Dynal. Separate strands were sequenced by using the T7 DNA sequencing kit 
(Pharmacia, Uppsala, Sweden) and [32PldA TP (Amersham, Buckinghamshire, 
United Kingdom). NCR3 served as a sense primer on the minus strand captured 
on the beads, and NCR4 (CACTCTCGAGCACCCTATCAGGCAGTACC; positions 
-57 to -29) was used as the antisense primer on the plus strand in the superna-
tant. DNA sequences were read manually from autoradiographs and were 
analyzed with the PC/Gene computerprogram (lntelligenetics Inc., Mountain 
View, Cali!.). 
Nucleotide sequence accession number 
EMBL data library accession numbers X58937 to X58953. 
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RESULTS 
Sixty-two patients with chronic HCV infection were anti-HCV positive by 
enzyme immunoassay which was confirmed by RIBA-4, and were HCV RNA 
positive by reverse transcription-PCR aimed at the 5' UTR. The sense primer 
HCV18, which was based on the first published HCV sequences [Garson et ai., 
1990; Okamoto et ai., 1990), was initially used for the diagnosis of HCV 
viremia by PCR. In the case of low yields of PCR products, sense primer HCV35 
improved the PCR results considerably [data not shown), and in these cases, 
PCR products obtained by HCV35 were used for sequence analysis. 
Nested PCR products were sequenced directly, and the results are 
represented in Fig. 1. If identical sequences were obtained from a number of 
isolates, only one representative sequence is shown. Several sequences have 
been reported previously and are identified by their original names. Limited 
sequence variations were observed essentially in two motifs: motif 1 is located 
between nucleotides (nt) -170 and -155, and motif 2 is located between nt -132 
and -117 [Fig. 1). On the basis these motifs, 58 of 62 isolates could be classi-
fied into the three HCV types as proposed previously. Thirty-four [55%) isolates 
were classified as type 1; this included the prototype sequence HCV-1. Isolate 
HC1-N8 showed a single nucleotide insertion at position -138. In one patient 
(isolate HC1I2L a double infection with types 1 and 2 was observed, as 
deduced from bands with identical mobilities in two different lanes on the gel 
(Fig. 2). Type 2 sequences, including the sequence of HC-J6, were observed in 
11 (18%) patients. These isolates are also recognized by the presence of a T at 
position -72 and a C at position -80. HC2-N2 contains a mutation at nt -127 in 
motif 2. Within type 2, sequence heterogeneity was observed at position -119, 
showing either a T or C. Type 3 sequences were detected in 12 (19%) patients. 
In addition to the type-specific sequence motifs, type 3 isolates could also be 
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identified by a TCA sequence at positions -93 to -95. HC3-N2 contained a point 
mutation at position -118 in motif 2. Four (6%) isolates were provisionally 
classified as type 4. These isolates showed additional sequence heterogeneity 
between positions -238 and -235 in comparison with the sequences of strains 
of types 1, 2, and 3. 
Table 1. Mean nucleotide variation among four HCV types in the entire 197-bp 6' 
UTR fragment and motifs 1 and 2. 
Fragment 
and type 
No. of 
isolates' 
% nucleotide variation 
197-bp 5'UTR 
1 34 2.5 
2 11 7.1 
3 12 7.1 
4 4 4.1 
Motifs 1 and 2 
34 0 
2 11 28.0 
3 12 28.0 
4 4 12.5 
. Sixty-one HCV isolates were analyzed for sequence variation 
in 197-bp fragments from the 5' UTR (nt -262 to -66). 
2 3 
2.0 
11.2 1.0 
6.1 6.1 
2.5 
35.5 0.3 
23.5 15.8 
4 
2.0 
1.5 
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Figure 1. Alignment of 5' UTR sequences from 62 patients. Sequences between 
position -262 and -66 were classified into types 1, 2, 3 las proposed by Chan 11992]), 
and 4. Previously published sequences are identified by their original names: HCV-1 
IChoo et aI., 1991J; DK7, SAW, US10, SAl, and DK13 [Bukh et aI., 1992J; HCV-BK 
ITakamizawa et aI., 1991J; HC-J6 [Okamoto et aI., 1992aJ; EB-12 and EB-7 IChan et 
al., 1992J and HCVl196 ILee et aI., 1992J. Numbers in parentheses indicate the 
number of isolates with that sequence. Hyphens indicate presence of nucleotides 
identical to those of the prototype strains. Characters in boldface type are newly 
obtained point mutations. Sequence motifs 1 and 2 are boxed. Underlined nucleotides in 
the HCV-1 sequence are involved in the putative double-stranded RNA stem structure 
IBrown et al., 1992]. Abbreviations: M IA or C); R IA or G); Y IT or C); W IA or T) and 
S IG or C). 
Sequence analysis of the 5'UTR 
Comparison between the sequences obtained in the present study (nt -
262 to -66) and all previously reported 5' UTR sequences [Bukh et aI., 1992; 
Cha et aI., 1992; Chan et aI., 1992;Han et al., 1991 I, revealed a number of 
new 5' UTR mutations within all HCV types (Fig. 1). 
The overall sequence heterogeneity among the four HCV types in the 
present study ranged from 4 % between types 1 and 4 to 11 % between types 2 
and 3, whereas heterogeniety within each type was less than 2.5% (Table 1). 
Mutations were not randomly distributed along the 5' UTR but were clustered in 
motifs 1 and 2. Comparison of these motifs among the four types revealed 
strong conservation within each type and showed significant differences 
between the types (Table 1). Further analysis of the sequence variation in motifs 
1 and 2 revealed the presence of covariants, i.e., compensatory mutations in 
each motif, maintaining the postulated secundary structure of the 5' UTR 
genomic RNA (Brown et aI., 1992). The P values for the occurence of one, two, 
or three covariant mutations in motifs 1 and 2 to have arisen by chance were 
very low (P = 0.06, P = 0.004, P = 0.0002, respectively). Covariance 
occurred at positions -164, -163, -161, and -155 in motif 1, and positions -132, 
-124, -122, and -121 in motif 2. This covariance was consistenly observed in all 
62 sequences, indicating the importance of this phenomenon. 
DIscUSSION 
Sequence analysis of the 5' UTR of HCV isolates from 62 patients with chronic 
HCV infection allowed consistent and efficient genotyping. Fifty-eight (94%) 
isolates could be classified into the 3 different types proposed by Chan et al. 
(19921. Identification of the HCV types is essentially based on the sequence 
variation in the defined motifs 1 and 2. 
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Figure 2. Direct sequence analysis of the 5' UTR from isolate HC1/2 with sense primer 
NCR3. Abbreviations: S (G or C): W (A or T): Y (T or C): R (A or G) and M (A or C). 
All three types reported so far were observed in the HCV-infected patient 
population in the Netherlands. The coexistence of HCV types in several geo-
graphic regions has been indicated earlier Cah et aI., 1992: Chan et aI., 1992]. 
However, little is known about the distribution of HCV types in Europe. The ma-
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jority of published isolates belong to type 1 [Cuypers et aI., 1991; Kremsdorf et 
aI., 1991]. Types 2 and 3 were detected in European isolates only recently 
[Bukh et aI., 1992; Chan et aI., 1992). 
Isolates belonging to a new HCV type, tentatively designated type 4, 
were observed in the Netherlands. Similar sequences were first found in isolates 
from South Africa [Cha et aI., 1992) and Denmark [Bukh et aI., 1992]. To justify 
classification of these isolates as a new type 4, sequence analysis of the coding 
regions is necessary. Preliminary results (data not shown) indicate significant 
nucleotide sequence differences between the core region from type 4 isolates 
and the corresponding sequences from type 1, 2, and 3 isolates. One sequence 
(SA 1), classified here as type 4, showed minor differences with the other type 4 
sequences, and might be classified as a separate type, HCV type 5 [Po Sim-
monds, unpublished data]. All types probably have a worldwide distribution, but 
the relative abundances per geographic region may differ considerably. 
A double infection involving types 1 and 2 was found in one patient. This 
was in accordance with the reported frequency of double infections which has 
been observed by others [Okamoto et aI., 1992c; Yoshioka et aI., 1992) by 
using type-specific primers or probes. 
New 5'UTR sequences were observed in 21 of the 62 isolates analyzed. 
The distribution of the sequence variation was not random. Recently, the 
putative secundary structure and possible functional elements of the 5' UTR of 
the HCV genome were postulated [Brown et aI., 1992; Tsukiyama-Kohara et aI., 
1992; Yoo et aI., 1992]. The defined sequence motifs 1 and 2 show partial 
complementarity and are able to form a stable stem-loop structure; e.g., nt A at 
position -170 is complementary to nt T at position -115 and the nt C (or T for 
type 2) at position -155 is complementary to nt G (or A for type 2) at position -
132. Covariance in motifs 1 and 2 consistently preserves the secundary structu-
re. Therefore, mutations are more likely to be tolerated in single stranded 
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regions. This is confirmed by the relatively high mutation rate in the single-
stranded RNA loop between positions -136 and -151. Most of the point muta-
tions are located outside the defined sequence motifs and do not affect classifi-
cation. Only two isolates showed single point mutations within the two motifs: 
HC2-N2 contains a G at position -127, and HC3-N2 contains a C at position -
118. Despite these variations, classification of HC2-N2 and HC3-N2 as types 2 
and 3, respectively, was obvious. 
The overall sequence variation between the 197 bp 5' UTR fragments 
was not statistically significant, because only 6 to 21 mutations were observed 
among the four types. Since the mutations were not randomly distributed along 
the 5' UTR, it is impossible to apply regular statistical methods to this problem, 
because these require random distribution of events. The secundary structure, 
i.e., the stem-loop structure formed by partial complementarity of motifs 1 and 
2, must be maintained (with a sufficiently low free energy) to function properly 
as an internal ribosomal entry site ITsukiyama-Kohara et aI., 19921. Therefore, 
mutations in these motifs have functional restrictions. Comparison of the 5' UTR 
sequences described in this report reveals the existence of covariants. These 
complementary mutations in motifs 1 and 2 indeed completely conserve the 
secundary structure, indicating the significance of covariance. On the basis of 
these findings, classification of HCV isolates should preferably be based on 
covariance in motifs 1 and 2. 
In conclusion, consistent genotyping based on 5' UTR sequence analysis 
is possible and may complement studies on antiviral treatment and the transmis-
sion of HCV. 
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ABSTRACT 
The 5' untranslated regions (5' UTR) derived from 54 patients with a chronic 
hepatitis C virus infection were analyzed to determine the (sub)type of hepatitis 
C virus. Labelled polymerase chain reaction products from the 5' UTR were used 
as probes for reverse hybridization in a Line Probe Assay (lnno-LiPA) and results 
were validated by comparison with direct sequencing data. Five different 
genotypes could be distinguished based on 5' UTR sequence diversity. Results 
of typing by LiPA and direct sequencing were similar. Antibody responses 
against core, NS-3, NS-4 and NS-5 epitopes were detected by RIBA-4 and Inno-
LlA HCV Ab II confirmatory assays. There was no consistent correlation 
between the genotype and the anti-HCV responses, although types 2 and 3 
HCV isolates show poor reactivity with NS-4 epitopes. 
INTRODUCTION 
Hepatitis C virus (HCV), the main etiological agent of post-transfusion hepatitis, 
is a small enveloped virus, which contains a positive sense, single-stranded RNA 
genome of approximately 9400 nucleotides (Choo et aI., 1989!. Based on 
genomic [Miller et aI., 1990) and physico-chemical characteristics [Bradley et 
aI., 1985) of the virus, HCV is classified as a distinct member of the Flavivi-
ridae. From worldwide HCV isolates, several full length [Kato et aI., 1990a; 
Takamizawa et aI., 1991; Choo et aI., 1991; Okamoto et aI., 1991, 1992a; 
Chen et aI., 1992) and numerous partial sequences [Chan et aI., 1992; Han et 
aI., 1991; Ogata et al., 1991; Takeuchi et aI., 1990; Kato et aI., 1990b; Mori et 
aI., 1992; Enomoto et aI., 1990; Weiner et aI., 1991; Lee et aI., 1992) have 
been obtained. Based on sequence diversity, several proposals were made to 
classify the different HCV isolates (Chan et aI., 1992; Enomoto et aI., 1990; 
Okamoto et aI., 1992b; Houghton et aI., 1991; Cha et aI., 1992), but there is 
no consensus in HCV nomenclature so far. A useful HCV classification was 
proposed recently [Stuyver et aI., 1993), based on phylogenetic trees determi-
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ned by Chan and colleagues [Chan et aI., 1992], differentiating between types 
(approx. 68% average sequence homology) as well as between subtypes 
(approx. 79% sequence homology). Homologies between isolates belonging to 
the same subtype usually exeed 90%. This system was further extended by a 
new type, provisionally designated as type 4 [Simmonds et aI., 1993]. 
There are indications that infections caused by different HCV (sub)types 
may have different clinical implications [Okamoto et aI., 1992b). The effective-
ness of antiviral treatment [Kanai et aI., 1992; Pozatto et aI., 1991; Yoshioka et 
aI., 1992], efficiency of viral transmission, distribution among various patient 
populations and the development of hepatocellular carcinoma may also be 
subtype-related. Preliminary results urge HCV subtyping which complements the 
routine diagnostic antibody and reverse transcription polymerase chain reaction 
(RT-PCR) assays. 
All available sequence data were used to develop type- and sUbtype-
specific probes for the reverse hybridization Line Probe Assay (LiPA], which has 
recently been described in detail [Stuyver et aI., 1993]. The assay is based on 
the observation that variation within the 5' untranslated region (5' UTR) is 
mainly restricted to two short (sub)type specific sequence motifs. 
In this study HCV isolates were analyzed from 54 patients by the new 
LiPA which allows classification of isolates into types 1, 2, 3 [Chan et aI., 1992; 
Stuyver et aI., 1993], and 4 [Simmonds et aI., 1993). Results of reverse 
hybridization were compared with data from direct sequencing of the 5' UTR. 
Furthermore HCV antibody profiles, determined by recombinant immunoblot 
assay (RIBA)-4 and Inno-UA HCV Ab II, were compared with the genotyping 
results. 
MATERIALS AND METHODS 
Patient sera 
Blood samples from 54 patients were obtained by venipuncture. Ethylenedi-
aminetetraacetic acid (EDTA)-plasma was prepared within 2 hours after collec-
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tion, aliquotted, quickly frozen in liquid nitrogen and stored at -70°C. All 
patients had a chronic HCV infection with elevated alanine aminotransferase 
(AL T) levels, biopsy-proven liver abnormalities and were anti-HCV and HCV-RNA 
positive (Kleter et ai, 1993J. 
RNA isolation, and RT-PCR 
HCV-RNA was isolated from freshly frozen plasma samples by a modified 
version of the acid guanidinium-phenol-chloroform method as described [Kleter 
et aI., 1993]. Briefly, cDNA was synthesized using antisense primer HCV19 
(positions -1 to -20; 5'-GTGCACGGTCTACGAGACCT-3') and amplified by PCR 
using HCV19 and sense-primer HCV18 (positions -323 to -304; 5'-GGCGACAC-
TCCACCATAGAT-3') or HCV35 (positions -318 to -296; TTGGCGGCCGCACT-
CCACCATGAATCACTCCCC). PCR was performed for 40 cycles, consisting of 1 
min. 94°C., 1 min. 55°C, and 1 min. 72°C. Amplification products were 
analyzed by agarose gelelectrophoresis and Southern blot hybridization using 
probe HCV17 (positions -88 to -69; 5'- GAGTAGTGTTGGGTCGCGAA-3'). 
Line Probe Assay (LiPA) 
Based on all available 5' UTR sequences, several type-specific sequence motifs 
were recognized [see also Stuyver et aI., 1993]. Motif 1 is located between 
positions -170 and -155, and motif 2 between -132 and -117. These motifs 
already allow discrimination between the different types, are partially comple-
mentary and can form a stable dsRNA stem structure [Brown et aI., 1992). A 
number of positions displaying more subtle, but consistent variations allow 
consolidation of typing by means of motif 1 and 2, or enable more detailed 
subtyping. 
The LiPA (prototype version, Innogenetics, Ghent, Belgium) is based on 
the hybridization of labelled PCR amplification products to specific oligonu-
cleotides directed against the variable regions of the 5' UTR. These probes were 
immobilized as parallel lines on membrane strips (reverse hybridization principle). 
During nested PCR, the product is biotinylated, which allows detection of 
hybrids by alkaline phosphatase labelled streptavidin. The HCV-LiPA (Fig. 1) 
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contains 15 probe lines, exposing 18 different 16-mer probes. Sixteen probes 
specifically recognize HCV (sub)types, and 2 (no. 21 and 22) are general HCV 
probes (location of the probes in the 5' UTR sequence is shown in Fig. 2). The 
development of the LiPA was recently described in detail [Stuyver et aI., 1993J. 
From the first round PCR, 0.5 III product was transferred into a new, 50 
III nested PCR reaction, containing primers HC3 (sense: -264 to -238: 5'-
TCTAGCCATGGCGTTAGTRYGAGTGT-3'), HC4 (antisense: -29 to -54: 5'-
CACTCGCAAGCACCCTATCAGGCAGT-3') and biotinylated "dUTP. The LiPA 
was performed according to the manufacturer's instructions. Briefly, biotinylated 
DNA w~s denatured by mixing 10-20 III of the nested PCR product with NaOH 
and hybridized to the probes on the LiPA strip in the presence of tetramethylam-
moniumchloride. After stringent washing, hybridization was detected by alkaline 
phosphatase conjugated streptavidin and substrate. The results of the LiPA were 
determined by scoring the presence or absence of hybridization with each probe 
line. 
Direct sequencing 
PCR products were reamplified using sense primer NCR3 (positions -314 to -
288; 5' -GGGGCGGCCGCCACCA TARRATCACTCCCCTGTGAGG-3'; underlined 
sequence is non-HCV specific) and LD58 (positions -66 to -35; 5' -Bio-GGCCGG-
GGCGGCCGCCAAGCACCCTA TCAGGCAGTACCACAAGGC-3') carrying a 5' 
biotin moiety. Biotinylated nested PCR products were used as template for direct 
sequencing, using the protocol suggested by the manufacturer of the Dynabeads 
(Dynal, Norway). Briefly, nested PCR products were mixed with streptavidin-
coated paramagnetic particles (Dynabeads M280, Dynal, Norway) in a binding 
and washing buffer (1x B&W buffer is 10 mM Tris-HCI, pH 7.5, 1 M NaCI, 1 
mM EDTA), to allow the binding of the biotinylated DNA. Complementary 
strands were separated by addition of NaOH, and sequenced using the T7 DNA 
sequencing kit (Pharmacia, Uppsala, Sweden) and [a-32PJ-dATP (Amersham, 
Buckinghamshire, UK). DNA attached to the beads or in the supernatant was 
sequenced with either NCR3 as a sense primer on the captured minus-DNA 
strand or NCR4 (positions -66 to -47; 5'-CACTCTCGAGCACCCTATCAGGCAG-
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TACC-3') as an antisense primer on the plus strand in the supernatant. Se-
quencing products were separated on an 8% polyacrylamide:bisacrylamide gel 
(19:1 w/w). DNA sequences were read manually from auto radiographs and 
analyzed with the PC/Gene computer program (Intelligenetics Inc., Mountain 
View, Calif., USA). 
Anti-HCV assays 
Antibodies to HCV were assayed by an Enzyme Immunosorbent assay (EIA; 
Abbott Chicago, II, USA) and confirmed by RIBA-4 (Ortho diagnostics, Raritan, 
NJ, USA) and Inno-UA HCV Ab II (lnnogenetics, Gent, Belgium) according to 
the manufacturer's instructions. 
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Figure 1. Positions of the probe lines on the LiPA strip. Probes 21 and 22 are general 
probes to identify general 5' UTR sequences. Probes 5-20 distinguish different types 
and subtypes of HCV as indicated. Representative results of isolates containing types 
1 a, 1 b, 2a, 2b, and 3 are shown, together with all type 4 isolates. One isolate is 
provisionally classified as type 5. Furthermore, isolates 50 and 20, displaying sequence-
specific variation and the single discrepant isolate 48, are shown. 
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RESULTS 
HCV-RNA was isolated from 64 patients with a chronic HCV infection, and 
amplified by RT-PCR using 6' UTR specific primers. These PCR products were 
analyzed by direct sequencing as described elsewhere (Kleter et aI., 1994]. 
Biotinylated amplification products from nested reactions were used as target to 
the probes in the reverse hybridization LiPA system. The location of the probes 
on the LiPA strip and typical LiPA results are shown in Fig. 1. 
All labelled nested PCR products hybridized to the general probes 21/22 
and with a subset of (sub)type-specific probes. Results of UPA analysis of 64 
patient isolates are summarized in Table 1. Four different types were detected 
and there were no isolates that could not be typed by LiPA. Observed hybridiza-
tion patterns were consistent and classification into types and subtypes was 
obvious for all isolates, including one double infection with subtypes 1 band 2b. 
One isolate contained the SA 1 sequence. This sequence can be classified 
provisionally as type 6 (Dr. P. Simmonds, personal communication]. 
Table 1. HeV types determined by the LiPA in 54 isolates 
Type No. of isolates % 
1a 7 13 
1b 24 44 
2a 7 13 
2b 1 2 
3 10 18 
4 3 6 
5 2 
1b + 2b 2 
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Probes 17 and 18 were aimed to discriminate further between type 3 
isolates, based on the presence of a G or A at -139 respectively. However, most 
type 1 isolates cross-reacted with probe 17, and to a lesser extent with probe 
18. Overall background staining on the strips was very low or completely 
absent. 
Reverse hybridization results from LiPA were compared with data ob-
tained from direct sequencing. Sequences were determined on nested products 
derived from the same first round PCR products as used for LiPA. 5' UTR 
sequences and the positions of LiPA probes are shown in Fig. 2. Comparison of 
LiPA and direct sequencing results revealed a small discrepancy in only one 
sample. Amplified HCV-cDNA from this isolate (no. 48, containing the DK7 
sequence figure 2.) hybridized with probe 7 (Fig. 1), indicating the presence of a 
G at position -99, but direct sequencing showed only an A. This isolate is 
therefore classified as 1 b by LiPA but as la by direct sequencing. On the other 
hand, some aberrant hybridization patterns observed in LiPA were validated by 
direct sequencing results. Isolate 50 (containing sequence HC2-N2) failed to 
hybridize with probe 9. This is in perfect agreement with the presence of a G at 
position -127. Isolate 20 (containing sequence HC3-N2) hybridized only very 
weakly to type 3-specific probe 15, which can be explained by the presence of 
a C at position -118. The presence of these mutations in regions used for typing 
never complicated the classification because 2 or 3 type-specific probes are 
present in the LiPA. Probe 19 contains a CIT degeneracy at position -167, 
which allows hybridization to all type 4 sequences in this study, including SA 1. 
Probe 20 does not hybridize to the SAl sequence. In a number of isolates 
additional sequence variation outside the defined motifs 1 and 2 was detected 
by direct sequencing, but this did not affect the classification by the LiPA. 
Antibodies against various HCV epitopes were assayed by RIBA-4 and LlA 
II. Results are shown in Table 2. One patient was negative by RIBA and LlA. 
One was indeterminate by LlA, as only a weak anti-core reaction was detected. 
From the single anti-HCV-negative sample, weak HCV-RNA signals were 
obtained. However, a sample from this patient, obtained one month earlier, was 
anti-HCV positive in RIBA. Only one patient specifically lacked core antibodies in 
80 
Table 2. 
Type # pat. 
1a 8 
1b 23 
2a 7 
2b 1 
3 10 
4 3 
5 
1 + 2 
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Anti-HCV profiles of 54 patient isolates determined by RIBA·4 and Inno· 
HCV LlA HCV Ab II 
RIBA-4 Inno·LIA 
511 C-100 C33c C22-3 total NS-4 NS-5 core total 
(NS4) (NS4) (NS3) (core) 
8 8 8 8 8 8 5 8 8 
22 19 22 22 22 22 13 22 22 
1 2 7 7 7 2 5 6 6 
0 0 1 0 1 
0 4 10 10 10 2 7 10 10 
0 3 3 3 2 2 3 3 
1 1 1 
0 0 0 
Anti-HCV detection by RIBA and LlA. 5-1-1 and C-100 are derived from the NS-4 region, C33c 
contains NS-3 and C22-3 covers core epitopes. Numbers in columns represent samples with a 
positive reaction against the specified epitope. 
both confirmatory assays; all other anti-HCV positive isolates were anti-core 
positive in both assays. All patients contained anti-NS-3 antibodies as deter-
mined by RIBA. 
Type 2- and type 3-infected patients showed a low response rate to type 
1 NS-4 epitopes, both in RIBA and LlA. NS-5 antibodies were detected by LlA in 
the majority of patients. The only double infection isolate did not contain 
antibodies against NS-4 epitopes. 
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Figure 2. Alignment of 5' UTR sequences (positions -265 to -68) and positions of the Line 
Probe Assay (LiPA) probes. Sequences between positions -210 and -170 are completely 
conserved and omitted from the figure. Sequences are grouped into 5 different types. HCV-1 
is the prototype sequence (Choo et aI., 1990). DK-7, SA1O, US10, and DK13 (Bukh et aI., 
1992). HC-J6 (Okamoto et aI., 1992). EB-7, EB-12 (Chan et aI., 1992) were previously 
reported and identified by their original name. The positions of the LiPA probes 5-20 are 
identified by boxes type-specific) or are underlined (subtype-specific). General probe 21 is 
underlined and probe 22 (positions -178 to -1941 is not shown in this figure. The SA 1 
sequence is tentatively classified as type 5. 
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DISCUSSION 
This study describes the use of a new reverse hybridization Line Probe Assay to 
determine the (sub)type of HCV in 54 well characterized patient plasma isolates. 
The system was evaluated by direct sequening and results are markedly similar. 
There are several advantages in using the 5' UTR of the HCV RNA 
genome for genotyping. First, the 5' UTR is generally used in diagnostic PCR 
assays with universal primers to detect viremia. Therefore it is convenient to 
perform subsequent typing analysis on the resulting DNA product. Secondly, the 
sequence variations within the 5' UTR are limited to specific regions, such as 
motifs 1 and 2, located between highly conserved flanking sequences. This 
allows the use of general PCR primers as well as (sub)type-specific probes. This 
relatively high degree of conservation in the 5' UTR omits the necessity of type-
specific primers to classify HCV using more variable coding regions of the 
genome [Okamoto et ai., 1992b]. A large number of 5' UTR sequences has 
been published so far [Chan et ai., 1992; Stuyver et ai., 1993; Bukh et al., 
1992J. Discrimination between types has been described using amplified cDNA 
derived from the 5' UTR for restriction fragment length polymorphism (RFLP) 
[Simmonds et ai., 1993; Nakao et ai., 1991; McOmish et ai., 1993]. Further-
more, the overall mutation rate of HCV has been estimated at approximately 1.5 
X 10.3 base substitutions per site per year [Okamoto et ai., 1992c; Ogata et ai., 
1991 L but mutations occur unevenly along the genome. A hypervariable region 
located at the N-terminus of E2/NS1 has a high mutation rate, whereas the 5' 
UTR has a very low rate. Studies on genetic drift of HCV for more than 8 years 
in a chronically infected chimpanzee [Okamoto et ai., 1992cJ and over 13 years 
in a chronic patient [Ogata et al., 1991 J showed complete conservation of the 
5' UTR. Finally, the putative secondary structure of the 5' UTR [Simmonds et 
ai., 1993; Brown et ai., 1992; Tsukiyama-Kohara et ai., 1992] implies functional 
conservation with respect to initiation of translation of the single open reading 
frame and genome replication [Yoo et ai., 1992], Therefore, there is probably 
high selective pressure on the function of this region. This is indicated by the 
existence of paired mutations (co-variants) in the complementary strands in the 
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stem of the putative RNA-hairpin. This covariance, observed among different 
types, conserves secondary RNA structure of motifs 1 and 2 [Simmonds et aI., 
19931. Extensive sequence comparisons have shown [Chan at aI., 1992J that 
sequence heterogeneity in the 5' UTR displays similar phylogenetic relationships 
between HCV types as other regions such as core, NS3 and NS5. Therefore, 
sequence analysis of the 5' UTR should allow consistent discrimination of HCV 
types. 
HCV-RNA isolates from 54 chronic HCV patients were genotyped by 5' 
UTR analysis. Amplified cDNA from the 5'UTR was biotin-labelled during nested 
PCR and used as a probe for reverse hybridization in the LiPA. Reverse hybrid-
ization offers a fast method of screening for the presence of specific sequences 
in a PCR product. The probes used in the LiPA described here cover a consider-
able part of the entire 5' UTR sequence. The LiPA contains both general and 
[subltype specific probes and therefore allows detection of known as well as 
unknown HCV types. Each of the 54 isolates described here hybridized to the 
general probes and could be further (sub)typed by LiPA. New HCV types will fail 
to hybridize with the current (sub)typing probes on the strip, but will hybridize 
to the general probes. Aberrant hybridization patterns can also be observed on 
the LiPA strip, as shown in isolates 20 and 50 (Fig. 2). Therefore the LiPA 
provides an instrument for rapid identification of new HCV types or SUbtypes. 
To evaluate the efficiency of the LiPA system, the presence or absence of 
hybridization to each probe was compared with the corresponding results from 
direct sequencing. Single nucleotide differences were efficiently detected, e.g. 
to discriminate between type 2a and 2b by probes 10, 11, 12, and 13. In 
addition to published sequences, new variations were also detected by LiPA and 
confirmed by direct sequencing, as observed in isolates containing sequences 
HC3-N2 and HC2-N2. There was only one discrepancy between LiPA and direct 
sequencing with isolate 48, although it was typed correctly as type 1 by LiPA. 
The question remains whether this isolate contains 1 a or 1 b sequences. A 
possible explanation is a co-infection with types 1 a and 1 b. A large excess of 1 a 
sequences over 1 b sequences could explain the failure of direct sequencing to 
detect both A and G at position -99 and the weak hybridization of the PCR 
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product with probe 7. The directly obtained sequence represents the major 
sequence present in an isolate. Furthermore the LiPA identifies subtype 1 a 
based on absence of hybridization with probe 7. Positive identification of each 
subtype could further improve the reliability of the LiPA. Probes 17 and 18 
cross-reacted with most of the type 1 isolates. The reason for this is unclear. 
The value of probes 17 and 18 in discriminating between the presence of a G or 
A at position -139, is doubtful. The target sequence for these probes is located 
in the region forming a single stranded RNA loop in the putative secundary 
structure of the genomic RNA (Brown et aI., 1992J. This might also explain the 
relatively high frequency of mutations detected in this region, including the 
insert in HC1-N8. Four isolates could not be classified as type 1, 2 or 3. Three 
of those are classified as type 4 and one (containing sequence SA 1) is tentative-
ly designated as type 5. More data from these isolates are necessary to justify 
this provisional classification. 
One double infection with subtypes 1 band 2b was detected (Fig. 1 and 
2; isolate HCl/2) both by LiPA and direct sequencing. It is much easier, both to 
detect and (sub)type the double infection by LiPA than by direct sequencing. 
Interpretation of double signals at one nucleotide position by direct sequencing 
can be difficult and may require advanced experience in reading sequence 
autoradiographs. 
Although the version of the LiPA described here did not yet contain type 
5 specific probes, it was possible to discriminate between type 4 and 5 se-
quences because probe 19 contains a degeneracy. Addition of type 5 specific 
probes onto the LiPA strip will further facilitate recognition of this type. 
Profiles of antibodies against specific HCV epitopes were determined. 
Two confirmatory immunoblot assays, capable to detect antibodies against 
epitopes from core, NS-3, NSA and NS-5, could not discriminate between 
different types. RIBAA uses expression products of recombinant cDNA clones, 
derived from various parts of the HCV genome, whereas the Inno-LiA exposes a 
number of synthetic peptides. At present, as many more sequences of types 1, 
2 and 3, and 4 became available, significant sequence heterogeneity in various 
parts of the genome (Chan et aI., 1992; Cha et aI., 1992J may be observed. 
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Consequently, infection with other HCV types may evoke antibodies against 
type-specific epitopes, which are not optimally recognized by type 1 epitopes in 
the RIBA and LlA. This is illustrated by the absence of antibodies against NS-4 
epitopes in most type 2 and 3 isolates (Table 2) (Chan et aI., 1991]. Antibodies 
against 5-1-1 are even completely absent in type 3 isolates. The single indeter-
minate LlA result on an isolate classified as type 2a may be partly explained by 
type-specific immune reactions. 
Antibodies against core and NS-5, epitopes show a higher degree of cross-
reactivity. It was possible to distinguish a number of type 1 and 2 isolates by 
assaying anti-core antibodies, directed against 2 different type-specific core 
peptides [Machida et aI., 1992], although specificity was limited. Type-specific 
serological assays would considerably facilitate discrimination between different 
HCV types. Sequence information of antigenic regions is still limited. Therefore, 
many more sequence data from all different types must be obtained, to develop 
(sub)type-specific antigens for antibody assays. However, there are considerable 
differences in immune reactivity among individual patients. In some patients, 
antibody responses are poor; e.g. in isolate 23, antibodies against core were 
undetectable. Also in immunocompromised patients serological testing is diffi-
cult, due to lack of sufficient antibody titers. These conditions prevent serolog-
ical HCV typing. 
In summary, sequence analysis of the 5' UTR of HCV allows consistent 
genotyping of all presently known HCV isolates. Furthermore, reverse hybridiza-
tion systems in a strip test format like the described LiPA, provide fast and 
reliable typing of HCV isolates and identification of new HCV types. This assay 
allows the use of the amplification products from 5' UTR after RT-PCR assays 
and therefore conveniently complements the routine HCV diagnosis. Screening 
of large patient populations is feasible, and could lead to rapid identification of 
new HCV types. 
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HCV genotyping by LiPA and corefE1 sequencing 
ABSTRACT 
Hepatitis C virus (HCV) isolates from a cohort of 315 patients from the Benelux 
countries (Belgium, The Netherlands, Luxembourg) with a chronic infection were 
genotyped by means of reverse hybridization Inno-LiPA (Line Probe Assay). HCV 
(sub)types 1 a, 1 b, 2a, 2b, 3a, 4a, and 5a were detected. From the cohort, 
isolates representing all types and those showing an aberrant LiPA pattern were 
further analyzed by sequencing parts of the 5' UTR, the core (nt 1 to 326: aa 
residues 1 to 108) and corefE 1 (nt 477 to 924: aa residues 159 to 308) regions. 
Typing by LiPA was completely confirmed by 5' UTR sequencing. Molecular 
evolutionary analysis of the core and the corefE 1 regions allowed discrimination 
between known and additional subtypes, especially within types 2 and 4. The 
core region is not suitable for classification of new subtypes because of the 
relatively high level of conservation. The corefE1 region displays a higher level 
of sequence variation and allows much more distinct discrimination between 
sUbtypes. Types 2 and 4 are particularly heterogeneous, with at least 7 and 10 
subtypes, respectively. In contrast to previous reports from Europe, HCV 
isolates from this study cohort constituted a highly heterogeneous population of 
virus variants, especially within types 2 and 4. 
INTRODUCTION 
Hepatitis C virus (HCV), the major etiologic agent of parenterally transmitted 
non-A, non-B hepatitis (Choo et aI., 1989; Kuo et al., 1989), is classified as a 
separate genus within the Flaviviridae [Miller & Purcell, 1990; Houghton et aI., 
1991]. The virus contains a positive-sense, single stranded RNA genome of 
approximately 9400 nt. Sequence comparisons revealed the existence of 
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mUltiple HCV strains or types. Since there are no methods available for 
biological characterization of HCV, due to the lack of an in vitro culture system, 
classification relies almost entirely upon nucleotide sequence analysis. Recently, 
a classification system has been proposed [Chan et aI., 1992; Simmonds et aI., 
1994a; Stuyver et aI., 1993], differentiating between types, subtypes and 
isolates. HCV genotyping may have clinical relevance, such as the efficacy of 
interferon therapy [Takada et aI., 1992; Yoshioka et aI., 1992; Tsubota et aI., 
19941. 
Analysis of different HCV strains can be performed by either serotyping or 
genotyping. Current serotyping methods allow identification of the major viral 
types [Simmonds et aI., 1993b; Tsukiyama-Kohara et aI., 19931 but do not 
discriminate between subtypes. Genotyping would be most reliable if complete 
genomes were analyzed. However, since this is not feasible on a routine basis, 
genotyping can also be accomplished by partial analysis of the genome, such as 
the 5'UTR [Stuyver et aI., 1993; Simmonds et aI., 1993al and the core region 
[Okamoto et aI., 1992bl. Phylogenetic studies of the core [Bukh et aI., 1994], 
the E1 [Bukh et aI., 19931 and the NS5 regions [Chayama et aI., 1993; 
Simmonds et aI., 1994bl suggested that any region of the genome could be 
used for classification of HCV isolates [Chan et aI., 1992], although the level of 
sequence heterogeneity differs considerably between different parts of the 
genome. More detailed studies indicated that the NS5B is probably most suited 
for classification of novel isolates [Stuyver et aI., 19941. 
A reverse hybridization Line Probe Assay (UPA) has been developed for 
genotyping of HCV isolates by 5' UTR analysis [Stuyver et aI., 1993; van Doorn 
et aI., 1994a]. The 5'UTR is highly conserved but shows significant sequence 
variation, mainly in two small 'motifs' (nt -132 to -117 and nt -170 to -155) 
[Kleter et aI., 1994; van Doorn et al., 1994a]. 5'UTR sequences of types 1 to 6 
as well as of several subtypes are distinct, which allows the use of this region 
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for HCV genotyping [Stuyver et aI., 1994]. 
In this study, 315 HCV isolates, obtained from patients living in the 
Benelux area of Western Europe were all genotyped by LiPA. Randomly selected 
isolates as well as isolates showing an aberrant LiPA pattern were subjected to 
sequence analysis of the 5'UTR, N-terminal core and part of the corelE 1 regions, 
in order to validate the 5'UTR classification in coding regions of the genome and 
to determine the genomic variability of HCV isolates from the Benelux region. 
MATERIALS AND METHODS 
Patients 
HCV isolates described in this study were obtained from participants in the trial 
for treatment with interferon-G, coordinated by the Benelux Study Group on 
treatment of chronic hepatitis C. All patients resided in either Belgium, the 
Netherlands or Luxembourg (Benelux), although their ethnic origin was diverse. 
All samples used in this study were obtained before the onset of therapy. 
HCV -RNA detection and genotyping 
HCV RNA was isolated by a modification of the guanidinium thiocyanate method 
[Chomczynski & Sacchi, 1987; Kleter et aI., 1993[. A small number of 
heparinized plasma samples were analyzed by an HCV RNA capture method as 
described earlier [van Doorn et aI., 1994b] since these samples could not be 
analyzed by conventional methods (Willems et aI., 1993[. Detection of HCV 
RNA was performed by RT-PCR with primers HCV35 (sense, positions -318 to -
296; 5'-TTGGCGGCCGCACTCCACCATGAATCACTCCCC-3'; underlined 
sequence is non-HCV specific) and HCV19 (antisense, positions -1 to -20; 5'-
GTGCACGGTCTACGAGACCT-3'). Genotyping was performed by a prototype 
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Inno-LiPA HCV genotyping assay (Stuyver et aI., 1993]. 
Sequence analysis of the 5'UTR, core and core/E1 regions 
PCR products from the 5'UTR were reamplified in a nested PCR with primers 
NCR3 (sense, positions -314 to -288; 5'-GGGGCGGCCGCCAACCA 
TARRATCACTCCCCTGTGAGG-3'; R= A or G) and LD58b (antisense, positions 
-35 to -64; 5'Bio-GGCCGGGGCGGCCGCCAAGCACCCTATCAGGCAGTACCAC-
AAGGC-3'). 
RT-PCR was also performed with primers HCV983 (antisense, positions 
963 to 983; 5' -GGIGACCAGTTCATCA TCAT-3'; I = inosine) and biotinylated 
LD58c (sense, positions -57 to -34; 5'-Bio-GGTACTGCCTGATAGGGTGCTTGC 
3'). cDNA synthesis was primed with primer HCV983. First round PCR products 
were reamplified with LD58c and 186c (antisense, positions 410 to 391; 5'-
ATITACCCCATGAGITCGGC-3') in a semi-nested PCR for analysis of the core 
region. To analyze corelEl sequences, first round PCR products were 
reamplified by HCV983 and HCV720b (5'Bio-GCCGACCTCATGGGGTACAT-3'). 
All biotinylated nested PCR fragments were subjected to direct sequence 
analysis as described earlier (Kleter et aI., 1994; van Doorn et aI., 1994aJ. 
Sequences were analyzed by the PCGene software (Intelligenetics) and 
phylogenetic trees were constructed using the Phylogeny Inference Package 
(PHYLlP; version 3.5c; Felsenstein, 1993). 
Nucleotide sequence accession number 
The sequence data reported here have been deposited in the Genome Sequence 
Data Base and assigned the following accession numbers: 5'UTR, X78856-
X78867 and X58937-X58953; core, Z29444-Z29474; corelEl, L39280-
L39318. 
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RESULTS 
A cohort of 315 HCV isolates was genotyped in the 5'UTR by means of LiPA. 
HCV (sub)types 1 a, 1 b, 2a, 2b, 3a, 4a, and 5a were detected and the 
prevalence of each (sub)type is shown in Table 1. Only four mixed infections 
were detected. One isolate (NE92) could be typed, but subtyping was not 
possible (designated type 2'). One isolate (NL96) resulted in an aberrant LiPA 
pattern and could not be typed. Within type 1, the prototype LiPA allowed 
positive identification of subtype 1 b only, and typing the remaining isolates as 
type 1. 
First, a total of 37 isolates (nine of type 1, four of 1 b, three of 2a, two of 
2b, one of 2', four of 3a, eight of 4a, five of 5a, and one un typeable, according 
to LiPA) were further analyzed by sequencing of the 5' UTR (Fig. 1). LiPA 
patterns were in complete agreement with 5' UTR sequence results for each 
isolate. 
Secondly, part of the core region sequence (nucleotides 1-326) was 
amplified from 36 isolates (12 of type 1, four of 1 b, three of 2a, two of 2b, one 
of 2', four of 3a, four of 4a, five of 5a, and one untypeable, according to LiPA) 
and subjected to direct sequence analysis. Phylogenetic distances among these 
and several reference sequences were calculated. The phylogenetic distances 
did not segregate into three non-overlapping distance ranges (results not shown) 
for types, subtypes and isolates. Further analysis revealed that isolates originally 
typed as HCV subtypes 2a or 4a were much more heterogeneous than other 
subtypes, suggesting the existence of multiple subtypes within these groups. 
Therefore, 36 isolates (seven of type 1, four of 1 b, five of 2a, one of 2b, one of 
2', four of 3a, eight of 4a, five of 5a, and one untypeable, according to LiPA) 
were sUbjected to sequencing of the more variable C-terminal core/N-terminal E 1 
region (nucleotides 477 to 924). Phylogenetic distances were calculated and 
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Table 1. 
Type 
1b 
2a 
2b 
2' 
3a 
4a 
5a 
multiple 
untypeable 
Prevalence of HCV Isub)types in 
a cohort of 315 patients from the 
Benelux countries as determined by LiPA. 
Number of patients Prevalence 1%) 
32 10.1 
187 59.4 
20 6.3 
3 0.9 
0.3 
45 14.3 
15 4.8 
7 2.2 
4 1.3 
0.3 
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the resulting phylogenetic tree is represented in Fig. 2. The frequency 
distribution of pair-wise phylogenetic distances in the corelE 1 region showed 
some overlap (Fig. 3), but the segregation into types, subtypes and isolates was 
much better than for the N-terminal core region. Remarkably, the average 
pairwise phylogenetic distance of type 2 isolates compared to the other types 
was 0.68 ± 0.05, whereas for all remaining intertype distances this was only 
0.57 ± 0.08. The frequency peak of 0.24 is mainly related to pairwise 
distances within type 4 (0.23 ± 0.04) compared to 0.36 ± 0.05 between 
subtypes of all other types. Although overlap regions were small, it WaS 
impossible to calculate exact border values for types, subtypes and isolates. 
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Therefore, phylogenetic distances were also compared with the ranges obtained 
by analysis of a larger core/E1 region of which NS5B sequences were also 
known [Stuyver et aI., 1994]. Final assignments were based on nucleotide 
distances, border values from the larger corelE 1 region [Stuyver et aI., 1994] 
and the position in the phylogenetic tree. 
Two isolates, NL43 and NL69, were identified as 1 b by LiPA but appeared 
to belong to subtype 1 a after core and core/E1 analysis. The isolates NL29 and 
NL35 were obtained from patients who probably contracted their HCV infection 
in Morocco. These two isolates could be classified into a separate subtype of 
type 1, and are distinct from the proposed subtype 1c isolates [HCG9, Okamoto 
et aI., 1994; Td-6, Td-34/92, Hotta et aI., 1994a and 1994b] from Indonesia. 
Two isolates (B84 and B207) were identified as type 1, but were not typed by 
LiPA as subtype 1b, due to a mutation at position -94 in the 5' UTR (Fig. 1). 
Four isolates (B58, B65, B75 and B207) contained a CIT mutation at position -
158, which resulted in an aberrant LiPA pattern, which did not influence typing. 
Figure 1. Nucleotide sequence alignment of the HCV 5' UTR sequences together with 
representative isolates for each (sub)type. Parts of the 5'UTR that were completely 
conserved among all isolates are not shown. Reference sequences are,: type 1 a, HCV1 
[Chao et al" 1991]; type lb, HCV-J [Kato et al" 1990] and HCV-BK [Takamizawa et 
aI., 1991]; type lc, HC-G9 [Okamoto et aI., 1994J; type 2a, HC-J6 [Okamoto et aI., 
1991J; type 2b, HC-J8 [Okamoto et aI., 1992aJ; type 2d, NE-92 [Stuyver et aI., 1994J; 
type 2c, S83 [Bukh et aI., 1993J; type 3a, NZL 1 [Sakamoto et aI., 1994J; type 3a, 
USl14 [Okamoto et aI., 1993J; type 3b, NE137 [Tokita et al., 1994J; type 4c, GB358 
[Stuyver at aI., 1994J; type 4d, DK13 [Bukh et aI., 1993J; type 5a, BE95 [Stuyver et 
aI., 1994J; type 6a, HK2 [Bukh et aI., 1993]. 
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Based on core/E 1 sequences, three type 2 isolates (NL33 and NL49 from 
Surinam, and NL50 from the Netherlands) could each be classified into a novel 
subtype, apart from subtype 2a (HCJ-6), 2b (HCJ-8), 2c (S83) and 2d (NE92). 
Isolate NL50 contained a mutation at position -127, whereas the other two 
subtypes were indistinguishable from subtype 2a in the 5'UTR. Subtypes 2b and 
2d could both be identified by unique covariant mutations in the 5'UTR 
sequence motifs, resulting in specific .LiPA patterns. The single type 2 isolate 
that could not be subtyped by LiPA was also analyzed in the NS5B region; it has 
been described earlier as NE92, classified as subtype 2d [Stuyver et aI., 1994J. 
Isolate B89 (from Belgium) appeared to contain an insertion of 2 amino acids 
between residues 197-198 in the E1 region. No insertions have been observed 
yet in any of the previously described E1 sequences. 
The four selected type 3 isolates all belonged to HCV sUbtype 3a. 
However, the single untypeable isolate, NL96, could be classified as a seventh 
subtype of type 3, different from subtypes 3a to 3f [Tokita at aI., 1994]. This 
isolate has also been analyzed in the E1/E2 region and the NS5 region (data not 
shown), confirming classification as a separate subtype within type 3. The 
characteristic type 3 'TCA motif' at position -95 to -92 is not present in this 
Figure 2. Phylogenetic tree drawn from the phylogenetic analysis of nucleotide 
sequences by the neighbor-joining method (Saitou & Nei, 1987]. reference sequences 
are: type 1 a, HCV1 (Chao et al., 1991]; type 1 b, HCV-J (Kato et aI., 19901 and HCV-
BK (Takamizawa et aI., 1991]; type 1c, HC-G9 (Okamoto et aI., 1994J; type 2a, HC-J6 
(Okamoto et al., 1991 J; type 2b, HC-J8 (Okamoto et al., 1992al; type 2d, NE-92 
(Stuyver et al., 1994]; type 2c, S83 (Bukh et aI., 1993]; type 3a, NZl1 (Sakamoto et 
aI., 1994J; type 3a, US114 (Okamoto et aI., 1993J; type 3b, NE137 ITokita et aI., 
1994]; type 4c, GB358 [Stuyver et al., 1994J; type 4d, OK 13 (Bukh et aI., 1993]; type 
5a, BE95 [Stuyver et al., 1994J; type 6a, HK2 (Bukh et aI., 1993J. 
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Figure 3. Frequency distribution ot' pair~wise molecular evolutionary distances in the 
core/E1 region (nt 477 to 924) among 37 selected HeV isolates and several reference 
sequences. 
isolate. A new sequence motif is present between position -167 and -159. 
The two sequence motifs in the 5'UTR of type 4 isolates were completely 
conserved in our group of patients. Additional point mutations, located outside 
the motifs, we;e present. Since the frequency distribution (Fig. 3) showed some 
overlap between isolates and subtypes, several of our type 4 isolates could not 
be formally classified as diff.erent subtypes after core/E1 analysis. However, 
among eight type 4 isolates, at least 4 subtypes could be distinguished. 8203 
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clustered with subtype 4c isolates, and NL52 with the subtype 4d isolate DK 13. 
Comparison with published type 4 sequence data [Stuyver et aI., 1994; Bukh et 
aI., 1993 and 1994) indicated that the remaining six isolates (from Egypt, Zaire 
and the Netherlands) clustered into two novel subtypes. Five of these isolates 
belong to the same newly identified subtype, which seems to be the 
predominant type 4 subtype in the Benelux countries. 
The 5 isolates of HCV type 5 are highly homogeneous, and were 
classified into a single subtype (5a). The isolates from South Africa (e.g. SA 1; 
[Bukh et aI., 1992]) also belong to the same subtype (data not shown). 
DISCUSSION 
Hepatitis C virus isolates from 315 chronically infected HCV patients living in 
the Benelux· area of Western Europe were genotyped by analysis of the 5'UTR 
with LiPA. The genotypic distribution (Table 1) differs from earlier reports 
[Dusheiko et aI., 1994; McOmish et aI., 1994] and illustrates that the major 
HCV types are all present in Western Europe including types 4 and 5 which 
were regarded as 'African' types. The version of LiPA used in this study did not 
permit the recognition of type 6, which seems to be exclusively present in the 
Far-East. 
-In order to investigate sequence variation in coding regions of HCV 
isolates from the Benelux area, we analyzed parts of the core and corelE 1 
regions from a number of randomly selected isolates as well as from isolates 
with an aberrant LiPA pattern. Phylogenetic analyses indicated a remarkable 
heterogeneity of HCV in the Benelux isolates. 
Within type 1, three subtypes were recognized. Two isolates from 
patients, probably infected in Morocco, could be classified as a novel sUbtype. 
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Initial phylogenetic analyses have suggested the importance of the G at position 
-99 in the 5'UTR for identification of subtype 1 b isolates. Recently, some 1 b 
isolates containing an A at -99, have been reported (Bukh et aI., 1992 and 
1993), suggesting that this position cannot be consistently used for recognition 
of subtype 1 b. In our limited number of isolates we observed two discrepancies 
(isolates NL43 and NL69). These two isolates were identified as 1 b by LiPA, but 
as 1 a by sequence analyses of the core and corelE1 regions. Low discrepancy 
levels have also been reported by others (Mahaney et aI., 1994; Gianinni et aI., 
1994J. 
Type 2 isolates show remarkable heterogeneity in the core and core IE 1 
regions. Most of these are indistinguishable in the 5'UTR and were initially 
identified as subtype 2a by the LiPA, together with HC-J6. From phylogenetic 
analysis of the corelE 1 region six subtypes can be detected in this group of 
patients. All type 2 isolates from our randomly selected group were different 
from the Japanese subtype 2a. This has also been confirmed for most of the 
remaining type 2 isolates of the entire cohort of 315 patients, by sUbtype-
specific PCR in the core region, as described by Okamoto (data not shown). 
Taken together, type 2 appears to comprise at least 7 different subtypes. Similar 
to observations by Bukh et al. (1993J our study also revealed that type 2 is the 
most distant group among the HCV types 1 to 5 and confirmed the high degree 
of heterogeneity of subtypes within this type. 
Type 3 isolates from Benelux patients appear to be highly homogeneous, 
except for isolate NL96 which can be classified as a separate subtype. This 
isolate was obtained from a patient who probably contracted the HCV infection 
in Indonesia, which may explain the rarity of such isolates in Western Europe. 
Recently, this isolate was found to be highly homologous to the Indonesian 
isolate Td-3/93 (Holta et aI., 1994bJ in the NS5B region (data not shown). 
Like type 2, type 4 isolates are a highly heterogeneous group. Patients in 
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this group originate from Egypt, Zaire, Belgium and the Netherlands. The 
average phylogenetic distance between putative subtypes in this group is 
remarkably lower than within other types (0.23 ± 0.04 vs. 0.36 ± 0.05). 
Therefore, in some cases, the corelE 1 region could not accurately predict the 
precise division of type 4 isolates into separate sUbtypes. The existence of at 
least eight subtypes within type 4 has been reported earlier [Stuyver et aI., 
1994), and comparison with these data led to the identification of at least two 
new sUbtypes. Therefore the total number of subtypes within type 4 increases 
to at least 10. Some of these subtypes can be identified by specific 5'UTR 
sequences. However, formal classification of all type 4 subtypes requires 
additional sequence analyses, preferably in the NS5B region [Stuyver et aI., 
1994]. 
Classification of isolates into the major types based on either 5'UTR, core 
or E1 was completely consistent. It is remarkable that analyses of 5'UTR and 
the corelE1 regions result in similar classifications. The 5'UTR is a non-coding 
region containing a highly conserved, presumably functional, element such as an 
internal ribosomal entry site with stringent constrains on the secondary structure 
of the RNA [Yoo et aI., 1992; Wang et al., 1993J. In contrast, the core and E1 
regions encode the putative nucleocapsid and envelop proteins, and would 
therefore be subjected to completely different selective pressures than the 
5'UTR. 
A HCV typing system based on subtype-specific primers in the core 
region has been described by Okamoto [Okamoto et aI., 1992b and 1993]. 
Comparison of core sequences described in this study and subtype-specific 
primers as described by Okamoto [Okamoto et aI., 1992bJ revealed that specific 
primer target sequences contained several mismatches, especially in type 2 
isolates. Experiments have shown that this PCR typing system does not allow 
efficient typing of type 2 isolates [Kleter et al. unpublished observationsJ. Type· 
105 
HCV genotyping by LiPA and corelEl sequencing 
specific PCR primers for types 4 and 5 have not yet been described and could 
be designed now. However, it seems likely that subtype-specific amplification 
with multiple different subtype-specific primers will not be an efficient 
genotyping method in heterogeneous HCV popUlations. 
HCV types 1 to 5 can be distinguished by differences in the 5'UTR. Very 
similar discrimination between viral variants is possible by analysis of the 
relatively well conserved core region as shown in this study. The more variable 
El region revealed identical, although more precise, classification of isolates. 
This indicates that genotypic differences are maintained throughout the HCV 
genome in all major types of HCV, although the degree of sequence variation 
differs considerably between the different regions of the HCV genome. It 
appears that the majority of types known today can be differentiated in the 
5'UTR. However, sequence variation in this region is not sufficient to recognize 
every single sUbtype. Whereas the 5'UTR and core region are very conserved, 
the Eland NS5 regions reveals additional variation, and the hypervariable region 
in the E2 region would allow identification of almost every single HCV isolate 
[Weiner et aI., 19911. However, discrimination between single isolates might be 
only useful for epidemiological studies. At present, it is unclear whether detailed 
subtyping of HCV isolates has any clinical significance. This is subject of further 
study. 
The classification system of HCV into types, subtypes and isolates and 
the nomenclature of the major types appears now to be generally accepted. 
However, classification and nomenclature of novel isolates is still a problem that 
requires consensus among the scientific community. Distinct criteria should be 
defined, in order for a new type or subtype to be classified. Based on this and 
other studies [Bukh et aI., 1993; Stuyver et aI., 1994) the El and NS5B regions 
might be the most appropriate regions to use for detailed phylogenetic analysis 
and classification. 
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In conclusion, genotyping of HCV isolates from a large patient cohort 
revealed the presence of a highly heterogeneous population of HCV types and 
subtypes in the Benelux countries of Western Europe. However, it should be 
noted that the Benelux region has a multiracial population, which might explain 
detection of HCV variants that had only been reported in distant regions of the 
world. It can be speculated that most HCV types have a worldwide distribution, 
although the relative regional prevalence of each type may vary considerably. 
Therefore, detection of minor subtypes may require analysis of larger patient 
cohorts. 
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ABSTRACT 
Two rapid genotyping methods for hepatitis C virus (HCV), the Line probe assay 
(lnno-LiPA) and the subtype-specific core amplification system [Okamoto et aI., 
(1992b) Journal of General Virology 73:673-6791. were applied on 58 HCV 
isolates which were typed as type 1 (n = 37) and type 2 (n = 21) by sequence 
analysis of the 5' untranslated region (5'UTR). The Line probe assay, targets the 
5'UTR and recognized 12 subtype 1 a, 25 subtype 1 b, 18 subtype 2a, 2 subtype 
2b and 1 subtype 2d in accordance to sequence analysis of this region. Sub-
type-specific core amplification revealed 7 discrepancies among the 37 type 1 
isolates when compared to LiPA. A different subtype was observed in 3 isolates 
(1 a versus 1 b), 2 isolates remained untyped and 2 isolates showed a coinfection 
of subtypes 1 a and 1 b. The first 5 discrepancies were confirmed by sequence 
analysis of the core region whereas the coinfection could not be confirmed. Of 
the 21 type 2 isolates only one could be typed by subtype-specific core amplifi-
cation. HCV RNA was detected in all 21 cases atter the general first round of 
polymerase chain reaction (PCR). Direct sequencing in the core region indicated 
sequence variation as a source of failure. It is concluded that LiPA results are 
conclusive for typing of HCV. However, LiPA is hampered occasionally for 
subtyping by lack of subtype-specific sequence variation in 5'UTR. Subtyping 
results by subtype-specific core amplification were accurate. However, it seems 
that this assay is not suitable for identification of type 2 isolates that circulate in 
patients living in Western Europe. 
INTRODUCTION 
Hepatitis C virus (HCV) is the major etiologic agent of post-transfusion non-A, 
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non-B hepatitis [Choo et aI., 1989J and is classified as a distinct genus of the 
Flaviviridae [Miller and Purcell, 1990J. Several full-length [Choo et aI., 1991; 
Kato et al., 1990; Okamoto et aI., 1991, 1992a; Takamizawa et aI., 1991J and 
numerous partial [Bukh et aI., 1992, 1993; Chan et aI., 1992; Enomoto et aI., 
1990; Kleter et aI., 1994; Mori et aI., 1992; Simmonds et aI., 1993a; Stuyver et 
aI., 1993bJ HCV sequences have been reported and comparison of those 
sequences revealed considerable heterogeneity between isolates. Recently, a 
useful classification system, based on phylogenetic analyses, was proposed and 
has been accepted by the scientific community [Simmonds et aI., 1994]. This 
system discriminates between types and subtypes. Genotypic variation seems to 
be maintained throughout the entire viral genome, although the level of hetero-
geneity diflers considerably between the various regions of the genome. 
Nucleotide sequence variation ranges from approximately 10% in the 5' UTR 
[Chan et aI., 1992J to nearly 50% in the E1 [Bukh et aI., 1993J and NS5 
[Simmonds et aI., 1993bJ regions. Currently, there is evidence for the existence 
of at least 9 major types [Tokita et aI., 1 994b J. 
Genotyping of HCV isolates is of interest for epidemiological studies 
[Dusheiko et aI., 1994; McOmish et aI., 1993J. The success of antiviral treat-
ment of chronic HCV infections appears to be related to the viral genotype [Hino 
et aI., 1994; Kobayashi et aI., 1993; Tsubota et aI., 1994; Yoshioka et aI., 
1992J and the level of viremia [Hagiwara et aI., 1993; Kobayashi et aI., 1993; 
Lau et al., 1993; Yoshioka et aI., 1992]. 
Genotyping can be undertaken by sequence analysis but this is tedious 
and time-consuming. Recently, several rapid methods for genotyping of HCV 
have been reported, including subtype-specific polymerase chain reaction (PCR) 
in either the core region [Okamoto et aI., 1992b, 1993J or the NS5B region 
[Chayama et aI., 1993], restriction fragment length polymorphism (RFLP) 
[McOmish et aI., 1993; Murphy et aI., 1994; Nakao et aI., 1991], hybridization 
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of PCR products with type-specific probes ICha et aI., 1992; Enomoto et aI., 
19901 and reverse hybridization IStuyver et ai., 1993a; van Doorn et aI., 19941. 
In the present study, two of these rapid methods were applied to 58 type 
1 and 2 isolates sequenced in 5'UTR origin. HCV Genotyping was carried out by 
reverse hybridization with the Line Probe Assay (LiPA), which is aimed at the 
5'UTR, and by the subtype-specific core amplification system IOkamoto et aI., 
1992b1. Discrepant results were analyzed. 
MATERIALS AND METHODS 
Patients 
Plasma samples were obtained by venepuncture and stored at -70°C. All 58 
patients had elevated alanine aminotransferase (AL T) levels, histological changes 
compatible with HCV infection, antibodies to hepatitis C virus, no recent history 
of infection with hepatitis B virus, hepatitis A virus, cytomegalovirus or Epstein-
Barr virus, and were between 26 and 74 years of age. The analyzed patients are 
living in the Netherlands or Belgium. 
HCV RNA PCR 
HCV RNA and cDNA were prepared as described previously IKleter et aI., 
19931. For 5' UTR analysis, PCR (40 cycles, 1 min at 94°C, 2 min at 48°C, 3 
min at 72°C) was undertaken with antisense primer HCV19 (GTGCACGGTC-
TACGAGACCT, positions -1 to -20) and sense primer HCV18 (GGCGACACT-
CCACCATAGAT, positions -304 to -324) or sense primer HCV35 (TTGGCGG-
CCGCACTCCACCATGAA TCACTCCCC, positions -296 to -318; underlined 
sequences are not complementary to HCV). 
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Genotyping by LiPA 
Rapid genotyping of HCV isolates by analysis of 5'UTR was carried out with the 
Line Probe Assay (lnno-LiPA HCV, Innogenetics, Gent, Belgium) [Stuyver et aI., 
1993a]. Briefly, first round 5'UTR PCR products were sUbjected to nested PCR 
with primers HC3 (TCTAGCCATGGCGTT AGTRYGAGTGT; positions -264 to -
238; R = A or G; Y = T or C) and HC4 (CACTCGCAAGCACCCTATCAGGCAGT; 
positions -29 to -54) in the presence of bio-11-dUTP. After nested PCR the 
biotinylated DNA products were denatured by alkaline treatment. Reverse 
hybridization of the DNA products to general and type-specific HCV probes 
which are applied onto a cellulose membrane strip was carried out in the 
presence of tetra methyl ammoniumchloride. After stringent washing, alkaline 
phosphatase and streptavidin conjungate were added. Finally, the HCV isolates 
were identified and classified by scoring the presence or absence of a purple 
precipitate at the probe lines. 
Genotyping by subtype-specific core amplification 
This rapid typing system was developed by Okamoto et al. [1992b) and is based 
on a universal first round PCR, followed by subtype-specific nested PCR. Four 
antisense primers in the second PCR yield subtype-specific amplification 
products of distinct lengths, allowing identification of subtypes 1 a, 1 b, 2a and 
2b by agarose gelelectrophoresis. In this study the originally described general 
sense primers 256 and 104 [Okamoto et al., 1992b) were replaced by, respec-
tively, LD58c (5'-bio-GGTACTGCCTGATAGGGTGCTTGC; positions -57 to -34) 
and LD58s (GCCTGATAGGGTGCTTGC; positions -51 to -34). These new 
general sense primers are located in a completely conserved part of the 5'UTR 
whereas the original sense primers 256 and 104 were not. The first round of 
PCR (40 cycles, 1 min at 94°C, 2 min at 48°C, 3 min at 72°C) was performed 
with LD58c and antisense primer 186c (A TITACCCCATGAGITCGGC; positions 
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410 to 391). One microliter of the first round PCR product was subjected to 
subtype-specific nested PCR (40 cycles, 1 min at 94°C, 1 min at 60°C, 1 min 
at 72°C) with universal sense primer LD58s and the four antisense primers 132 
to 135 as described [Okamoto et ai., 1992b], exept for primer 133 which was 
slightly modified by a degeneracy (T and C) at position 273. The antisense 
primers 132, 133, 134 and 135 are specific for HCV subtypes 1 a, 1 b, 2a and 
2b respectively. In addition, antisense primer 296 (GGA TAGGCTGACGTCTA-
CCT; positions 196 to 177), which is subtype 1 a-specific, was also used for 
subtype-specific core amplification [Kinoshita et ai., 1993J and, together with 
subtype 1 b-specific primer 235 (CGTGGAAGGCGACAAC; positions 175 to 190) 
used as a 32p radioactive labelled probe in Southern blot analysis. All PCR reacti-
ons were undertaken in a Biomed 60 PCR processor (Bittfurth, Germany). 
Direct sequencing of peR products 
First round PCR products from the 5' UTR were subjected to nested PCR with 
primers NCR3 (GGGGCGGCCGCCACCATRRATCACTCCCCTGTGAGG, positions 
-288 to -314) and antisense primer LD58 (5'-bio-GGCCGGGGCGGCCGCCAAG-
CACCCTATCAGGCAGTACCACAAGGC, positions -37 to -64). The first round 
PCR products from the core region had a biotin moiety at the 5' end of primer 
LD58c. Biotinylated PCR products were captured onto streptavidin-coated 
paramagnetic particles (Dynabeads M-280, Dynal, Oslo, Norway) and processed 
as described previously [Hultman et ai., 1991; Kleter et ai., 1994]. 
Phylogenetic analysis 
Molecular evolutionary distances between individual isolates were determined by 
the DNADIST program of the PHYLIP program version 3.5c [Felsenstein, 1993J. 
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Nucleotide sequence accession number 
The nucleotide sequences have been deposited in the EMBL data library (acces-
sion numbers X58937-X58953, X78858-X78860 and X78862 for 5'UTR 
sequences; Z29444-Z29474 and for core sequences). 
RESULTS 
HCV isolates were obtained from a large population of patients participating in a 
study on treatment of chronic hepatitis C, organized by the Benelux Study 
Group [Brouwer et aI., 1993J. All patients lived in the Netherlands or Belgium 
and were born in different countries (Table 1). After sequence analysis on 
5'UTR, 37 isolates were assigned as type 1 and 21 as type 2. 
Table 1. Country of birth of patients infected 
with HCV types 1 and 2 
HCV type 
Country of birth 2 
Belgium 5 3 
Germany 
Indonesia 2 
Italy 3 
Morocco 2 
Nigeria 
Spain 2 
Surinam 9 
the Netherlands 21 5 
Turkey 3 
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5'UTR genotyping 
HCV genotyping as performed by sequence analysis of the 5' UTR [Kleter et aI., 
19941 and LiPA [van Doorn et aI., 19941 resulted in identical subtyping for type 
1 as well as type 2 isolates (Table 2). One type 2 isolate (NE92) has been 
provisionally classified as "2d" (accession number X78862) because novel 
covariant mutations were observed at positions -163 and -122 [Kleter et aI., 
19941. Sequence analysis of the E1 and NS5B coding regions of this particular 
isolate confirmed classification as a separate subtype within type 2 [Stuyver et 
aI., 1994]. 
Table 2. Genotyping of 58 HCV type 1 and 2 isolates by LiPA 
15'UTRI and subtype·specific core amplification 
LiPA Core 
132' 296b 
Type N Type N N 
1 a 12 1a 8 7 
1b 
1a + 1b 2 2 
untypedC 2 
1b 25 1a 2 2 
1b 23 23 
2a 18 untyped 18 nd d 
2b 2 2b nd 
untyped nd 
2d untyped nd 
aSubtype-specific core amplification with antisense primers 132/133/134/135 
bSubtype-specific core amplification with antisense primers 296/133/134/135 
eNo reaction in the subtype-specific nested peR 
dnot determined 
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Subtype-specific core amplification 
The 58 type 1 and 2 isolates were analyzed subsequently also by a modified 
version of the subtype-specific core amplification method (Okamoto et aI., 
1992b]. In this study the originally described general sense primers 256 and 
104 were replaced by primers LD58c and LD58s respectively. This modification 
was introduced to circumvent possible failure of amplification by the general 
primers due to primer target mismatches (Fig. 1, 8207), a phenomenon which 
was also noticed by Okamoto et al. (1993). First round PCR products were 
obtained and subsequent subtype-specific amplification was completely depen-
dent on the antisense primers employed in the nested PCR. The core typing 
results are summarized and compared with LiPA in Table 2. 
Type 1 isolates. In 2 of the 37 type 1 HCV isolates, coinfections of subtypes 1 a 
and 1 b were detected by subtype-specific core amplification, whereas these 
isolates were typed as subtype 1 a by LiPA (Table 2). In order to confirm this 
finding, nested PCR products were analyzed by Southern blot hybridization with 
subtype 1 a- and 1 b-specific probes (Fig. 2). Probe 235, which is 1 b-specific, did 
not hybridize to the 1 b fragment of 342 bp. Probe 296, which is 1 a-specific, 
hybridized to the 255 bp (1 a) as well as the 342 bp (1 b) PCR fragment. This 
result indicated the presence of 1 a sequences also in the 342 bp (1 b) PCR 
fragment (Fig. 2, lane 12 and 13) and therefore, the subtype 1 b primer 133 had 
falsely amplified the subtype 1 a sequence. Additionally, direct sequencing of the 
N-terminal core region indicated that these two isolates contain only subtype 1 a 
sequences. Direct sequencing of 17 of the 37 type 1 isolates confirmed the 
subtype-specific core amplification results (Fig. 1). 
Two other isolates, NL29 and NL35, remained untyped by subtype-
specific core amplification (Table 2). Isolate NL35, typed as subtype 1 a by 
5'UTR analysis, could not be typed by subtype-specific core amplification (Fig 2, 
lane 25). Moreover, Southern blot hybridizations of the first round PCR 
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Type \ Primers 
"d 
positions 
" NL54 
Nl9 
NL56 
NL57 
Nl48 
NL43 
NL69 
1b 
HCV-J 
HCV-BK 
Nl5 
Nl6 
B207 
85S 
884 
865 
B75 
NL59 
probe 235 
1d 
NL35 
Nl2'! 
2, 
HCJ-6 
2b 
HCJ-8 
NL42 
B201 
2, 
(Ne) 
(Ne) 
(Ne) 
(It) 
(Ne) 
eNe) 
(Ne) 
(Ja) 
(Ja) 
eNe) 
(Ne) 
(Be) 
(Be) 
(Be) 
(Be) 
(Be) 
(Ne) 
(MO) 
(Mo) 
(Ja) 
(Ja) 
(Ne) 
(Be) 
583 (It) 
2c primerQ 
2d 
NE92 (Ni) 
2* 
NL49 
NL50 
NL33 
(5u) 
(Ne) 
(Su) 
256 --;::==+_ 1 1D4l 
139 167 
CGCGCGACGAGAAAGACTTCCGAGCGGTC 
1296 1 l132 l 
175 204 
CGAGGTAGACGTCAGCCTATCCCCAAGGCT 
1 133 _ 
272 291 
TGGGGTGGGCAGGATGGCTC 
-----------G----------------- -----------------------------G GC------------------
-- - -- - - -- - -G-- - -- --- -- --- -- -- - -- - - - - - -- - -- -- -- -- - -- -- -- - --A GC-- - --- - -G- -- - -- ---
----------------------------- -----------------------------G GC------------------
-----------G----------------- -----------------------------G GC--------G---------
- - - --- - -- - -G-- - -- --- -- - -- -- -- - -- -- - -- -- - -- -- - - - -- -- -- - -- --A GC- - - -- - - -G- -- - -- ---
-----------G----------------- -----------------------------G GC-T------G---------
-----------G----------------- -----------------------------G GC--------G---------
- - - -- - - -T --G-- - -- -- - -- --- -- -- - - T - -A--G- -A- -A-- --- -- -- -- - ---
-- - ---C-C--G-- -- - -- - -- -- - -- -- - - T - -A- -G- -A- -A-- --- -- -- -- - -- - -A-- - -- - --- --- -- - ---
-- - -- - -- T --G-- -- - -- - -- -- - - - -- - - T--A--G- -A- -A-- -- - -- -- -- - - - - - - -- - -- - -- - -- - -- - ---
-- - -- - --T --G-- --- -- - -- -- -- - -- - - T--A- -G- -A- -A--C- --- -- -G- - - - - - -- - -- - -- - --C-- - ---
-- - -- - --T --G- - -- - -- --- -A-- - - T - - T --A- -G- -A- -A-- -- -- - -- -- -- --
-- - -- - -- T --G-- -- - -- --- -- -- - -- --T --A- -G- -A- -A-- -- -- - -- -- -- --
-- - -- - -- T --G- - --- -- --- -- -- - -- --T--A- -G- -A- -A-- -- -- - -- -- ----
-- -A- - --T--G- - -- --- -- - -A-- --- --T --A- -G- -A- -A-- -- -- - -- -- ----
-- - -- - -- T --G- - -- --- --- -- -- -- - --T --A- -G- -A- -A-- -- - T - - - -- ----
-- - -- - -- T --G- - -- --- -- - -- -- --- - -T --A- -G- -A- -A-- -- -- ----- ----
--T --A- -G- -A--A-
1 '34 _ 
302 324 
GAGGTTCCCGTCCCTCTTGGGGC 
- T - -C- - T- -G- - TAGC-- - ---
- T - -C- - T - -G- -TAGC-- - ---
- T - -C- - T - -G- - TAGC- -- ---
- T - -C- - T - -G- -TAG- -- - ---
- T - -C- -T - -G- --AGC--- ---
- T - - -- - T - - G- - TAGC-- - ---
- T - -- - - T - -G- - TAGC-- - ---
- T - -C--T - -G-- TAG- -- - ---
-C- -C--- - -G-- TAG- - - - ---
-C--C-- T--G--TAGC- - - ---
-T--C-----G--TAG-------
-T--C-----G--TAG-------
-T-----T--G--TAG-------
-C--C--T--G--TAG-------
- T --C- - - --G- - TAG-- --- --
- T--C-- - - -G- - TAG-- --- --
od 
1 135 _ 
251 270 
CTCTGTACGGAAACGAGGGT 
-C--C-----C--T-----C 
-C--C--T--C--T------
-C--C-----C--------C 
-C--C--T--C--------C 
-C- -C--- --C-- T - - - --C 
-C--C--T--C--T-----C 
-C--C--T--C--T-----C 
-C--C--T--C---------
----C--T--C--T-----C 
-C- - C-- T - -C- - T --- --C 
-C--C-- T - -C- -T -- - --C 
-C--C--T - -C--T -- ---C 
-C--C--T - -C-- T -- ---C 
-C--C- - T - - CooT -- ---C 
-C--C--T--C--T-----C 
-C--C--T--C--T-----C 
od 
-- - -- - --C--G- - -- --- -- - -- -- -- - -- T -AC- -G- -A-- --- -- - T -- T -- -- -- GC- -A- - -- -G- - -- - -- - - -C--C- - T - -G- - -AG- - -- -- - -C- -C-- T - -C- - T- -- --C 
-- - -- - -- T --G- - -- -- - ----- -- -- - -- T- -C- -G- -A-- - -- -- -- -- --- -- -- GC- - -- - -- -G- - -- - -- - - -C- -C- - T - -G- --AA- - -- -- - -C- -C-- T - -C- - T - - - --C 
-- - -- - --A--G- - -- -- - -G-- - -- -- - --T- -A- -G- -C-- - --C- -- --T- - --A- -C-CC- - -- - -- --- - - --- -C--A-- -- -G--T -- ---A 
-- - -- - --A--G- -- - -- - - T-- - - -A- - --T - -AC-- - -C-- -- -C- -- --G- -A-A- GC- -C- -- - -G- - T- -- - -- -C- -G- - T - - - - - TA- -- - -- - - -C-- -- -- - -- -- -- -- ---
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product with either subtype 1 a- or 1 b-specific probes (296 and 235 respective-
ly) were also negative (Fig. 2, lane 24). Isolate NL29, typed as subtype 1 a by 
5'UTR analysis, was also identified as 1 a by subtype-specific core amplification 
with primer 132 (Fig. 2, lane 23). However, nested PCR with primer 296 (1a) 
instead of primer 132 did not yield a PCR fragment (Table 2). Southern blot 
hybridizations of first and second round PCR products with subtype 1 a- and 1 b-
specific probes were also negative (Fig. 2, lane 22 and 23). The isolates NL29 
and NL35 were obtained from patients born in Morocco (Table 2). Phylogenetic 
analysis of 310 nucleotides of the N-terminal core region revealed that these 
two isolates possibly belong to an additional type 1 subtype (Table 3). Further 
analysis of the E 1 and NS5B regions confirmed classification into subtype 1 d 
(unpublished observation). 
In 3 of the 37 type 1 isolates different sUbtypes were detected when 
comparing 5'UTR and Core typing. Two isolates (NL69 and NL43) were typed 
as subtype 1 b by LiPA but as subtype 1 a by subtype-specific core amplification 
(Fig. 2, lane 16 and 18). In one isolate (NL59) the opposite was observed (Fig. 
2, lane 20). Sequence analysis of the N-terminal core region (nt 1-310) con-
firmed the results of subtype-specific core amplification (Fig. 1). 
Figure 1. Comparison of type 1 and type 2 nucleotide sequences in the target region of 
the 2 universal sense (256 and 104) and the 4 subtype-specific antisense (132 (la), 
133 [lb), 134 [2a) and 135[2b)) core primers as described by Okamoto et al. [1992b). 
Probes 296 and 235 are sUbtype 1 a- and 1 b-specific, respectively. Dashes indicate 
identical nucleotides. The origin of the HeV isolates is given in parentheses: Be, 
Belgium; It, Italy; Ja, Japan; Mo, Morocco; Ne, the Netherlands; Ni, Nigeria and Su, 
Surinam. HCV-J [Kato et al" 1990); HCV-BK [Takamizawa et aI., 1991); HC-J6 and 
HC-J8 (Okamoto et aI., 1991, 1992a]); S83 [Bukh et aI., 1994); 6 subtype "2a" primer 
for European isolates as described by Silini et al. t 1993]. 
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Type 2 isolates. All 21 samples of type 2 isolates as deduced from sequence 
analysis of 5'UTR were HCV RNA positive after the first round of PCR with 
general primers LD58c and 186c. After the subtype-specific nested PCR, only 
one isolate was typed as subtype 2b (Fig. 2, lane 4) whereas all other type 2 
isolates remained untyped (Table 2). Five of the 20 untyped samples were 
sequenced and 3 to 6 mismatches were found to the type 2 subtype-specific 
primers 134 (2a) or 135 (2b; Fig. 1). The obtained sequences showed also 
mismatches to the HCV subtype "2a" primer for European isolates as described 
by Silini et al.[1993). This primer appeared to be specific for HCV subtype 2c 
(Fig. 1, S83). The subtype 2b isolate that was identified by PCR contained only 
a single mismatch at the very 5' end of subtype-specific 2b primer 135 (Fig 1, 
B201). 
Type 2 core sequences were subjected to phylogenetic analysis and 
molecular evolutionary distances were determined between our and published 
HCV subtype 2a (n=51. 2b (n=8), 2c (S83) and 2d (NE92) sequences (Table 
3). From this analysis it appeared that type 2 sequences are highly heteroge-
neous. The 3 isolates [typed as subtype 2a by LiPA (Fig 1, NL33, NL49 and 
NL50)) had greater molecular evolutionary distances to subtype 2a than the 
distances observed between subtypes 2c and 2d (Table 3). The distances 
among the 3 isolates were also greater (range 0.0647-0.0765) than the maxi-
mum distance between confirmed subtype 2a sequences (Table 3, 0.0605). 
These results suggest that these 3 isolates belong to 3 additional HCV type 2 
sUbtypes. This observation has been confirmed by sequence analysis of the E 1 
and NS5B regions (unpublished observations). Interestingly, 2 of the 3 new 
subtypes were detected in patients born in Surinam. In contrast to this heteroge-
neity, the core sequence of the two isolates typed as 2b by LiPA, were highly 
homologous to published 2b core sequences (Table 3). 
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Figure 2. Identification of subtype-specific nested peR products obtained with sense 
primer LD58c and antisense primers 132, 133, 134 and 135. Top: ethidiumbromide 
staining of agarose gels. Middle: Southern blot hybridization with sUbtype 1 a-specific 
probe 296. Bottom: Southern blot hybridization with subtype 1 b-specific probe 235. 
Typical results of subtype 1 a 1255 bpi, 1 b 1342 bpI. 2a 1372 bpi and 2b 1321 bpi are 
shown in lanes 1 to 4, respectively. Lanes 5 and 21 contain marker DNA, i.e., pBR322 
digested by Hinf!. Lanes 6 to 11 show subtype 1 a sequences, Lanes 12 and 13 show a 
coinfection of HeV subtypes 1 a and 1 b. Lane 14, negative peR control. Lanes 15, 17, 
19,22 and 24 show the first round PCR product of primer set LD58c/186c and lanes 
16, 18, 20, 23 and 25 show nested PCR products of isolate NL69 11 ai, NL43 11 al. 
NL59 11bl, NL29 11dl and NL35 11dl. respectively. 
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DISCUSSION 
The most reliable approach for genotypic classification of HCV isolates would be 
nucleotide sequencing of the entire RNA genome. Genotypic variation seems to 
be maintained throughout the viral genome [Chan et aI., 19921 and therefore, 
only part of the genome needs to be analyzed. However, for analysis of a large 
number of samples this is laborious and rapid HCV genotyping assays are 
therefore required. In this study sUbtyping of type 1 and type 2 HCV isolates 
was compared by two rapid assays, i.e., the LiPA and subtype-specific core 
amplification. 
5' UTR genotyping by LiPA 
For detection of HCV viremia RT-PCR is generally aimed at the 5'UTR. There-
fore, LiPA offers a convenient method for genotyping of HCV isolates supple-
mentary to HCV RNA detection in a routine diagnostic setting. The 58 isolates 
in this study showed that all LiPA results were in accordance with 5'UTR 
sequence analysis. However, in 7 [19%) of the 37 type 1 isolates subtyping 
results by LiPA were not similar to that obtained by subtype-specific core 
amplification. In the case of 5 HCV isolates this observation may be explained 
by the minimal sequence difference between subtypes 1 a and 1 b at position -
99. At this particular position subtype 1 a contains an Adenosine whereas 
subtype 1 b contains a Guanosine. This minor difference should be considered as 
lack of sufficient sequence variation in the highly conserved 5' UTR between 
subtypes 1 a and 1 b, rather than by recombination between these subtypes. On 
the other hand, nucleotide variations in the 5'UTR are analyzed thoroughly by 
LiPA. Each HCV type is recognized by 2 or more probes. By assessing hybridiza-
tion to multiple probes 26-41 % of the 5'UTR sequence is determined [Stuyver 
et aI., 1993a]. This contrasted the use of one subtype-specific primer for HCV 
genotyping in the subtype-specific core amplification system. 
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Table 3. Molecular evolutionary distances (range and mean ± SO) between HCV 
subtypes and isolates in the core region (nt 1 ~31 0) 
HCV type 1 isolates 
subtype! 
isolate 1a 1b lc NL29 
la 0.0065-0.0436 
0.0259 ± 0.0092 
lb 0.0682-0.1290 0.0197-0.0641 
0.0895 ± 0.0128 0.0369±0.0130 
lc 0.0572-0.0868 0.0716-0.1242 0.0000-0.0230 
0.0738 ± 0.0080 0.0941 ± 0.Q112 0.0177 ± 0.0066 
NL29 0.0596-0.0712 0.0489-0.0859 0.0593-0.0743 
0.0633 ± 0.0037 0.0659 ±0.0109 0.0653 ± 0.0057 
NL35 0.0900-0.1097 0.0757-0.1009 0.0900-0.1053 
0.0947 ± 0.0035 0.0853 ± 0.01 06 0.0990±0.0057 .0524 
HCV type 2 isolates 
subtype! 
isolate 2a 2b 2c 2d 
2a 0.0262-0.0605 
0.0384 ±0.0096 
2b 0.0719-0.1236 0.0065-0.0431 
0.1018±0.0135 0.0258 ± 0.0094 
2c 0.0711-0.0928 0.0858-0.1079 
0.0805 ± 0.01 00 0.0937 ±0.0065 
2d 0.0600-0.0817 0.0860-0.1079 
0.0672 ± 0.01 07 0.0955 ± 0.0056 0.0467 
NL33 0.0817-0.1037 0.1044-0.1271 
0.0891 ±0.0093 0.1100±0.0124 0.0572 0.0533 
NL49 0.0683-0.0975 0.0947-0.1093 
0.0821 ±0.0127 0.1020 ± 0.0056 0.0616 0.0649 
NL50 0.0716-0.1008 0.0978-0.1166 
0.0861 ± 0.0112 0.1068 ± 0.0079 0.0717 0.0824 
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Subtype-specific core amplification 
Two problems were encountered with subtype-specific core amplification in this 
study population of residents in Western Europe. First, although identification of 
type 1 isolates was clearly possible, 2 (5.5%) of the 37 HCV type 1 isolates 
were diagnosed as a 1 a and 1 b coinfection. Theoretically, this phenomenon 
could be explained by the presence of a small amount of subtype 1 b sequences 
that could have been detected by the highly sensitive nested PCR. However, 
direct sequencing and Southern blot analyses with subtype 1 a- and 1 b-specific 
probes revealed that these isolates only contained subtype 1 a sequences. A 
more likely explanation therefore seems to be imperfect annealing of primer 133 
to the subtype 1 a genome, resulting in aspecific amplification [Andonov and 
Chaudhary, 1994J. Non-specific amplification occurred only in HCV subtype 1 a 
isolates (Fig. 1 and 2). The opposite phenomenon, i.e., nonspecific amplification 
of '1 a' sequences in subtype 1 b isolates was not observed. 
Secondly, identification of type 2 isolates by subtype-specific core 
amplification was a major problem. Of the 21 HCV type 2 isolates, only 1 isolate 
could be subtyped as subtype 2b although a positive result was obtained in all 
cases after the first round of PCR. The remaining 20 untyped isolates did not 
yield any nested PCR fragment, even after reducing the annealing temperature in 
the nested PCR to 55°C (data not shown). The antisense core primers are 
subtype-specific. Therefore, failure of the nested PCR may be explained by 
mismatches between the subtype-specific primers and their target sequences as 
is illustrated in Figure 1 (i.e. NL42: 3 mismatches to primer 135). 
Recently, identical 5'UTR sequences were described for subtypes 2a and 
2c [Bukh et aI., 1993J. Therefore, it is possible that the 18 isolates, typed as 2a 
by LiPA, belong to HCV subtype 2c. However, phylogenetic analysis carried out 
on 3 of these 18 samples suggested that each of these isolates could be 
classified into yet another subtype. This observation suggests the existence of 
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multiple subtypes among type 2 isolates in Western Europe and requires 
confirmation by sequence analysis of the E1 and NS5B regions. Theoretically, 
the subtype-specific "2a" primer as described by Silini et al. (1993) would not 
allow typing of the 3 type 2 isolates due to mismatches at essential positions 
(Fig. 1). These results indicate that HCV type 2 isolates in our study population 
are considerably different from the published type 2 isolates from Japan 
[Okamoto et aI., 1991, 1992b). Technically, subtype-specific core amplification 
is a feasible assay for subtyping of HCV isolates. However, improvement of the 
subtype-specific core amplification assay for typing of HCV isolates will be 
difficult due to the extended variation among HCV sUbtypes. At present more 
than 29 HCV subtypes have been reported [Bukh et aI., 1994; Stuyver et al" 
1994; Tokita et aI., 1994a, 1994b). 
In summary, it appeared that several HCV RNA isolates remained untyped 
by subtype-specific core amplification, indicating that this typing method is 
restricted to the patient population to be analyzed. Furthermore, rapid geno-
typing results obtained by either LiPA or subtype-specific core amplification 
were generally in accordance with sequence analysis at respectively the 5'UTR 
and core regions. However, the specificity of both rapid genotyping assays is 
occasionally hampered due to a lack or excess of sequence variation in their 
respective target regions as is sequence analysis for HCV typing if restricted to 
one of these regions. 
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HCV type and patient related factors 
ABSTRACT 
HCV RNA isolates from 292 chronically infected patients living in the Benelux 
countries were genotyped by the Line Probe Assay (LiPA). Subsequently, the 
relationship with geographical origin of the patient, route of transmission, 
clinical characteristics and severity of liver disease was analyzed. Patients of 
European origin were predominantly infected with HCV subtype 1 b (164/257, 
64%, 95%CI 58-70). Also, the 13 patients of Asian origin were most frequently 
infected with HCV subtype 1 b (54%). The ten patients originating from Surinam 
(South America) had predominantly type 2 (90%) while this was only 5% in 
Europeans. Africans were mainly infected with type 4 (7/12, 59%); this was 
only 4% in Europeans. Blood transfusion was established as the most suspected 
route of transmission in 145 (49%) patients; in these HCV subtype 1 b was 
predominant (68%, 95%CI 61-76). In the group of 40 (14%) patients that might 
have contracted their infection by intravenous drug abuse (lVDA) HCV subtype 
1b was only 17% (P<0.001). Patients infected by IVDA had mainly subtype 1a 
and type 3, respectively 10 (25%) and 18 (45%) individuals. Occupational 
needle accident or tattoo was a possible mode of transmission in 11 (4%) 
patients. In 96 (33%) patients risk factors for exposure to the virus could not be 
identified. Cirrhosis was observed in 70 (24%) patients. No significant 
relationship was found between a specific HCV (sub)type and the presence of 
cirrhosis, although 10 (43%) of the 23 HCV type 2 infected patients had 
cirrhosis and this was absent in the seven patients with HCV type 5 (P = 0.09). 
In summary, the HCV types 1 to 5 as detected in this population were related to 
the country of origin and the route of transmission. No evidence was found that 
HCV (sub)types have an influence on the clinical characteristics or on the 
severity of liver disease. 
INTRODUCTION 
Sequence analysis of the hepatitis C virus (HCV) RNA genome revealed 
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considerable heterogeneity between patient isolates. Currently, there is evidence 
for the existence of at least 9 major HCV types [Tokita et aI., 1994al. These 
types are classified according to an useful system based on nucleotide variations 
[Simmonds et aI., 1993]. By sequence analysis of 222 nucleotides in the NS5 
region, HCV isolates can be provisionally classified as a new HCV type when 
sequence similarities are less than 72% with any known sequence whereas 
sequence similarities of 75% to 86% would provide evidence for a new HCV 
subtype. Classification could be confirmed by both sequence analysis of another 
coding region and phylogenetic analysis, which would indicate the relationship 
with already characterized HCV (sub)types. This method for classification of 
HCV isolates has been accepted by the international community [Simmonds et 
aI., 19941. 
For identification of HCV isolates several rapid typing assays have been 
designed. They include techniques such as (sub)type-specific reverse 
hybridization at the 5' untranslated region (5'UTR) by a Line Probe Assay [LiPA; 
Stuyver et al., 1993; van Doorn et aI., 1994], restriction fragment length 
polymorphism (RFLP) at 5'UTR [McOmish et aI., 19931 and subtype-specific 
amplification of either the core region [Okamoto et aI., 19921 or the NS5B region 
[Chayama et al., 1993]. 
Fast typing of HCV isolates revealed that the distribution of HCV 
(sub)types was different between various countries or geographical areas 
[Takada et aI., 19931. In Japan HCV subtype 1b is most prevalent (70-80%) 
[Takada et aI., 1993; Chayama et aI., 1993; Yamada et aI., 19941 and in the 
USA HCV subtypes 1 a and 1 b were detected in 74% of the patients [Mahaney 
et aI., 19941. HCV type 2 co-exists with subtype 1 b at an incidence of about 
20% in Japan as well as in the USA [Takada et al., 1993; Chayama et aI., 
1993; Yamada et aI., 1994; Mahaney et aI., 19941. In European countries the 
prevalence of HCV type 1 as determined in blood donors was 47% in Scotland 
and as high as 98% in Hungary [McOmish et aI., 19941. Approximately 40% of 
the Scottish blood donors were infected with HCV type 3 [McOmisch et aI., 
1994]. This type was also frequently found in small populations from Nepal and 
Thailand [Mori et aI., 1992; Tokita et al 1994b; Apichartpiyakul et aI., 19941. 
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HCV type 4 was observed in the majority of patients from the African countries 
[Stuyver et aI., 1993; Dusheiko et aI., 1994; Xu et aI., 1994], and HCV types 5, 
6 and 7-9 were locally detected in, respectively South-Africa, Hong-kong and 
Vietnam [Bukh et aI., 1992; Simmonds et aI., 1994; Tokita et aI., 1994a]. Since 
different HCV [sub)types exist, it is of interest to know whether differences in 
prevalence of HCV types are related to the mode of transmission. High rates of 
HCV antibodies have been found among patients infected by blood transfusion 
[Alter et aI., 1989; Esteban et aI., 1989; Kuo et al., 1989; van der Poel et aI., 
1989], haemophiliacs [Esteban et aI., 1989; Roggendorf et aI., 1989; van der 
Poel et aI., 1991], intravenous drug addicts [Esteban et aI., 1989; Roggendorf et 
aI., 1989J and in non-A, non-B hepatitis patients without identified risk factors, 
so called sporadic hepatitis C [Kuo et aI., 1989; Roggendorf et aI., 1989J. In 
contrast, rather low prevalence figures have been recorded among sexual 
partners and in children from HCV positive mothers [Brettler et aI., 1992; Reinus 
et aI., 1992; Wejstal et aI., 1992; Bresters et aI., 1993; Lam et aI., 1993]. 
HCV causes a chronic infection in the majority of cases [Alter et aI., 
1989; Gerber 1993J and may progress towards liver cirrhosis and hepatocellular 
carcinoma [Bruix et aI., 1989; Colombo et aI., 1989; Kew et aI., 1990; Saito et 
aI., 1990; Bukh et aI., 1993]. This process of liver damage may take decades 
[Yano et aI., 1993], although some patients developed cirrhosis within 5-10 
years after detection of onset of the disease [Realdi et aI., 1982; Hay et al., 
1985J. The clinical implications of different HCV (sub)types were only partially 
analyzed in either small patient cohorts or in a selected number of (sub)types 
[Dusheiko et aI., 1994; Qu et aI., 1994; McOmish et aI., 1993; Takada et aI., 
1992; Yamada et aI., 1994J. It has been suggested that HCV subtype 1 b causes 
a more serious liver disease than other (sub)types in either uncompromised 
patients [Pozatto et aI., 1991; Dusheiko et aI., 1994J or in patients after liver 
transplantation [Feray et aI., 1995). 
In the present study we used LiPA (Innogenetics, Gent, Belgium) for 
typing of 292 HCV RNA isolates from chronically infected patients and 
correlated the typing data with geographical origin of the patients, route of 
transmission, clinical characteristics and severity of liver disease. 
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MATERIALS AND METHODS 
Patients 
The 292 patients investigated in the present study were derived from a 
population of 355 patients with a chronic HCV infection who enrolled in a mulli-
centre randomized trial organized by the 8enelux Study Group on treatment of 
hepatitis C [8rouwer et aI., 1993]. Resulls of interferon therapy will be 
described elsewhere. The patients lived in the Benelux (Belgium, the Netherlands 
or Luxembourg) area of Western Europe and were between 26 and 74 years of 
age, had elevated alanine aminotransferase (AL T) levels of at least twice the 
upper limit of normal (i.e. 301U/L) for more than 6 months, confirmed antibodies 
to HCV except for one, detectable HCV RNA and liver histology compatible with 
chronic non-A, non-B hepatitis. Patients with concomittant other causes of liver 
disease were excluded. 
HCV genotyping was performed in 320 (90%) of the 355 cases. 
Information on the background of the HCV infection was received in 312 (88%) 
of the 355 patients. In 14 of these 312 cases the HCV type was not determined 
due to reconsideration of diagnosis in 5, and no blood being available in 9. 
Additionally, in 6 cases, liver histology could not be determined because liver 
biopsy was not done. The clinical characteristics of the 63 patients excluded did 
not differ from the 292 patients discussed in this study. 
Questionnaire 
The patients were specifically orally questioned by their local physician for the 
backgrounds of the HCV infection with the use of a questionnaire. Questions 
were related to: (il the ethnic origin (race, nationality, country of birth and living 
abroad for 6 months or morel. (iii the mode and date of acquisition: i.e. type of 
surgery in the past, use of blood-products and occurrence of jaundice; 
intravenous drug abuse; receipt of tattoos; promiscuity. Subjects who had no 
risk factors, identified were scored as sporadic hepatitis C. 
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Liver biopsy 
Liver tissue was obtained by needle biopsy and examined by the local 
pathologist for inflammatory activity and stage of fibrosis. From the 292 liver 
biopsies 246 (84%) were re-evaluated by one central pathologist. Discordant 
results for cirrhosis were found in 22 (8.9%) cases. The kappa value was 0.74 
meaning a good correlation. Therefore, biopsy results from the local pathologist 
were used in the analysis. 
Antibodies 
Antibodies to HCV, as locally determined by screening assays, were confirmed 
by R18A-2 (Ortho Diagnostics, Raritan, NJ, USA) andlor Inno-UA HCV Ab II 
andlor III (Innogenetics, Gent, 8elgium) according to the instructions of the 
manufacturer. Hepatitis 8 core antibodies were detected by EIA (Abbott, North 
Chicago, IL, USA). 
Blood samples 
For HCV RNA detection and HCV genotyping, plasma samples obtained prior to 
interferon treatment were analyzed. EDTA-blood was collected by venipuncture 
and plasma was prepared within 2 hours after sampling. Samples were stored at 
-70°C and shipped on frozen carbondioxide. 
HCV genotyping 
The viral RNA was isolated as described previously [Kleter et aI., 1993J and RT-
PCR (40 cycles, 1 min at 94°C, 2 min at 48°C, 3 min at 72°C) was performed 
at the 5'UTR with sense primer HCV35 (TTGGCGGCCGCACTCCACCATGAAT-
CACTCCCC, positions -296 to -318; the underlined sequence is not complemen-
tary to HCV) and anti-sense primer HCV19 (GTGCACGGTCTACGAGACCT, 
positions -1 to -20). The amplification products were used in the Line Probe 
Assay (Inno-LiPA, Innogenetics, Gent, Belgium) for HCV typing [Stuyver et aI., 
19931. 
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Statistics 
Percentages were compared using the Chi-square test, or Fisher's exact test if 
appropriate. Continous data were compared using the t-test. Logistic regression 
was used to investigate the relation between the percentage of cases with 
cirrhosis and various characteristics simultaneously. P=0.05 (two-sided) was 
considered as the limit of significance. 
RESULTS 
HCV (sub)types 
By means of LiPA, 286 (98%) of the 292 HCV isolates were identified as type 1 
to 5 (Table 1). Four HCV isolates were provisionally classified as type "1 '''. 
Two of these isolates did not react with the type 1 subtype probes and two 
isolates from patients originating from Morocco could be classified as subtype 
1d as indicated by core, core/E1 and NS5B sequence analysis (unpublished 
observations). Mixed HCV infections were observed in two patients. One was 
infected with HCV subtypes 1 a and 1 b whereas the other had HCV types 1, 3 
and 4. 
Geographical regions 
In the 292 patients analyzed, a significant association between HCV type and 
origin was noted. HCV (sub)types 1 a, 1 b, 2, 3, 4 and 5 were found in 257 
European patients (Table 1). In this group HCV subtype 1 b was predominant 
and identified in 164 cases (64%, 95%CI 58-70%). The other HCV (sub)types 
were detected at frequencies ranging from 3-15% (Table 1). Similarly, HCV 
subtype 1 b was documented in 7 of the 13 Asian patients. The distribution of 
HCV types in the 13 Asian patients was not significantly different from that 
observed in the 257 Europeans. In contrast, HCV type 2 was predominantly 
present in the ten patients originating from Surinam, a former Dutch colony in 
South America (90%; 95%CI 67-100). This type was observed in only 5% of 
the Europeans. Similarly, HCV type 4 was most prevalent in the 12 Africans 
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Table 1. Distribution of HeV types per geographic origina of the patient 
South 
HCV Total Europe Asia Africa America 
(sub)type 292 257 13 12 10 
1a 24 (8%) 22 (8%) 2 (15%) 0 0 
1b 172 (59%) 164 (64%) 7 (54%) 1 (8%) 0 
1* 4 (1%) 2 (0.7%) 0 2 (17%) 0 
2 23 (8%) 13 (5%) 0 1 (8%) 9 (90%) 
3 44 (15%) 39 (15%) 4 (31 %) 0 1 (10%) 
4 16 (5%) 9 (4%) 0 7 (59%) 0 
5 7 (2%) 7 (3%) 0 0 0 
multiple 2 (1%) 1 (0.3%) 0 1 (8%) 0 
aorigin was determined by country of birth 
(59%; 95%C( 26-91) while this was only found in 4% of the patients of 
European origin. The seven African patients infected with HCV type 4 were born 
in Egypt (n = 4), Zaire (n = 2) and Morocco (n = 1). 
Mode of acquisition 
HCV transmission by blood transfusion was established in 145 (49%) of the 
292 cases (Table 2). In these patients HCV types 1 to 5 were present but 
subtype 1b was predominant (68%, 95%CI 61-76). Contraction of the HCV 
infection by intravenous drug abuse (IVDA) was documented in 40 cases (Table 
2). In contrast to blood transfusion subtype 1 b was found in only 17% of the 
IVDA group (P<0.001). Patients infected by IVDA had mainly subtype 1a 
(25%) and type 3 (45%). IVDA was the major route of transmission for subtype 
1 a (42% of the cases) and type 3 (41 % of the cases), whereas it was a minor 
cause of infection for all other types (mean 6%). 
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Table 2. Prevalence of HCV (sub)types per route of transmission 
HCV Transfusion 
(sub)type 145 (49%) 
la 9 (6%) 
lb 99 (68%) 
l' 1 (1 %) 
2 10 (7%) 
3 15 (11 %) 
4 3 (2%) 
5 6 (4%) 
multiple 2 (1%) 
aintravenous drug abuse 
IVDN 
40 (14%) 
10 (25%) 
7 (17%) 
0 
3 (7%) 
18 (45%) 
2 (5%) 
0 
0 
boccupational needle accident or tattoo 
cincluding promiscuity 
Needleb 
11 (4%) 
0 
3 (27%) 
0 
(9%) 
4 (37%) 
3 (27%) 
0 
0 
SporadicC 
96 (33%) 
5 (5%) 
63 (66%) 
3 (3%) 
9 (9%) 
7 (7%) 
8 (8%) 
(1 %) 
0 
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Total 
292 
24 (8%) 
172 (59%) 
4 (1 %) 
23 (8%) 
44 (15%) 
16 (5%) 
7 (2%) 
2 (1%) 
The route of HCV transmission remained unknown in 96 (33%) cases, 
therefore these infections were classified as sporadic hepatitis C (Table 2). In 6 
sporadic cases, patients had marked promiscuity as a possible source of their 
HCV infection. In these so·called sporadic cases, HCV (sub)types 1 a, 1 b, 2, 3, 
4, and 5 were found at a similar incidence rate as in patients who had 
undergone blood transfusion. Similarly, clinical characteristics (age, gender, anti· 
HBc) and liver disease (AL T and histology) were comparable in both groups. The 
median age of the patients infected by blood transfusion was 48 (range 24·73) 
years and it was 47 (range 24·72) years for those with sporadic hepatitis C. The 
prevalence of a previously resolved HBV infection was 14% (95%CI 9·20) in 
transmission by blood transfusion and 21 % (95%CI 13·29) in sporadic hepatitis 
C. The median serum levels of AL T were 131 (range 45·926) lUlL and 114 
(range 37·505) lUlL for respectively, blood transfusion and sporadic 
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Table 3. Comparison of clinical characteristics with different HeV (sub)types 
HCV Male Jaundice Anti-HBc Agea Durationa.b 
Isubltype 177 (61%1 34 (12%1 57 (20%1 45 (22-731 13 (1-451 
la 18 (75%1 1 (4%1 6 (25%1 35 (22-671 10 (1-241 
lb 93 (54%1 18 (10%) 24 (14%1 49 (24-721 13 (1-451 
1 * 4 (100%1 0 2 (50%1 45 (24-681 25 (17-331 
2 15 (65%1 3 (13%1 12 (52%1 47 (26·681 17 (4-381 
3 30 (68%1 5 (11 %1 8 (18%1 37 (22-731 10 (1-311 
4 13 (81%1 3 (19%1 4 (25%1 37 (24-681 15 (5-271 
5 3 (43%1 3 (43%1 1 (14%1 49 (30-651 16 (1-281 
mUltiple 1 (50%1 1 (50%1 0 34 (34-351 2 (1-21 
aData expressed as median (range) in years 
bDuration of infection could be determined in 193 patients 
hepatitis C. Cirrhosis was found in 26% (95%CI 19-341 of the patients infected 
by blood transfusion and in 25% (95%CI 17-35) of those infected by sporadic 
hepatitis C. 
Clinical characteristics 
Gender and jaundice were not significantly related to a specific HCV (sub)type 
(Table 31. A previously resolved HBV infection, anti-HBc positivity, was found in 
57 (20%) of the 292 patients (Table 3). A high incidence of hepatitis B core 
antibodies was observed in HCV type 2 infected patients (52% for type 2 
versus 16% in all other types, P<O.OOll. An association between age and HCV 
(sub)type was also observed (Table 31. Older patients appeared to be infected 
with HCV (sub)types 1 b, 2 and 5, whereas the younger ones were infected with 
1 a, 3 and 4 (P< 0.0011. 
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Table 4. Comparison of the activity of liver inflammation and liver histology 
with different HCV Isub)types 
HCV ALT' CPH CAH Cirrhosis 
Isub)type 147 137-927) 68123%) 154153%) 70124%) 
1a 141 142-291) 6125%) 14 158%) 4 117%) 
1b 144 138-927) 39 123%) 90 152%) 43 125%) 
1 • 144198-194) 1 125%) 1 125%) 2 150%) 
2 145 137-439) 3114%) 10 143%) 10 143%) 
3 165 154-505) 9120%) 26 160%) 9120%) 
4 161 153-322) 5131%) 9156%) 2 113%) 
5 132 150-272) 3143%) 4157%) 0 
multiple 65 157-72) 2 1100%) 0 0 
aAL T, alanine aminotransferase; data expressed as median (range) in lUll 
CPH, chronic persistent hepatitis; CAH, chronic active hepatitis 
Liver disease 
Neither the activity of liver cell necrosis (as measured by AL T concentrations in 
serum) nor the presence or absence of cirrhosis (P=0.09) were related to any of 
the HCV (sub)types (Table 4). In the study popUlation, 70 (24%) patients had 
cirrhosis and the duration of infection could be established in 193 (66%) 
patients (Table 4). Multivariant regression analysis of the probability of the 
presence of cirrhosis was significantly independentlY associated with both older 
age (P<0.001) and longer duration of infection iP=0.009). The median age in 
cirrhotic patients was 55 (range 36-73) years whereas it was 42 (range 22-71) 
years in those without cirrhosis. The median duration of infection in patients 
with cirrhosis was 16 (range 2-42) years whereas it was 7 (range 1-45) years 
when cirrhosis was absent (P<O.OO1). 
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DISCUSSION 
In this report HCV isolates from 292 chronically infected patients were 
investigated for the HCV (sub)type. Subsequently, the relationship with the 
geographical region of origin, routes of transmission, clinical characteristics and 
liver disease was studied. 
HCV typing 
Typing of HCV RNA isolates was performed by means of LiPA. We previously 
reported on the similarity between the results of LiPA and direct sequencing of 
the 5'UTR [van Doorn et aI., 1994). Furthermore, sequence data of the coding 
regions core, E 1 and NS5B obtained from several of our HCV isolates, indicated 
that they were correctly divided into the major HCV types [Stuyver et al,. 1994; 
van Doorn et aI., 1995]. However, subtype-specific core amplification revealed 
that 3 (8.1 %) of 37 analyzed HCV type 1 isolates were not correctly subdivided 
by LiPA into the subtypes 1 a and 1 b [Kleter et aI., 1995). In addition, the LiPA 
version used did not discriminate between types 1 and 6. This limitation of LiPA 
was not of influence on our results because none of the studied patients 
originated from Hong-Kong or other areas with a high prevalence of HCV type 6. 
Distribution and Transmission 
A significant difference was found in the distribution of HCV (sub)types 
according to the geographical region of origin as defined by birth. HCV subtype 
1 b was predominant in Europeans and Asians, whereas HCV type 2 was more 
common in Surinam patients (South-America) and HCV type 4 in Africans. The 
observed predominance of subtype 1 b in Europe is in accordance with previous 
reports on smaller European populations [Ou et aI., 1994; Nousbaum et aI., 
1993; McOmish et aI., 1994; Pistello et aI., 1994; Yun et aI., 1994]. In these 
studies the majority of HCV isolates from European origin belonged to HCV type 
1. HCV subtype 1 b was most prevalent when HCV typing was performed by 
subtype-specific core amplification, except for Sweden IYun et al., 1994). The 
similarity with other European studies indicates that the somewhat reduced 
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reliability of dividing HCV type 1 isolates into 1 a and 1 b by LiPA did not 
influence final results. 
Seven (54%) of the 13 patients born in Asia were infected with HCV 
subtype 1 b. In Japan, approximately 70% of the HCV infected patients have 
subtype 1 band 18% have subtype 2a [Chayama et aI., 1993; Yamada et aI., 
1994]. HCV typing results indicated that type 1 is the most abundant type in 
the western world [McOmish et aI., 1994; Chayama et aI., 1993; Yamada et al., 
1994; Mahaney et aI., 1994], although it cannot be excluded that the 
prevalence of other HCV types is underestimated. Indeed, the first generation 
anti-HCV screening assays appeared to be less sensitive for detection of HCV 
type 2 and 3 [Chan et aI., 1991; van Doorn et aI., 1994J since the applied 
recombinant antigens, i.e., clones 5-1-1 and C100-3, were derived from HCV 
type 1 sequences. 
The ten patients from Surinam origin were all except one infected with 
HCV type 2. This type appeared to be rather rare in the neighbor country Brasil, 
since most patients studied from Brasil were infected with HCV type 1 [Stuyver 
et aI., 1993], In the 12 patients of African origin, HCV type 4 was predominant. 
This had also been observed by others in small African populations, e.g in 
patients originating from Burundi [Stuyver et aI., 1993], Egypt [Dusheiko et aI., 
1994J or Gabon [Xu et aI., 1994J. These data suggests that HCV type 4 is the 
most common type in Northern and Central African countries. 
Analysis of HCV transmission routes revealed that HCV transmission by 
IVDA was clearly correlated with the HCV subtype 1 a and and type 3. Within 
our population of 40 drug addicts the prevalence of subtype 1 a and type 3 was 
respectively 25% and 45%. This observation is in accordance with others who 
reported also a high frequency of either HCV subtype 1 a [Andonov et aI., 1994; 
Apichartpiyakul et aI., 1994; Qu et aI., 1994) or HCV type 3 [McOmish et aI., 
1993; Apichartpiyakul et aI., 1994J transmission by IVDA. In these studies the 
groups of drug addicts ranged from 9 to 34 patients. The similarity found for 
HCV subtype 1 a, might be an indication for the reliability of HCV subtyping into 
1 a and 1 b by LiPA. This is because HCV typing was performed by either 
subtype-specific amplification or subtype-specific hybridization of the core or 
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NS5 regions [Andonov et aI., 1994; Apichartpiyakul et aI., 1994; Qu et aI., 
1 994). In contrast, patients who acquired their infection by blood transfusion 
and those without identified risk factors, i.e. sporadic hepatitis C, were 
predominantly infected with HCV subtype 1 b (Table 2). No significant 
differences were found between so-called posttransfusion and sporadic cases in 
the prevalence of HCV (sub)types nor in the clinical characteristics or the 
severity of liver disease. Although non-parenteral HCV transmission has been 
reported [Thaler et aI., 1 991), the risk for vertical as well as horizontal 
transmission is probably less than 5% [Brettler et aI., 1992; Reinus et al., 1992; 
Wejstal et aI., 1992; Bresters et aI., 1993; Lam et aI., 1993). Therefore, it could 
be speculated that hidden parenteral factors such as non-single use of needles in 
e.g. vaccination are involved in patients with sporadic hepatitis C. 
Clinical characteristics and liver disease 
Neither gender nor jaundice were statistically associated with a specific HCV 
(sub)type. The jaundice incidence of 12% (Table 3) was similar to that reported 
by others who found this in 6-17% of the cases [Miyamura et aI., 1990; van der 
Poe I et aI., 1991; Crawford et aI., 1994). 
Young individuals were more frequently infected with HCV (sub)type(s) 
1 a, 3 and 4 than older ones. This observation could be caused by the fact that 
younger patients had acquired the HCV infection more often by IVDA. The 
median age for HCV infection by IVDA was 32 (range 22-43) years whereas it 
was 47 (range 24-73) years for other modes of transmission (P< 0.001). 
The activity of liver cell damage as estimated by AL T was not related to 
any of the HCV types 1 to 5. Similar results are reported for HCV types 1, 2 and 
3 [McOmish et aI., 1993; Yamada et aI., 1994). From a small study it has been 
suggested that HCV subtype 1 b causes a more serious liver disease than other 
(sub)types [Pozatto et aI., 1991} and therefore the presence of this subtype 
could have clinical implications. This finding was supported by others 
[Nousbaum et aI., 1993; Dusheiko et aI., 1994, Pistello et aI., 1994). In our 
study no significant relation was observed between the HeV (sub)types and the 
presence of cirrhosis. Recently, Mahaney et al. [1994) reported a more severe 
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liver disease in patients with HCV type 2 (P=0.0027). In our study, 10 (43%) 
out of the 23 patients with HCV type 2 had cirrhosis, but this might also be 
caused by the high percentage of hepatitis B infection in this group (52%). The 
presence of cirrhosis appeared to be related to older age and longer duration of 
infection as indicated by multivariant analysis. The fact that elderly are more 
often infected with HCV subtype 1 b or HCV type 2 might explain why small 
studies using univariant analysis appear to find a relation between the HCV type 
and cirrhosis [Pozatto et aI., 1991; Nousbaum et aI., 1993; Dusheiko et aI., 
1994, Pistello et aI., 1994; Mahaney et aI., 1994}. In two Japanese studies 
with respectively 251 and 148 patients similar results as ours were obtained 
concerning the severity of liver disease [Yamada et aI., 1994; Mita et aI., 19941. 
The HCV isolates analyzed by these investigators contained mainly the HCV 
subtypes 1 band 2a. These subtypes were not related with AL T and cirrhosis. 
These and our findings suggests that the HCV (sub)type is not an important 
factor in the progression towards cirrhosis. Since these studies are based on 
retrospective analysis, a final statement on this point can only be made when 
large cohorts of hepatitis C patients have been prospectively followed for over 
20 years. 
In conclusion, this retrospective analysis revealed no evidence for a 
marked influence of HCV (sub)type on clinical characteristics nor on the 
presence of cirrhosis. However, HCV genotyping seems to be a valuable tool to 
study the epidemiology of hepatitis C. 
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(samenvatting en discussie) 
Summary and general discussion 
Hepatitis C virus detection 
After the discovery of hepatitis C virus IHCV) as the causative agent for 
parenterally transmitted non-A non-B hepatitis INANBH), several detection 
assays were developed for diagnosis of HCV infection. Firstly, HCV screening 
and confirmation assays Isuch as RIBA-2 and LlA-11) allow detection of HCV 
antibodies to peptides or cloned HCV antigens. HCV antibody assays were used 
because the level of circulating HCV antigens in serum is too low to be detected 
by conventional enzyme immunoassays. The disadvantage of antibody detection 
for HCV diagnosis is the problem of discrimination between an ongoing and a 
resolved infection. Furthermore, HCV antibodies can only be detected after a 
window period of seronegativity Ii.e. absence of HCV antibodies) and are hardly 
present in immuno-compromised patients. Currently, HCV RNA detection is the 
only feasible method to determine HCV viremia. Confirmation of HCV viremia by 
other methods such as cell culture is yet not available, therefore reliable HCV 
RNA test results are required for adequate diagnosis. 
For direct detection of HCV viremia an HCV RNA assay based on the 
reverse transcription polymerase chain reaction IRT-PCR) technique, with 
primers directed to the highly conserved 5'untranslated region IUTR), was 
developed. 5'UTR primer sets appear to be superior in universal detection of 
hepatitis C when compared with primer sets derived from coding regions such 
as core, NS4 or NS5 [Garson et ai., 1990 and 1991; Cristiano et ai., 1991; In-
chauspe et ai., 1991; Bukh et ai., 1992; Cuypers et ai., 1992l. Since qualitative 
data are produced by PCR, 'negative' test results Ii.e. HCV RNA undetectable) 
will have an additional value if the detection limit of the PCR assay is known. 
Analysis of HCV dilution series by the branched DNA assay IHCV-Quantiplex, 
Chi ron, Emeryvile, CAl revealed a detection level for our HCV RNA PCR assay of 
500-1000 HCV genome equivalents per mi. Besides sensitivity, false positivity is 
a well-known problem of highly sensitive amplification methods. Therefore, our 
"in-house" developed HCV RNA PCR assay was evaluated in two quality control 
panels IChapter 2). Both proficiency panels, "1992" and "1993", each consi-
sted of 10 undiluted samples and two dilution series. In these quality control 
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studies, our laboratory had produced results of high sensitivity and specificity 
[Zaaijer et aI., 1993; Cuypers et aI., 1994] and no false-positive results were 
obtained. Furthermore, the strategy followed for HCV RNA detection was useful 
since highly reliable HCV RNA results were produced. HCV samples were 
analyzed in two independent experiments and confirmed results were accepted 
as valid and formed the final test result. In case of a discordant result, sample 
analysis was repeated in two independent experiments. Test results that 
remained discordant were classified as indeterminate. 
The advantage of powerful amplification techniques for detection of small 
quantities of DNA or RNA is also their disadvantage. Therefore, in assays for 
HCV RNA detection by RT-PCR or other amplification methods like nucleic acid 
system based amplification (NASBA) and ligase chain reaction (LCR), positive as 
well as negative controls are crucial to determine the quality and sensitivity in 
each experiment. RT-PCR test results are dependent on enzyme activity and 
pi petting accuracy of laboratory workers [Mahony et aI., 1994]. A low level 
positive control is necessary to ensure the reproducebility of each experiment 
and sufficient negative controls are required to exclude false-positive results 
which are mostly caused by cross-contamination. Interestingly, even the appli-
cation of a semi-automatic PCR assay (HCV-Amplicor, Roche) did not guarantee 
exclusion of false-positive results [Cuypers et aI., 1994]. The quality of the 
Roche Amplicor HCV-test results seems to be related with a good performance 
of the in-house developed PCR assay. These results indicated that besides a 
good strategy for analysis, only well trained laboratory workers are able to 
produce reliable PCR results. 
For treatment of HCV, alpha interferon (IFN) has been used as the 
standard drug for several years. The effect of IFN therapy was initially deter-
mined by monitoring alanine aminotransferase (AL T) levels in serum. From these 
studies it appeared that 50% of the patients with normalizing AL T during 
treatment (i.e. biochemical response) relapsed after cessation of therapy. 
Monitoring HCV RNA revealed that alpha IFN suppresses viral replication in most 
of the patients who had a biochemical response during treatment [Chayama et 
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aI., 1991; Shindo et aI., 1991; Chapter 3]. Additionally, relapse of the disease, 
defined as AL T elevation after treatment, is observed in some patients with 
undetectable HCV RNA and in almost all patients with detectable HCV RNA 
levels at the end of therapy. Therefore, the conflict in these results indicated 
that monitoring AL T levels during therapy is insufficient to define the outcome 
of treatment. A better definition for a sustained response would be both nor-
malization of AL T (i.e. biological) and an undetectable level of HCV RNA (i.e. 
virological) in blood. The absence of detectable HCV RNA for a prolonged period 
after treatment suggests the possible eradication of the virus. Interestingly, HCV 
RNA is still undetectable after 2-3 years of IFN treatment in all four patients with 
both a biochemical and virological response at 6-9 months of follow-up (Chapter 
3). 
In order to predict the effect of IFN on viral replication in the early phase 
of treatment, HCV RNA was measured at week 4 as well as other time points 
(Chapter 3). From this study it appeared that HCV RNA assessment at 4 weeks 
of treatment has clinically relevant and prognostic value; patients still HCV RNA 
positive at week 4 have a very low chance of sustained remission. 
Characterization of hepatitis C virus RNA by genotyping 
Initial full-length sequence comparisons from HCV isolates of patients living in 
the United States and Japan revealed the existence of different viral strains or 
types. Comparison of large numbers of virus isolates revealed sequence hetero-
geneity at different levels throughout the viral genome. The 5'UTR and core 
region are conserved, Eland NS5 regions are variable, whereas part of the N-
terminal E2 region is hypervariable. Sequencing of complete HCV genomes is 
the most reliable approach for classification of different HCV (sub)types. Howe-
ver, this is not feasible for analysis of large groups of patients since sequence 
analysis is tedious and time consuming. For characterization of HCV isolates a 
useful classification system, based on different levels of sequence homology 
between HCV isolates, has recently been proposed by Simmonds [Simmonds et 
aI., 1993a). From sequence data of a 222 bp fragment of the NS5B region, it 
appeared that HCV isolates could be provisionally classified as a new HCV type 
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when sequence similarities were less than 72% with known sequences, where-
as sequence similarities of 75% to 86% would provide evidence for a new HCV 
subtype. Final classification of new HCV (sub)types should be confirmed by 
both sequence analysis of another coding region (e.g. E1) and phylogenetic 
analysis. The branching order will indicate the relationship between previously 
classified isolates [Simmonds et aI., 19941. Comparison of 8 full-length sequenc-
es gave rise to the proposed classification system, although different degrees of 
sequence variation along the genome have been observed. Sequence similarities 
of 67.1 % to 68.6% were found between isolates belonging to different types 
whereas this was 77.0% to 78.9% between those of different subtypes. 
Chapters 4 to 7 describe the analyses and comparisons of small regions 
(200 to 500 nt) of the HCV genome. HCV sequences from chronically infected 
patients were investigated in order to identify prognostic markers for the 
outcome of IFN therapy and to determine the clinical relevance of distinct HCV 
(sub)types. 
In chapter 4, 5'UTR sequences were determined to discriminate between 
HCV types. Sequence data indicated that the 5'UTR is highly conserved and 
sequence variation was mainly detected in two "motifs". These sequence motifs 
appear to be essential for the formation of a stable hairpin structure which was 
identified as an internal ribosomal entry site (IRES; possible starting point for 
viral protein translation) [Brown et aI., 1992; Tsukiyama-Kohara et aI., 1992]. 
Variations in these motifs were (sub)type-specific and occurred mainly by 
covariance (= pair-wise). Therefore, 5'UTR allows consistent discrimination 
between HCV types. 
In chapter 5 evaluation of a reverse hybridization assay, the Line Probe 
Assay (LiPA), was described. Biotin labelled PCR products from the 5'UTR were 
used as probes for reverse hybridization with general as well as type- and 
subtype-specific probes which are applied onto a strip. By LiPA, sequence 
variation is detected at the level of a single nucleotide difference. Typing results 
of both sequence analysis and LiPA were identical for all 54 HCV isolates, 
except in 1. The discordant isolate was typed as subtype 1 a by direct sequen-
cing and as subtype 1 b by LiPA. After repeating the LiPA, subtype 1 a was 
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found. 
After typing 315 HCV isolates by UPA, 5'UTR typing results were 
validated by sequence analysis of part of the core and corelE 1 regions (Chapter 
6). For this study 40 samples belonging to types 1 to 5 were selected. Se-
quence data were analyzed for their phylogenetic relations by pair-wise com-
parisons. The phylogenetic tree from both regions showed 5 branches with 
clusters of sequences. This result indicated that HCV typing into types 1 to 5 by 
LiPA was in accordance with sequence variation in the core and E1 regions. 
However, phylogenetic analysis of the core and corelE 1 regions allowed 
discrimination between known and new HCV sUbtypes. Although HCV subtypes 
can be recognized at the core region, confirmation for classification of new HCV 
(sub)types is not possible. The core region is relatively well conserved. The 
corelE 1 region displayed a higher level of sequence variation and allowed a 
much better discrimination between HCV subtypes. Analysis of HCV isolates 
belonging to types 2 and 4 revealed the existence of several subtypes. In the 
selected 7 HCV type 2 and 8 HCV type 4 samples respectively, 6 and 4 subty-
pes were identified whereas the selected type 3·and type 5 samples belonged to 
only one subtype. Some of our type 4 isolates could not be properly classified 
as different subtypes, since the frequency distribution of pair-wise molecular 
evolutionary distances in the corelE 1 region showed a slight overlap. For final 
classification these isolates should be analyzed in another coding region, 
preferably NS5B [Simmonds at aI., 1993al. However, phylogenetic analysis of 
large numbers of NS5B sequences revealed also some overlap in the frequency 
distribution when analyzing the 222 bp fragment [Stuyver et aI., 19941. Recent-
ly, studies by Stuyver [19941 and Tokita [19941 revealed that a fragment of at 
least 340 bp in the NS5B region should ba sequenced for reliable classification. 
The introduced classification system is useful and comparison of novel HCV 
sequences to reported data is still in progress. However, there is still a clear 
need for international agreement on classification of new HCV (sub)types to 
overcome the problems of nomenclature. For classification of new HCV (subl-
types at least two regions of the HCV genome should be sequenced. Both the 
NS5B region and the E1 region seems to be good. The E1 region would have the 
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advantage of possible correlation with biological differences. 
To identify HCV (sub)types, different fast genotyping assays have been 
described and are based on PCR, either using subtype-specific primers, or 
analysis of the PCR product in (reverse) hybridization assays with type and 
subtype specific probes or by digestion of the PCR product with several combi-
nations of restriction enzymes (restriction fragment length polymorphism 
[RFLPJ). In general, genotyping syste!1ls recognize a small sequence which is 
representative for an HCV type and/or HCV sUbtype. Recently, HCV isolates can 
also be typed by detection of type-specific antibodies [Machida et ai., 1992; 
Simmonds et al., 1993b; Stuyver et ai., 1993]. Serotyping assays aimed at 
either the core or the NS4 region are based on amino acid sequence variation. 
Therefore, type-specific HCV antibodies are a reflection of the nucleotide 
sequence variation. Serotyping has the advantage over genotyping in terms of 
speed, simplicity and special facilities are not required. However, besides 
problems with low or absence of antibody responses serotyping allows only dis-
crimination between HCV samples at the level of types whereas genotyping 
assays can discriminate between sUbtypes. Serotyping results have not yet been 
evaluated by comparison to either genotyping assays or sequence data. 
In order to assess the reliability of HCV subtyping by 5'UTR analysis, the 
rapid HCV typing assays UPA and subtype-specific core amplification were 
compared (Chapter 7). From this study it appeared that 5 of the 37 (14%) type 
1 isolates were mistyped at the subtype level by UPA. Other studies on Europe-
an cohorts infected with type 1 showed a frequency of approximately 5% in 
mistyping between HCV subtypes 1 a and 1 b [Stuyver et ai., 1994; Gianinni et 
ai., 1994]. This difference can be explained by the heterogeneity of our studied 
population. Two of the five wrongly subtyped isolates were obtained from 
patients born in Morocco. Sequence analysis of the E1 and NS5B regions 
revealed that these two isolates could be classified as a new HCV subtype, 1 d. 
These two samples were recognized as 1a by UPA whereas they remained 
correctly untyped by the subtype-specific core amplification assay. By sUbtype-
specific core amplification two mixed infections of HCV subtypes 1 a and 1 b 
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were detected but could not be confirmed. This false amplification of 1 a sequen-
ces by the 1 b specific primer was also observed by others (Andonov et aI., 
1994]. 
Samples typed as 2a (n ~ 18) by LiPA appeared to be a rather heteroge-
neous group. None of these 18 samples could be typed as 2a by sUbtype-
specific core amplification and therefore remained untyped. Core sequence 
analysis as performed in 3 of these 18 cases confirmed the core amplification 
result. Interestingly, additional sequence analysis of the El region revealed that 
the three samples could be classified as three new type 2 subtypes besides the 
already characterized subtypes 2a-2d. 
Our typing studies revealed that both LiPA as well as subtype-specific 
core amplification have different strengths and weaknesses. Typing at the 
5'UTR has the advantage over core in terms of HCV RNA detection by general 
PCR in diagnosis of infection. The limited nucleotide differences found at the 
5'UTR allow discrimination between the different HCV types but differentiation 
between subtypes is sometimes hampered. In contrast, subtype-specific core 
amplification allowed accurate discrimination between subtypes, due to a higher 
degree in sequence variation when compared to 5'UTR. However, a large 
number of samples (n ~ 22) remained untyped. By subtype-specific core amplifi-
cation, an HCV subtype is recognized by a subtype-specific primer of 20 
nucleotides at the target site, whereas HCV isolates are typed by LiPA with mul-
tiple type- and subtype-specific probes. 
Recently, several research groups reported modifications for typing by 
subtype-specific core amplification assay. The improvements include adaption of 
subtype-specific as well as general primers (Kinoshita et aI., 1993; Okamoto et 
aI., 1993; Silini et aI., 1993); addition of new subtype-specific primers for 
detection of novel HCV subtypes (Okamoto et aI., 1993; Xu et aI., 1994); 
additional analysis for confirmation of 1 all b mixed infections (Andonov et aI., 
1994); equalization of all primer melting temperatures to increase the stringency 
in the subtype-specific nested PCR (Widell et aI., 1994]. Technically, sUbtype-
specific core amplification is an elegant and accurate assay for identification of 
HCV subtypes. However, it is very likely that subtype-specific core amplification 
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with multiple subtype-specific primers will not be an efficient method in hetero-
geneous HCV populations. Currently, 52 HCV subtypes have been described. 
For more precise and efficient typing of HCV isolates it would be useful to apply 
the strength of the LiPA test format on sequence variation in the 5'UTR as well 
as the core region [Stuyver et aI., 19951. 
HCV (sub)types and patient related parameters 
In order to asses the clinical relevance of HCV genotyping we investigated the 
relationship of HCV (sub)types with geographical regions, routes of trans-
mission, clinical characteristics and liver disease. Nowadays there is evidence 
for the existence of 9 HCV types. In chapter 8 a study is described on 292 HCV 
RNA isolates from chronically infected patients. This study and other reports 
revealed that the distribution of HCV (sub)types vary considerably per geograp-
hical region. HCV types 1, 2 and 3 are distributed worldwide, whereas the other 
types generally appear to be restricted to more specific geographical areas. Type 
4 was found in several Northern- and Central-African countries, types 5 and 6 
were detected in respectively South-Africa and Hong-Kong, and recently types 
7-9 were identified in patients from Vietnam. In European patients HCV subtype 
1 b was predominant (64%) and the (sub)types 1 a, 2, 3, 4, and 5 were preva-
lent at frequencies ranging from 3-15%. 
Remarkably, HCV types 4 and 5 were detected at a frequency of 3-4% in 
patients originating from Belgium and the Netherlands. Neither type has ever 
been detected in Japanese patients and it seems that they are highly prevalent 
in Africans. Besides historical data of the patient, knowledge about routes of 
transmission could be useful in understanding the distribution of HCV (sub)-
types. The study described in chapter 8 revealed that HCV subtype 1 b was 
predominantly transmitted by blood transfusion whereas HCV subtype 1 a and 
type 3 were correlated with transmission by IV drug abuse. This study also 
revealed that the HCV types 1-5 were both parenterally as well as inapparent 
parenterally transmitted. Furthermore, when comparing both modes of transmis-
sion (i.e. blood transfusion versus no risk factors identified) similar clinical 
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characteristics, ALT levels and frequencies of cirrhosis were found. Since the 
incidence of non-parenteral transmission is very low, it could be speculated that 
hidden parenteral risk factors such as injection with contaminated needles are 
included in the population classified as sporadic hepatitis C. Interestingly, when 
the patients were recruited, approximately 40% reported to have no known 
parenteral cause of transmission. However, after more extensive questioning, 
over 30% of these presumed sporadic cases proved to have concealed paren-
teral contacts in the past. Taken together, the pattern of HCV type distribution 
might be caused by blood transfusion and (imported) blood(products) (Kinoshita 
et aI., 19931 as well as needle sharing. 
Comparison of HCV types with general clinical characteristics revealed 
the following: (i) no relationship was found with sex; (ii) HCV subtype 1 a and 
types 3 and 4 were most common in young individuals, whereas HCV subtype 
1 b and types 2 and 5 were predominant in patients of approximately 50 years 
of age or more. The difference in prevalence of HCV (sub)types by age could be 
ascribed to the mode of acquisition. 
Comparison of HCV type with liver disease revealed that no specific HCV 
(sub)type was related with a history of jaundice, the activity (i.e. AL T concen-
tration in serum) of liver inflammation or with cirrhosis. Recently, similar results 
were reported by two Japanese studies with respectively 148 and 251 patients 
[Yamada et aI., 1994; Mita et aI., 19941. In previous small populations the seve-
rity of liver disease appeared to be related with either type 1 or type 2. Multi-
variate analysis as described in chapter 8 revealed that the presence of liver 
cirrhosis was highly correlated with age and longer duration of infection. This 
result suggests that the development of liver cirrhosis occurs faster in older 
patients than in young individuals. Since our study was based on selected 
populations and HCV carriers without elevated transaminases were not included, 
a more definite statement can only be made when unselected large populations 
have been followed for a long period of time. 
Remarkably, the HCV type is not related to the severity of liver disease 
whereas they do affect IFN therapy efficacy [Hino et aI., 1994; Kobayashi et aI., 
1993; Tsubota et aI., 1994; Yoshioka et aI., 1992]. Also, the level of viremia 
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seems to be associated with the success of IFN therapy [Hagiwara et ai., 1993; 
Kobayashi et ai., 1993; Lau et ai., 1993; Yoshioka et ai., 1992]. Recent reports 
using multivariate analysis revealed several prognostic markers for sustained 
response. The most important markers were HCV type 2 and low concentrations 
of HCV RNA. Similar results were obtained for the patients described in this 
thesis. The HCV type and HCV RNA at 4 weeks of treatment had relevant 
prognostic value. In patients with high virus concentrations prior to treatment, it 
is less likely that HCV RNA becomes undetectable after 4 weeks of therapy 
when compared to those with low concentrations. Therefore, it could be specu-
lated that the HCV RNA level at the onset of treatment is, in addition to the 
HCV type, an important predictive marker for the success of therapy. 
In conclusion, this study revealed that HCV viremia was reliably determined by 
the "in-house" HCV RNA PCR assay. The presence of HCV RNA after 4 weeks 
of interferon alpha therapy was highly predictive for non-response to treatment. 
Direct sequencing of the 5'UTR as well as the coding regions of core and E 1 
revealed that HCV isolates could be reliably separated into the major HCV types 
by LiPA. No relationship was found between a specific HCV (subltype and the 
severity of liver disease. HCV typing appears to have its greatest value in the 
epidemiology of infection. 
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Samenvatting en discussie 
Dit praefschrift beschrijft in 3 delen de karakterisering van hepatitis C virus 
(HCVI isolaten die verkregen zijn van chronisch ge'infecteerde patiiinten. In 
hoofdstuk 1 is beknopt de algemene kennis van hepatitis C beschreven. In 1987 
werd door Houghton en zijn medewerkers vastgesteld dat HCV de veroorzaker 
was van het ziektebeeld dat bekend is als post transfusie non-A, non-S hepati-
tis. Deze lange naam geeft aan dat de diagnose voorheen gebaseerd was op 
uitsluiting van virale hepatitis infecties. Na de belangrijke ontdekking van HCV 
zijn er testen ontwikkeld voor specifieke diagnose van dit virus. De eerste 
diagnostische testen waren gericht op het aantonen van HCV anti-lichamen 
omdat de concentratie van HeV antigenen, de virus eiwitten, in serum te laag 
zijn veor detectie met conventionele test systemen. Het nadeel van anti-lichaam 
detectie is echter dat er geen onderscheid gemaakt kan worden tussen een 
actieve HCV infectie en een HCV infectie die reeds is opgelost. Nog een nadeel 
is dat anti-lichamen pas kunnen worden aangetoond na een immunologische 
reactie. Detectie van het HCV RNA genoom is tot nu toe de enige toepasbare 
methode vaor het vaststellen van aetieve virus replicatie (= viremie). Veor aen 
adequate diagnose is een betrauwbare HCV RNA test uitslag absoluut noodza-
kelijk omdat HCV viremie maar met sen parameter kan worden vastgesteld. 
Het eerste deel van dit proefschrift, hoofdstuk 2 en 3 zijn gericht op 
detectie van HCV RNA. In hoofdstuk 2 wordt de ontwikkeling van een univer-
sele HCV RNA PCR test beschreven. Het virale RNA genoom wordt gedetec-
teerd door toepassing van de zogeheten reverse transcription polymerase chain 
reaction (RT-PCR) techniek met primers die gericht zijn tegen het sterk geconser-
veerde 5'onvertaalde gebied (5'UTR). Met de PCR techniek worden kwalitatieve 
data gepraduceerd. Een negatief test resultaat, beter gezegd HCV RNA niet 
aantoonbaar, krijgt meer betekenis als de detectie grens van de RT-PCR test 
bekend is. Na analyse van een verdunnings reeks met de branched DNA test 
(bDNA, Chiron) bleek dat de limiet van onze PCR test rand de 500-1000 HCV 
genoom equivalenten per milliliter zit. 
Vals positiviteit is een zeer bekend probleem bij de toepassing van de PCR 
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techniek. Daarom is de "in-house" ontwikkelde HCV RNA PCR test geevalueerd 
in 2 kwaliteit controle studies. Onze test is zeer gevoelig en specifiek. Va Is 
positieve resultaten werden niet geproduceerd door toepassing van een strate-
gie. HCV plasma monsters werden geanalyseerd in 2 onafhankelijke experimen-
ten. Gelijke resultaten werden beschouwd als geldig en vormden tevens het 
uiteindelijke test resultaat. Indien het resultaat ongelijk was dan werd het 
monster opnieuw geanalyseerd in 2 onafhankelijke experimenten. Test resultaten 
die weer ongelijk waren werden beschouwd als 'indeterminate'. Een interessant 
gegeven uit de laatste kwaliteit controle studie was dat de toepassing van een 
semi-automatische PCR test (HCV amplicor, Roche) geen garantie was voor het 
vermijden van vals positieve resultaten. De kwaliteit van de HCV Amplicor resul-
taten waren gecorreleerd aan een goede uitvoering van de "in-house" ontwikkel-
de PCR test. Deze resultaten geven aan dat naast een goede strategie aileen 
goed getraind laboratorium personeel in staat is om betrouwbaar PCR test 
resultaten te produceren. 
Voor behandeling van hepatitis C wordt al jaren interferon alfa aan de 
patient gegeven. Het effect van dit medicijn werd vroeger bepaald door het 
monitoren van de concentraties alanine aminotransferase (ALT), een specifiek 
lever enzym, in serum. Met deze parameter werd in eerdere studies vastgesteld 
dat ongeveer 50% van de patienten die een normale AL T hadden bereikt tijdens 
de behandeling weer een verhoging Van AL T vertoonden na interferon therapie. 
Door het volgen van de parameter HCV RNA, zoals beschreven in hoofdstuk 3, 
werd aangetoond dat interferon alfa de virale replicatie onderdrukt in bijna aile 
patienten met een biochemische response (normale AL T) tijdens de behandeling. 
Een relapse, verhoogde AL T waarden na behandeling, werd gevonden in een 
paar patiiinten met niet aantoonbaar HCV RNA en in bijna aile patienten met 
aantoonbare hoeveelheden HCV RNA aan het einde van de therapie. Deze 
resultaten geven aan dat het volgen van AL T concentraties tijdens de behande-
ling onvoldoende is v~~r het vaststellen van de uitkomst van interferon therapie. 
Een batere definitie voor een blijvende response is de combinatie van een 
normale AL T concentratie en niet aantoonbaar HCV RNA. De afwezigheid van 
aantoonbaar HCV RNA voor een lange periode na behandeling suggereerde dat 
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de HCV infectie is geklaard. Interessant om te vermelden is dat HCV RNA na 2-
3 jaar na therapie nog steeds niet aantoonbaar is in aile 4 patienten met een 
biochemische en virologische response. 
Om het uiteindelijke effect van interferon op de virale replicatie al in een 
vroeg stadium van de behandeling te voorspellen werd HCV RNA bepaald na 4 
weken therapie. Uit deze studie kon worden vastgesteld dat de HCV RNA 
bepaling na 4 weken van behandeling prognostische waarden heeft en daardoor 
klinisch relevant is. Patienten die na 4 weken therapie nog steeds HCV RNA 
positief zijn hebben een zeer kleine kans op een blijvende response. 
Het tweede deel van dit proefschrift, hoofdstukken 4 tim 7, is gericht op de 
karakterisering van HCV isolaten. Sequentievariatie tussen de HCV isolaten die 
verkregen waren van chronisch ge'infecteerde patienten werden geanalyseerd 
om voorspellende markers ta identificeren vaor de uitkomst van interferon 
therapie en om de klinische relevantie vast te stellen van de verschillende HCV 
(subltypen. 
Eerdere onderzoeken waarbij complete genoom sequenties werden 
vergeleken, toonden aan dat er verschillende HCV typen bestaan. Door een 
groot aantal virus isolaten te vergelijken werd vastgesteld dat sequentievariatie 
over het hele genoom op verschillende niveaus voorkomt. Zo zijn het 5'UTR en 
core geconserveerd; de E 1 en NS5 regios zijn variabel en de N-terminus van het 
E2 gebied is hypervariabel. Sequentie analyse van complete HCV genomen is de 
meest betrouwbare maniar om virus isolatan ta classificeren in verschillende 
(subltypen. Het is echter niet haalbaar om grote patient populaties op deze 
manier te analyseren. Daarom worden kleine delen van het HCV genoom 
geanalyseerd om het isolaat te typeren. Recentelijk is er voor de karakterisering 
van HCV isolaten een classificatie systeem gs'introduceerd die gebaseerd is op 
verschillende niveaus van sequentie homologie tussen isolatan. Vaor dit systeem 
werd een klein fragment, 222bp, in het NS5 gebied als model gebruikt. Van een 
nieuw HCV type is sprake als de sequentie homologie minder is dan 72% met 
reeds bekende sequenties, sequentie homologie tussen de 75% en 86% is aen 
mogelijk bewijs voor een nieuw sUbtype. De uiteindelijke classificatie van 
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nieuwe HeV (sub)typen moet bevestigd worden door analyse van en andere 
regio, bijvoorbeeld E1. 
In hoofdstuk 4 werden 5'UTR sequenties bepaald om de verschillende 
HeV typen en sUbtypen te onderscheiden. De sequentie data lieten zien dat het 
5'UTR sterk geconserveerd is en dat de beperkte sequentievariatie hoofdzakelijk 
voorkomt in 2 motieven. Deze sequentie motieven zijn van belang voor de 
vorming van de secundaire RNA structuur die een functioneel onderdeel bevat in 
de levens cyclus van het virus. De sequentievariaties in deze motieven waren 
meestal gepaarde mutaties (covariatie) die type-specifiek zijn. Hierdoor kan het 
5'UTR op een snelle manier gebruikt worden om de verschillende typen te 
identificeren. 
Hoofdstuk 5 beschrijft de evaluatie van een 'reverse hybridisatie' test, line 
probe assay (LiPA). De gevonden variaties zoals beschreven in hoofdstuk 4 
vormde de basis van deze test. De typerings resultaten van 54 isolaten die 
waren verkregen met LiPA correleerden zeer goed met de sequentie data. De 
enige discrepant was na herhaling met de LiPA gelijk aan de sequentie analyse. 
Om aan te tonen dat het 5'UTR betrouwbaar gebruikt kan worden voor 
Hev genotypering werd een graep van meer dan 300 isolaten met behulp van 
de LiPA gekarakteriseerd. Voor deze studie, beschreven in hoofdstuk 6, werden 
na 5'UTR genotypering een 40 tal monsters geselecteerd die representant zijn 
voor de verschillende (sub)typen. Sequentie analyse werd verricht op core en 
core/E 1, en vervolgens werden de data geanalyseerd op hun phylogenetische 
relatie door iedere sequentie met aile andere te vergelijken. Deze gepaarde 
vergelijkingen leveren een phylogenetische boom met verschillende takken en zij 
lakken. De typering van isolaten op basis van 5'UTR analyse correleerde zeer 
goed met de indeling gebaseerd op core en core/E 1 sequenties. De core sequen-
ties zijn relatief goed geconserveerd en de core/E 1 sequenties vertonen veel 
meer variatie. Daarom is deze regio beter geschikt am onderscheid te maken 
tussen HeV sUbtypen. HeV isolaten van het type 2 en 4 vertonen meer intra-
typische variatie dan de andere typen. Aangetoond is dat isolaten die behoren 
tot deze 2 groepen bestaan uit een aantal verschillende subtypen die niet 
allemaal herkend kunnen worden op 5'UTR. 
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Identificatie van verschillende HCV sUbtypen binnen de typen 1 en 2 door 
toepassing van snelle typerings testen is beschreven in hoofdstuk 7. Snelle 
genotyperings methoden zijn gebaseerd op herkenning van een klein stukje (± 
20bp) van het HCV genoom. Om een indruk te krijgen in de betrouwbaarheid 
van subtypering op basis van 5'UTR analyse werden 58 isola ten, 37 type 1 en 
21 type 2, geanalyseerd met LiPA en subtype-specifieke core amplificatie. De 
verkregen typerings resultaten werden geevalueerd door sequentie analyse in 
beide regios. Deze studie toonde aan dat zowel LiPA als subtype-specifieke core 
amplificatie hun verschillende sterktes en zwaktes hebben. Een praktisch 
voordeel van genotypering op 5'UTR is dat deze regio routine matig wordt 
gebruikt voor HCV diagnostiek. De verkregen PCR producten kunnen direct 
gebruikt worden voor genotypering. Het 5'UTR heeft als nadeel dat de gelimi-
teerde nucleotiden variatie wei voldoende is om onderscheid te maken tussen de 
verschillende typen maar soms onvoldoende is Vaor het aantonen van een 
subtype. Hier tegenover staat dat subtype-specifieke core amplificatie goed in 
staat is om te discrimineren tussen verschillende subtypen vanwege de hogere 
graad in sequentievariatie. Echter in onze populatie konden 22 van de 58 (38%) 
isolaten niet gekarakteriseerd worden met dit systeem dat gericht is op herken-
ning van de typen 1 a, 1 b, 2a en 2b. Onlangs zijn er diverse modificaties 
gerapporteerd die tot een verbetering hebben geleid. Technisch is sUbtype-speci-
fieke core amplificatie een elegante en accurate test. Praktisch gezien zal dit 
systeem geen efficiente methode zijn om heterogene populaties te karakterise-
reno Vaor een meer nauwkeurige en efficiente manier om Hev isolaten te 
typeren is het zinvol om de sterkte van het LiPA test format te combineren met 
de sequentievariatie in zowel 5'UTR als core. 
Het derde deel van dit proefschrift, hoofdstuk 8, beschrijft de relatie tussen de 
HCV (sub)typen en regio van infectie, route van transmissie, klinische karakteris-
tieken en lever ziekten. In deze studie werden 292 HCV isolaten geanalyseerd 
van chronisch ge'infecteerde patienten. De eerste karakterisering studies van het 
HCV genoom suggereerden een relatie tussen een HCV type en de geografische 
verspreiding. Dit had tot gevolg dat isolaten al snel werden bestempeld als het 
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'Amerikaanse type' (type 1 a) en het 'Japanse type' (type 1 b). Op dit moment 
zijn er 9 verschillende HCV typen bekend. Onze studie en die van anderen 
toonden aan dat de prevalentie van de HCV typen nogal sterk verschilt per 
geografische regio. De HCV typen 1, 2 en 3 zijn wereldwijd verspreid terwijl 
andere meer verbonden zijn aan een specifieke regio. Type 4 komt het meest 
voor in Noord en Centraal Afrika. De typen 5 en 6 werden gevonden in respec-
tievelijk Zuid-Afrika en Hong-Kong. Zeer recentelijk werden de typen 7, 8 en 9 
geidentificeerd in Patienten uit Vietnam. Bij Europeanen is HCV subtype 1 b 
predominant (64%) en de prevalentie van de (sub)typen 1 a, 2, 3, 4 en 5 
varieerde tussen de 3% en 15% (hoofdstuk 8). Merkwaardig was dat de typen 
4 en 5 werden gevonden met een lage frequentie in patienten afkomstig uit 
Belgie en Nederland. Misschien heeft dit te maken met onze multi-raciale 
samenleving. 
Kennis over de route van transmissie kan ons beter doen begrijpen hoe de 
verschillende HCV (sub)typen zich verspreiden. De studie in hoofdstuk toonde 
aan dat subtype 1 b hoofdzakelijk werd verspreid door bloed transfusie terwijl 
subtype 1 a en type 3 waren geassocieerd met transmissie door intraveneus drug 
gebruik. Tevens werd vast gesteld dat de typen 1 tim 5 zowel parenteraal als 
non-parenteraal (= risico factor onbekend) worden over gedragen. 
Bij de vergelijking van HCV typen en klinische karakteristieken werd allen 
een relatie gevonden met de leeftijd. HCV subtype 1 a en de typen 3 en 4 
werden veelal gevonden bij jongeren terwijl subtype 1 b en de typen 2 en 5 
predominant waren bij patienten van ongeveer 50 jaar en ouder. De relatie 
tussen het HCV type en leeftijd kan worden toegeschreven aan de route van 
transmissie. 
In eerdere studies waarbij kleine patient populaties werden bestudeerd 
vonden de auteurs dat HCV type 1 of type 2 gerelateerd was aan een ernstiger 
vorm van lever ziekten. In onze populatie vonden we geen relatie tussen een 
specifiek HCV type en de activiteit van lever ontsteking (verhoogde AL T 
concentraties in serum) en cirrhose. Overeenkomstige resultaten werden onlangs 
gerapporteerd in 2 grote studies uit Japan. Omdat de resultaten van onze studie 
zijn verkregen uit een geselecteerde groep van HCV patienten met verhoogde 
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AL T concentraties kan een definitieve uitspraak pas gemaakt worden na analyse 
van een niet geselecteerde groep die voor een lange periode wordt vervolgt. 
Reeds gepubliceerde studies toonden aan dat het HCV type van invloed is 
op de efficientie van interferon therapie. De meest belangrijke prognostische 
markers voor een blijvende response na interferon therapie zijn de HCV typen 2 
en 3 en een lage HCV RNA concentratie. Dvereenkomstige resultaten werden 
gevonden voor de in dit proefschrift beschreven patienten. 
De studies die zijn weergegeven in dit proefschrift hebben een bijdrage 
geleverd aan een betrouwbare bepaling van HCV viremie en de karakterisering 
van HCV isolaten die van belang is voor de predictie van de uitkomst van 
interferon therapie. 
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